var title_f22_26_22944="Normal mesenteric fixation";
var content_f22_26_22944=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal small bowel mesenteric attachment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 387px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal mesenteric fixation. Normal rotation and fixation results in a wide-based mesentery (demonstrated by the red line) that extends from the ligament of Treitz in the left upper quadrant to the ileocecal valve in the right lower quadrant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22944=[""].join("\n");
var outline_f22_26_22944=null;
var title_f22_26_22945="Hydatid membranes";
var content_f22_26_22945=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Hydatid membranes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiopancreatography showing hydatid membranes that have been extracted from the common bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22945=[""].join("\n");
var outline_f22_26_22945=null;
var title_f22_26_22946="Patient information: Frozen shoulder (The Basics)";
var content_f22_26_22946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16309\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/37/12895\">",
"         Pendulum stretch exercise",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/4/9295\">",
"          Armpit stretch",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/8/13455\">",
"           Walk-up-wall stretch",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/47/21247\">",
"            Towel stretch",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/53/29522\">",
"         Patient information: Rotator cuff injury (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/21/37201\">",
"         Patient information: Frozen shoulder (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/49/24341\">",
"         Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Frozen shoulder (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/frozen-shoulder-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H26854777\">",
"      <span class=\"h1\">",
"       What is a frozen shoulder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A frozen shoulder is a condition that causes the shoulder to be stiff and unable to move easily. When people have a frozen shoulder, the tissue around the shoulder joint gets thick and tight. This might happen after a person&rsquo;s shoulder gets hurt or if he or she has shoulder surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26854784\">",
"      <span class=\"h1\">",
"       What are the symptoms of a frozen shoulder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with a frozen shoulder usually have a stiff and painful shoulder and trouble reaching overhead or around to their lower back.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26854791\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might. Your doctor or nurse will talk with you and do an exam. He or she will probably do an imaging test, such as an X-ray or MRI scan. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26854798\">",
"      <span class=\"h1\">",
"       How is a frozen shoulder treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In most cases, a frozen shoulder will get better on its own, but it can take months to heal completely. To help your shoulder get better, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rest your shoulder &mdash; Avoiding raising your arm overhead, reaching, and lifting things.",
"       </li>",
"       <li>",
"        Ice your shoulder &mdash; Put a cold gel pack, bag of ice, or bag of frozen vegetables on the injured area every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and your skin.",
"       </li>",
"       <li>",
"        Take a pain-relieving medicine &mdash; Ask your doctor or nurse about taking an over-the-counter medicine for pain, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol&reg;),",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;), or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26854805\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Different exercises can help your shoulder get better.",
"     </p>",
"     <p>",
"      To help loosen your shoulder joint, you can do an exercise called the pendulum stretch. To do this exercise, let your arm relax and hang down, while you sit or stand. Move your arm back and forth, then side to side, and then around in small circles (",
"      <a class=\"graphic graphic_figure graphicRef50148 \" href=\"UTD.htm?12/37/12895\">",
"       figure 1",
"      </a>",
"      ). Try to do this exercise for 5 minutes, 1 or 2 times a day.",
"     </p>",
"     <p>",
"      After the pendulum stretch, you can do the following stretches. Try to do each of these 10 to 20 times, 1 or 2 times a day.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Armpit stretch &mdash; Use your good arm to lift your affected arm onto a shelf, dresser, or other object that is chest high (",
"        <a class=\"graphic graphic_picture graphicRef51493 \" href=\"UTD.htm?9/4/9295\">",
"         picture 1",
"        </a>",
"        ). Gently bend your knees to stretch open your armpit. Try to push the injured arm up a little farther with each stretch.",
"       </li>",
"       <li>",
"        Wall walk &mdash; Face a wall, and stand three-quarters of an arm&rsquo;s length away. Walk your fingers up the wall until your arm is at shoulder level (",
"        <a class=\"graphic graphic_picture graphicRef78109 \" href=\"UTD.htm?13/8/13455\">",
"         picture 2",
"        </a>",
"        ). Try to use your shoulder muscles as little as possible and keep them level (do not shrug them).",
"       </li>",
"       <li>",
"        Towel stretch &mdash; Hold a 3-foot-long towel in both hands behind your back in the horizontal position. Then use your good arm to pull the towel so that your injured arm moves toward your lower back (",
"        <a class=\"graphic graphic_picture graphicRef77955 \" href=\"UTD.htm?20/47/21247\">",
"         picture 3",
"        </a>",
"        ). You can also hold the towel at an angle to do this exercise.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other types of exercises can help make the shoulder muscles stronger. Your doctor, nurse, or physical therapist (exercise expert) can show you how to do these types of exercises. He or she will tell you when to start them and how often to do them.",
"     </p>",
"     <p>",
"      When you do shoulder exercises, it&rsquo;s important to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Warm up your shoulder first by taking a hot shower or bath, or putting a heating pad on it.",
"       </li>",
"       <li>",
"        Start slowly and make the exercises harder over time.",
"       </li>",
"       <li>",
"        Know that some soreness is normal. If you have sharp or tearing pain, stop what you&rsquo;re doing and let your doctor or nurse know.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26854812\">",
"      <span class=\"h1\">",
"       What if my shoulder doesn&rsquo;t get better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your symptoms don&rsquo;t get better, talk with your doctor or nurse about other possible treatments, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Getting a shot of medicine or fluid into the shoulder",
"       </li>",
"       <li>",
"        Surgery",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26854819\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/53/29522?source=see_link\">",
"       Patient information: Rotator cuff injury (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/21/37201?source=see_link\">",
"       Patient information: Frozen shoulder (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=see_link\">",
"       Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?22/26/22946?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16309 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22946=[""].join("\n");
var outline_f22_26_22946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26854777\">",
"      What is a frozen shoulder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26854784\">",
"      What are the symptoms of a frozen shoulder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26854791\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26854798\">",
"      How is a frozen shoulder treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26854805\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26854812\">",
"      What if my shoulder doesn&rsquo;t get better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26854819\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16309\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/37/12895\">",
"      Pendulum stretch exercise",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/4/9295\">",
"       Armpit stretch",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/8/13455\">",
"        Walk-up-wall stretch",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/47/21247\">",
"         Towel stretch",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/21/37201?source=related_link\">",
"      Patient information: Frozen shoulder (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/53/29522?source=related_link\">",
"      Patient information: Rotator cuff injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=related_link\">",
"      Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_26_22947="Contact dermatitis nickel";
var content_f22_26_22947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contact dermatitis due to nickel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This boy developed an eczematous eruption at the site where the nickel snap on his blue jeans contacted his skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's photoguide of common skin disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22947=[""].join("\n");
var outline_f22_26_22947=null;
var title_f22_26_22948="Transection of redundant sigmoid colon sagittal view";
var content_f22_26_22948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Transection of redundant sigmoid colon sagittal view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 659px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the sagittal view of a transected redundant sigmoid colon. A suture rectopexy is shown between the presacral fascia and the seromuscular layer of posterior rectal wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22948=[""].join("\n");
var outline_f22_26_22948=null;
var title_f22_26_22949="Ciclesonide (oral inhalation): Pediatric drug information";
var content_f22_26_22949=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciclesonide (oral inhalation): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/5/34902?source=see_link\">",
"    see \"Ciclesonide (oral inhalation): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/34/35365?source=see_link\">",
"    see \"Ciclesonide (oral inhalation): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8002707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alvesco&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8002711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alvesco&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F11162661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Inhalant (Oral)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F11162669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/5/34902?source=see_link\">",
"      see \"Ciclesonide (oral inhalation): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral inhalation: Asthma:",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be titrated to the lowest effective dose once asthma is controlled:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 4-11 years: Limited data available; efficacy results variable: 40-160 mcg once daily; duration of therapy for efficacy clinical trials limited to 12 weeks; a safety trial in 661 children 5-8 years of age evaluated use for 1 year and 2 months follow-up, no untoward effects were noted (Gelfand, 2006; Pedersen, 2010; Skoner, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;12 years, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prior therapy with bronchodilators alone: Initial: 80 mcg twice daily, may increase dose after 4 weeks of therapy if response inadequate (maximum dose: 320 mcg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prior therapy with inhaled corticosteroids: Initial: 80 mcg twice daily, may increase dose after 4 weeks of therapy if response inadequate (maximum dose: 640 mcg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prior therapy with oral corticosteroids: Initial: 320 mcg twice daily, may increase dose after 4 weeks of therapy if response inadequate (maximum dose: 640 mcg/day)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8002812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alvesco&reg;: 80 mcg/inhalation (6.1 g); 160 mcg/inhalation (6.1 g) [contains ethanol; 60 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8002712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11162670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Oral inhalation: Shaking inhaler before use is not necessary since drug is formulated as a solution aerosol. With initial use or if inhaler not in use for 10 days, prime the inhaler by releasing 3 puffs into the air. Do not spray into eyes or face while priming. Rinse mouth with water after use to reduce incidence of oral candidiasis. Do not wash any part of inhaler in water. Dose indicator will turn red when 20 puffs remain; discard when dose indicator reads zero. If inhaler dropped, dose indicator may be inaccurate; manual tracking of inhaler actuations recommended.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F11162666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F), excursions to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F) permitted. Do not puncture. Do not use or store near open flame or heat; canister may burst if exposed to temperatures &gt;49&deg;C (120&deg;F); do not throw canister into fire or incinerator.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11162662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Maintenance treatment of asthma (prophylactic management) (FDA approved in ages &ge;12 years and adults);",
"     <b>",
"      NOT",
"     </b>",
"     indicated for the relief of acute bronchospasm",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8002730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Facial edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Dizziness, dysphonia, fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Gastroenteritis, oral candidiasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; Skeletal: Arthralgia, back pain, extremity pain, musculoskeletal chest pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic: Ear pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Hoarseness, nasal congestion, nasopharyngitis, paradoxical bronchospasm, pharyngolaryngeal pain, pneumonia, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Influenza",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: ALT increased, angioedema (with swelling of lip/pharynx/tongue),  candidiasis (pharyngeal), cataract, chest discomfort,  GGT increased, intraocular pressure increased, nausea,  palpitation,  rash,  weight gain, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11162663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ciclesonide or any component; primary treatment of status asthmaticus or acute asthma episodes requiring intensive measures",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13134558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended dosages; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercorticism (Cushing's syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity [mean: 1 cm/year (range: 0.3-1.8 cm)] may occur when corticosteroids are administered to pediatric patients, even at recommended doses via inhaled route; reduction in growth velocity is related to dose and duration of exposure; monitor growth. Use ciclesonide with extreme caution in patients with respiratory tuberculosis, untreated systemic infections, or ocular herpes simplex. Rare cases of increased IOP, glaucoma, or cataracts have been reported with inhaled corticosteroids, including ciclesonide.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11162664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after switching from systemic corticosteroids to aerosol steroids; several months may be required for full recovery of hypothalamic-pituitary-adrenal (HPA) function; patients receiving higher doses of systemic corticosteroids (eg, adults receiving &ge;20 mg of prednisone per day) may be at greater risk; during this period of HPA suppression, aerosol steroids do not provide the systemic glucocorticoid or mineralocorticoid activity needed to treat patients requiring stress doses (ie, patients with major stress such as trauma, surgery, infections, or other conditions associated with severe electrolyte loss). When used at high doses, HPA suppression may occur; use with inhaled or systemic corticosteroids (even alternate-day dosing) may increase risk of HPA suppression. Acute adrenal insufficiency may occur with abrupt withdrawal after long-term use or with stress; withdrawal or discontinuation of corticosteroids should be done carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery).  Switching patients from systemic corticosteroids to aerosol steroids may unmask allergic conditions (eg, rhinitis, conjunctivitis, eczema, arthritis, and eosinophilic conditions) previously suppressed by the systemic steroid. Immunosuppression may occur; patients may be more susceptible to infections; avoid exposure to chickenpox and measles. Bronchospasm may occur after use of inhaled ciclesonide; if occurs, therapy should be discontinued, a fast-acting bronchodilator used to treat, and alternative treatment initiated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <i>",
"      C. albicans",
"     </i>",
"     infections of the mouth and pharynx may occur with orally inhaled corticosteroid use, mostly mild to moderate in nature; interruption of therapy may be necessary at times while antifungal therapy is employed; advise patients to rinse mouth after use. The incidence of oral candidiasis and other localized oropharyngeal effects observed with ciclesonide use has been reported to be approximately one-half of that seen with other commonly inhaled corticosteroids such as budesonide and fluticasone. Small particle size, minimal activation, and deposition in the oropharynx may explain this decreased incidence. Hypersensitivity reactions with angioedema and swelling of the lips, tongue, and pharynx have been reported rarely.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8002758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8002759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8002714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8002715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were reported following subcutaneous administration of ciclesonide in animal reproduction studies.  Hypoadrenalism may occur in infants born to mothers receiving corticosteroids during pregnancy. Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy (ACOG, 2008; NAEPP, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11162671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Check mucus membranes for signs of fungal infection; monitor growth in pediatric patients; monitor IOP with therapy &gt;6 weeks. Monitor for symptoms of asthma, FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow, and/or other pulmonary function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11162667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ciclesonide is prodrug that is hydrolyzed to the active metabolite des-ciclesonide which has a high affinity for the glucocorticoid receptor where it acts to control the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13134561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: &gt;4 weeks for maximum benefit",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11162668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: 52% (lung deposition)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Ciclesonide: 2.9 L/kg; des-ciclesonide: 12.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &ge;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Ciclesonide hydrolyzed to active metabolite, des-ciclesonide via esterases in nasal mucosa and lungs; further metabolism via hepatic CYP3A4 and 2D6",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: Ciclesonide: 0.7 hours; des-ciclesonide: 6-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration:  ~1 hour (des-ciclesonide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Feces (66%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F11162672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/34/35365?source=see_link\">",
"      see \"Ciclesonide (oral inhalation): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This is not a bronchodilator and will not relieve acute asthma attacks. Full response to this medication may not be seen for 2-5 weeks. Use regularly. Do not stop treatment, even if feeling better. Notify physician if condition being treated persists or worsens; do not decrease dose or discontinue without physician approval. Avoid exposure to chicken pox or measles; if exposed, seek medical advice without delay. May cause dry mouth. Rinse mouth after inhalation to decrease chance of oral candidiasis. Report sore mouth or mouth lesions, or persistent headache to physician; carefully read and follow the patient instructions for use leaflet that accompanies the product.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F11162673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When using ciclesonide oral inhalation to help reduce or discontinue oral corticosteroid therapy, begin corticosteroid taper after at least 1 week of ciclesonide inhalation therapy; reduce dose of oral corticosteroid gradually, with next decrease after 1-2 weeks depending on patient&rsquo;s response; do not decrease prednisone faster than 2.5 mg/day in adolescents and adults on a weekly basis; monitor patients for signs of asthma instability and adrenal insufficiency; decrease ciclesonide to lowest effective dose after prednisone reduction is complete.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gelfand EW, Georgitis JW, Noonan M, et al, \"Once-Daily Ciclesonide in Children: Efficacy and Safety in Asthma,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2006, 148(3):377-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/26/22949/abstract-text/16615971/pubmed\" id=\"16615971\" target=\"_blank\">",
"        16615971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pedersen S, Engelst&auml;tter R, Weber HJ, et al, &ldquo;Efficacy and Safety of Ciclesonide Once Daily and Fluticasone Propionate Twice Daily in Children With Asthma,&rdquo;",
"      <i>",
"       Pulm Pharmacol Ther",
"      </i>",
"      , 2009, 22(3):214-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/26/22949/abstract-text/19141327/pubmed\" id=\"19141327\" target=\"_blank\">",
"        19141327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pedersen S, Potter P, Dachev S, et al, \"Efficacy and Safety of Three Ciclesonide Doses vs Placebo in Children With Asthma: The RAINBOW Study,\"",
"      <i>",
"       Respir Med",
"      </i>",
"      , 2010, 104(11):1618-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/26/22949/abstract-text/20619624/pubmed\" id=\"20619624\" target=\"_blank\">",
"        20619624",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skoner DP, Maspero J, Banerji D, et al, \"Assessment of the Long-Term Safety of Inhaled Ciclesonide on Growth in Children With Asthma,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(1):1-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/26/22949/abstract-text/18070931/pubmed\" id=\"18070931\" target=\"_blank\">",
"        18070931",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Berg A, Engelst&auml;tter R, Minic P, et al, \"Comparison of the Efficacy and Safety of Ciclesonide 160 microg Once Daily vs Budesonide 400 microg Once Daily in Children With Asthma,\"",
"      <i>",
"       Pediatr Allergy Immunol",
"      </i>",
"      , 2007, 18(5):391-400.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/26/22949/abstract-text/17617808/pubmed\" id=\"17617808\" target=\"_blank\">",
"        17617808",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16757 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-92133E1D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22949=[""].join("\n");
var outline_f22_26_22949=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002707\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002711\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162661\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162669\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002812\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002712\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162670\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162666\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162662\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002730\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162663\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13134558\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162664\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002758\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002759\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002714\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002715\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162671\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162667\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13134561\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162668\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162672\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162673\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16757\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16757|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/25/35220?source=related_link\">",
"      Ciclesonide (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/37/27221?source=related_link\">",
"      Ciclesonide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/33/3604?source=related_link\">",
"      Ciclesonide (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/5/34902?source=related_link\">",
"      Ciclesonide (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/34/35365?source=related_link\">",
"      Ciclesonide (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_26_22950="WATCHMAN device";
var content_f22_26_22950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    WATCHMAN implant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 375px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF3AkoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6P8T6+NBXTlXTr7UrnULr7JBb2ZiDs4iklJJldFACxP8AxelZ/wDwlGr/APQieJP+/wDp3/yVR4y/5GPwJ/2GpP8A03XlZLHUtQ1nxjcXHi7VdI07SLxYUitYbQxxxCyt5mYmSB2J3SuevTHFAGt/wlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXFfC7xBH8SdMvLzQfHHjCEWkwhlhu7XTEkGVyrYW3YbTzjn+E8V3/wAPdQutX8A+GtS1CXzr280y2uJ5NoXfI8SsxwAAMkngACgCr/wlGr/9CJ4k/wC/+nf/ACVR/wAJRq//AEIniT/v/p3/AMlV1VFAHK/8JRq//QieJP8Av/p3/wAlUf8ACUav/wBCJ4k/7/6d/wDJVdVRQByv/CUav/0IniT/AL/6d/8AJVH/AAlGr/8AQieJP+/+nf8AyVXVUUAcr/wlGr/9CJ4k/wC/+nf/ACVR/wAJRq//AEIniT/v/p3/AMlV1VFAHK/8JRq//QieJP8Av/p3/wAlUf8ACUav/wBCJ4k/7/6d/wDJVdVRQByv/CUav/0IniT/AL/6d/8AJVH/AAlGr/8AQieJP+/+nf8AyVXVUUAcr/wlGr/9CJ4k/wC/+nf/ACVR/wAJRq//AEIniT/v/p3/AMlV1VFAHK/8JRq//QieJP8Av/p3/wAlUf8ACUav/wBCJ4k/7/6d/wDJVdVRQByv/CUav/0IniT/AL/6d/8AJVH/AAlGr/8AQieJP+/+nf8AyVXVUUAcr/wlGr/9CJ4k/wC/+nf/ACVR/wAJRq//AEIniT/v/p3/AMlV1VFAHK/8JRq//QieJP8Av/p3/wAlUf8ACUav/wBCJ4k/7/6d/wDJVdVRQByv/CUav/0IniT/AL/6d/8AJVH/AAlGr/8AQieJP+/+nf8AyVXVUUAcr/wlGr/9CJ4k/wC/+nf/ACVR/wAJRq//AEIniT/v/p3/AMlV1VFAHK/8JRq//QieJP8Av/p3/wAlUf8ACUav/wBCJ4k/7/6d/wDJVdVRQByv/CUav/0IniT/AL/6d/8AJVH/AAlGr/8AQieJP+/+nf8AyVXVUUAcr/wlGr/9CJ4k/wC/+nf/ACVR/wAJRq//AEIniT/v/p3/AMlV1VFAHK2/i64/tfTLDUvDGt6Z/aMzW8E9y9o8fmLFJLg+VO7DKxPztxmpdW8Uy2evzaRYeH9X1a5gtYruVrNrZUjSV5VQEzTRkkmF+gPb1qLxl/yMfgT/ALDUn/puvKNN/wCSp+If+wLpn/o+/oAP+Eo1f/oRPEn/AH/07/5Ko/4SjV/+hE8Sf9/9O/8AkqvOY/EeqWnh/wABy6h4m8Y32seKbOOaG30220oKJPJSRxmWFQo+fjLHpWhpOvXmqeFNP8TaL4t8STQHWLOxls9StbBQQ97FBKjeXAD912wVfrjmgDtv+Eo1f/oRPEn/AH/07/5Ko/4SjV/+hE8Sf9/9O/8AkquqooA5X/hKNX/6ETxJ/wB/9O/+SqP+Eo1f/oRPEn/f/Tv/AJKrqqKAOV/4SjV/+hE8Sf8Af/Tv/kqj/hKNX/6ETxJ/3/07/wCSq6qigDlf+Eo1f/oRPEn/AH/07/5Ko/4SjV/+hE8Sf9/9O/8AkquqooA5X/hKNX/6ETxJ/wB/9O/+SqP+Eo1f/oRPEn/f/Tv/AJKrqqKAOV/4SjV/+hE8Sf8Af/Tv/kqj/hKNX/6ETxJ/3/07/wCSq6qigDlf+Eo1f/oRPEn/AH/07/5Ko/4SjV/+hE8Sf9/9O/8Akqup3DdjvjNKaAOV/wCEo1f/AKETxJ/3/wBO/wDkqj/hKNX/AOhE8Sf9/wDTv/kqulEwKseynFQTXSiNsMM9BTs9ylBswf8AhKNX/wChE8Sf9/8ATv8A5Ko/4SjV/wDoRPEn/f8A07/5KrqhwMUUiTlf+Eo1f/oRPEn/AH/07/5Ko/4SjV/+hE8Sf9/9O/8AkquqoyKAOV/4SjV/+hE8Sf8Af/Tv/kqj/hKNX/6ETxJ/3/07/wCSq6qigDlf+Eo1f/oRPEn/AH/07/5Ko/4SjV/+hE8Sf9/9O/8AkquqooA5X/hKNX/6ETxJ/wB/9O/+SqP+Eo1f/oRPEn/f/Tv/AJKrqqKAOV/4SjV/+hE8Sf8Af/Tv/kqj/hKNX/6ETxJ/3/07/wCSq6qigDlf+Eo1f/oRPEn/AH/07/5Ko/4SjV/+hE8Sf9/9O/8AkquqooA5X/hKNX/6ETxJ/wB/9O/+SqP+Eo1f/oRPEn/f/Tv/AJKrqqKAOa0nxTLea/DpF/4f1fSbme1lu4mvGtmSRIniVwDDNIQQZk6gd/SulrldS/5Kn4e/7Aup/wDo+wrqqAOV8Zf8jH4E/wCw1J/6bryuP8UaDrPijRfibofh24tLW7v9YhgkmuWZVWE2Fl5mNqkklcjHuea7Dxl/yMfgT/sNSf8ApuvKtap4K8K6vfy32q+GtEvr2XHmXFzYRSyPgADLMpJwAB9AKAOK8CfDLUPA/wAQpdS0rVFu/D93pkVndRXWxJxLCAsTKsUaoVCALzzySc11fwn/AOSWeDf+wLZf+iEo/wCFceB/+hN8N/8Agrg/+JrpbS2gs7SG1s4YoLaFFjiiiQKkaAYCqBwAAAABQBLRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByvjL/kY/An/Yak/9N15Rpv8AyVPxD/2BdM/9H39HjL/kY/An/Yak/wDTdeUab/yVPxD/ANgXTP8A0ff0AeaN4Gv/ABb4J+EF/Z2ejaha6PpkMtzY6pIyR3Ae2iAHEUg4IzyvpWnp3hK/8HfDs2Wp3Nu73HijT7uK2tWZoLKN9RttsERYAlVx6Dr09e4/4Vx4H/6E3w3/AOCuD/4mpbTwD4Os7qG6s/Cfh+C5gdZIpYtOhR43U5DKwXIIIBBFAHS0UUUAFFFFABRRQCDQAUUmRVa5uRGDzj8KaTeiGlcskgdaWsM343ceuOlaVhL5sbn0bH6Vc6birspwsrliQbkYA4JHBrJt9R82Bjk7l5Ix74NbFcKLkW3iC9t2+55xGP8AZbn+tOjHmdjpwlFVVJdVqaQ1cR6hbBmGDIEb6Nx/PFdMxCqWJwAMmvH/ABfO9pPJGp+ZeVI49wf5V6NcatHL4Ok1RWG2SzMoPuV6fmadWnyteZ2Y3A8kaU4bS0KNlfM2mzSHJ+UH6ZOay4tVEmo2cDH/AFk6L+tU4JjB4cY56lY2+gFcnaaokfiPTZHPyLdRZJ9NwH9a7XQ9x/10PToYBTVRpbX/ACPdqbI6xozuQqqMkntQ7rGjO7BUUZLMcAD1rirvWX167eLTmAsIDlpG4D+/09PzrzoQc9j5zD4aVdtrZbs6UX3nN8gO3sO59z6Ur38aAqDuPcjpXKzaksaukZCW6nt1b3J703SUutanZbY+VbIcSTkdD/dUdz/KtpUuVXZ3fUVGPPLRI623vlkk2DLMew5NaAqtY2cNlD5cC4HVmJyzH1J71ZrnPMqOLfu7BRRRQQFFFFABRRRQAUUUUAFFFFAHK6l/yVPw9/2BdT/9H2FdVXK6l/yVPw9/2BdT/wDR9hXVUAcr4y/5GPwJ/wBhqT/03XldVXK+Mv8AkY/An/Yak/8ATdeV1VABRRRQAUUUUAFFFFABRRUc08UIzLIifU4oAkorMuNbsoQcu74/uITVJvE9u2RDG2f9s7f0pXFzI6CiudfWLl87BGo9hmom1C9JOZsZ9hRcXMjp6K5n7Zdkc3Dfhihp7l1w1xJg9aLhzHQT3MMC5lkVfx5rNh8SaXLeG1+07JuyupXP41kPH8+Dx6msHWrAf2hb3MS4lX+L6UrkubR6YrKy5Uhh6g0tchZSOoDROyf7v+fary3t4cDzT9doouUpHQ0Vzf2q8BGbhufYU9b+9AH7wHp1QU7hzI6GiuYvNems4GkmePGOPl5P05rKstU1/UJDLJKtnbZ+RQilj9aLhzo7yiucg1O8gP71lmX3UA/mK1bXU4J+GPlv6N/jRcaki9RQCCMjkUUxhRRRQAUUUUAFFFFABRRRQByvjL/kY/An/Yak/wDTdeUab/yVPxD/ANgXTP8A0ff0eMv+Rj8Cf9hqT/03XlGm/wDJU/EP/YF0z/0ff0AdVRRRQAUUUUAFFFFABVGa5CvIo6g4/QVerjru+X7bcqG6SN298f0rSnHmlYuEeY6OCXfJgjqDWJq1z5ZcEnjParekyh/NxguEJWuZ16cIrFiT1zXbh6V6li7ash+3HzvbPauy8My+bZTN6TEfoK8gS/JvAA3f/Oa9S8BPv0mc4x/pDD9BWmYQ5Yo2lG1G50teWeJ5fK8YX47Hyyf++RXqdeNX0v8AaniK+nVlVHmbDucAIvGT+VcWH+K535HC9Scnsl+q/wAij4k3XIRlBZz1J9PeqFpresRaM2ivNAdNJwF8slwN27AbPTPtWtMAwwuSvbI/pVI2RYhtuK9CMFN6o+spOn7NQmk0tVfoyea+LWojz1/KuW1K3kbLRE4HOPeula0bAwO1VJ7fHJFbT5mzahOFP4SnFq+u3lgtlqOq3NxaA5MUhBLezN1I9icV0UeqiDTYrdQEjX5j6ux7n29q5uUCNsgYx696wtS1QqGLdB0HrWSSj0HLDQq6Rikr30VtTsDqLXt3BbiYR+dIke89F3EDP4V7np9nBYWcNraoEhiXao/qfevju715ckEnafTjNex/Cf4ofaGttH8RzAtJiO1vWIG49o5PfsG79Dz148SpS1PIz7LKs6MZ0dVHdfr8j2qigUVxHxAUUUUAFFFFABRRRQAUUUUAFFFFAHK6l/yVPw9/2BdT/wDR9hXVVyupf8lT8Pf9gXU//R9hXVUAcr4y/wCRj8Cf9hqT/wBN15XVVyvjL/kY/An/AGGpP/TdeV1VABRRRQAUUVUvL+C14dsydkHWgC3VK71O3t8gN5j/AN1Oaxb3UpbnIz5cf91SOfqazGuYEIDzID6FlHapbIczVuNUuZjhW8pfRev51XSHc2XDEnknGarQ3cEgzFNGRnGQwPNXQ7tGACNv0HPGaRN7iNEu3JQgHnJx/nvVaezR8lQD3wcVfAmYlSTk844yf84/SkYMdxZiQTyeME8Yz+lILGXFbLlthKsMnbUpEi5yc/gKlv4iimZDgjkjjIHr9MetTRbJ4RMrDb/e3DA9j78dBTFYolyPYj6Y/wA/4VNFcc4Jwfw5q4YAWC7Tn8Mnp+A71WubWPy94bH+0CMfh69aQ7MUsGOSOTzxiq18paL5R1PcD17UiSMjYfj64qa4GbcFRknHUj16UxbkluVMKHBXIBxx/nt+tTA5AA6d8Af59aZCG+zxDIAI+85Ayc9vUU+V1tiDLlCegOMmgaJFUA5YZz1PB/z3pk0qgZbAzz0H+e9MEk0p+RCPduT+X41E0P7tpnyyrkluMD6e/t70DKFzbrd3KudxVexx1q+vG1B1PACgU3Sk86PzXXaCcDOOuOnvWmIxFgAHHGQcdPp+fX0pCSvqUxEx7YHvg0yWKMLyRnuMD0q/5ZkGOgzg4wfoeP6elRyLBHGdzLnHQEZ6Z/DtxRcdimkskP8AqXkX/dNTLqd2h++x/wB5QapPeFcrFC0nvwBUDW+o3LZknWEf3IgP1J+tMm7N2DW3BxNEGHqvBrVtr2C44jcbv7p4NcYNCDHL3Vy7e8nA7dvYU1tNuYiXgvpV7gMFYetFylJnfUVyFtrWo2LbbuH7XEP4kIDD8K6DTtVtL/iCXEo6xv8AKw/CqTKUky/RRRTKCiiigDlfGX/Ix+BP+w1J/wCm68o03/kqfiH/ALAumf8Ao+/o8Zf8jH4E/wCw1J/6bryjTf8AkqfiH/sC6Z/6Pv6AOqooooAKKKKACiiigANeYSTgzu5AJZmOTjuc16VeP5VpNJ/cRm/IV49I7NsG7HAY8j0rqwsbyZ0UVozuNAkLXERBxk47VyvimcJ5pzwCf51vaBP9nUSnLhFJ7cntXG+LJT5T/jxxya9TDQ/etluOrZy1q+6+GD8pOa9p+GpLaDM3rdSf0rwnTpP9MXr1Ne7fDNceF1b+/PKf/Hsf0qc1VooqpK9E1vFV+dO0C8uFP7wJsj/3m4H868jtYwoVcdBXafE69zJZaep45nfn04X+tcpZx7mXFcOGhp6n0GUUvZYXne8vy6F6yszKVGCSa3fsdrZIvnKXlIzgAcUlqBZWIk/5bP0PoKw9T1LZuJYk9zmvRinLRaIfv4idovQ0Z76CPiGCJOepAJzWBqVzE7EtsDHsqgVgalrRU4zXNX2uNzl8CtYuET0qGBlHVGrq06ICVxXAa7dOCwQtj68GrF7rTMSd3sATzXNajeeazEt3qaii1dHp0U6fxGfdT9zn2zT7DVDGCkhzG3BWqVy2c81ktNsfnG3pivJlW5ZHNXxTpzufanwM8cHxLoz6bqExk1OwRf3jfemh6Bz/ALQPB/A969Qr4S+Gfi+bwv4p07VFcmKB9syf34W4cfXHI9wK+6YJY54Y5YXDxOoZWHQg8g1z1Er80dmfGZzho0q3tKa92Wvo+pJRRRWZ5AUUUUAFFFFABRTWYKMscClU5GcY+tAC0UUUAcrqX/JU/D3/AGBdT/8AR9hXVVyupf8AJU/D3/YF1P8A9H2FdVQByvjL/kY/An/Yak/9N15XVVyvjL/kY/An/Yak/wDTdeV1VABRmo7ieK3haWd1jjQZZmOAK5DUtXu9WzFYlrWzJ5lPDyL3x6D9aTdhN2NDW/EcFoTHFKu7+8CCfwH9a5r7VfXzJ9jhA8zkySnJH4VdsNItLdy7KGmbq74YjrxWoCMEAjaccE9uePoP1qbmestznTolzLA7ajqDyFsERxrtGPrV618Pafgs9ukhK4+bHTHU/ma0ppP3ZAJ+bGSMc/5x0qSK4CRqCQcc8nr9fWkFkZz+G9LYR7IBEUGEKNtJ4PQelOj0+ayLtFcmZD94OQSvTA3dfTpVxr0YIHfrjr0/lTGuXYjaG46YwMUw0CKZiCCnzY5UN7dfXuamE+DynzDPJwdvXgCqjNIzEgHcM8A5NIhaQZVgR06ilYLl5po3RkZm2nIxkEsOOpP0qlpheFpYnZUUsWEhfOM+gx6U/Y464B6jdge/+fwqKXKFdxOG4zTBs0zswQfmDH7oIYv15PQiorsN5UwZh5gU5BOBGODxmq6ws54wT6A8nnt6/wD1qaysJEjDkhs5PUAeuP8APakO5E0atGzEhEABA43Ma82+Mnj8+DdEs4LKSOHU9RmEKTyYYWsefnlK9zjoD65r0mdPKkCvIUGMMcgsPTj/ADzXm3xT8A2XjeziiuHKXEBYxSx8bSev1HSmiXpueAfES48L63rD3sfi7U1nfBMckbXKJ/usCMDvitPwP8T7TwDaL/Z2ralrjmVDLbXSFIvL6MEySVbB6+3SmX3wA12J1Fre2sy45JOMVs+GvgDOt0kusXgEakELGRzQO6tufT+kaxZapYWl/ZzeZa3cazI/TKsMjOOc9fxqW9uPOiMcZYkkZY4AwOcfnisjw/pw07S7S0tX2wwII0XaAAB0Aq7KzpKkbOSf9kDAPSlYLuxdtJfJhijijJYAEtu5LZ5I/wA9qmM05z5aqFHJGc/w9z/nrVcLMjAbxwfbJ5pBcSgcxqMYIA6DjPA/OgLlkrI3MkyA88jGB9D+PaoLmNUVgjNI5zjkAZ/z60C6QsflYDHHzDJPbJ/zxTA7Eltvy44wR6UAx9vGu796T/wHFWtqhc+YM/UY6Z69+aqbn3HCn0+9196glmlBwiBm9N3P8uKYI1McEAhl5GSQPQcZ/Go2KkE7vXjI/oPYVjzS6ictFBGVGcnf9Paqx1a+gR3u7GdUH3dnz5HfkdMUrBzG86Ek5+b/AD/iaoXVoj8nIYHKsDhl989qZa63azyBBIgmIztyCR9aumVG64H0xQLRkumaxNbMIr9zLF0Ev8S/72Ov1610qOroGRgysMgg5BFcjOqvyh5+o9TWj4duWVzascrgsnt6iqTLi+hv0UUVRZyvjL/kY/An/Yak/wDTdeUab/yVPxD/ANgXTP8A0ff0eMv+Rj8Cf9hqT/03XlGm/wDJU/EP/YF0z/0ff0AdVRRQaACioJpzCCZEO0d15/Sqv9s6er7JbqOJ/SQ7P50k7lKEnqkaNFRwzRTpuhlSRfVGBFSUyTN8ST/Z9Bv5PSFh+Yx/WvG55M3uwHgDB6dq9U8eT+T4dkXOPNkSP9c/0rxp7gNfTANj94VxnsK9PL4Xuz0MNS5qfN5nommBmsZWX7qJuY5HSuI8ZTYSQL7/AIV2umOP+EfvCCcrs5zXmnjK4YyMB0B7Hp7V6eGjeb9QSvcwtGnLXiAnnJ78V9C/DNceCdNP94O35yNXzjo0gN4GwF6kj8a+i/B1wth8OrC5kOFitDKc/iaxzhe6l5mUk5QUV1aOJ8U3f23xDfyggqsnkIc8YXj+eaTTV+f2rnLq7YGJWO12y7AnuTz/ADNdHofzxszdFQueaww8LK59lUgqFFQ7Kxe1nURsAU7VVQoGRXDatqHByf1q/rt9tOM8+ma4bW77huf8/wCFbVHy+6juwGFUI3M/VtSwWw+PxrlbzUGb+PIqPU7guxJ+mM1h3M5HeuWpU5Dtq1VSRemvC3JY/nVaS4z1P4Vky3gBwSarvejnB5+tcizBJ2Z5VXGLuaFxMDkD+dYt3IA5POKSa9+bGapXUu70/GuStJTndbHi4vGqcfM0dNvNsoGQR/Svuf8AZ715tc+GWniZ99xYM1lIScnCY2f+OFa+AIJdrBgef5V9Vfsga7/xMda0eRwVuIEu4xn+JDtbH4Mv5VcbuLR5tWr9YwrT3jqfT9FAoqTyAooyKyL7XbS3ysTCeTphDwD7mmk3sXCnKo7RVzXqo97GW2w4kbuQflH41zc+qy3H+ukCp/cU4X/69S217H3fp/CK09kzqWEcVeR0UXzHc53N+g+lTkgDJrLtrtXx0x25rQSRWA5H51ly2ZzVIOL1JRRRRQZnK6l/yVPw9/2BdT/9H2FdVXK6l/yVPw9/2BdT/wDR9hXVUAcr4y/5GPwJ/wBhqT/03XldVXK+Mv8AkY/An/Yak/8ATdeV0t05jtpHBAIU4zQBzOtT/b7vYW/0eI/KoP3m9T/Sq6HaAEyMY5z0qVo8HJ3cD1FNC46H9agye4KTnk5J6nNO3EAd/wAaVQMdeP5VU1TUrTS7Zp7uQBVxlQeSTwAP/rUgJ3duMnA4HJrE1HxBZ20jQxF7m4UgFIhkZPHUe9UXXVvEp8lS2nWEuFHmIQ8gI5x6Y9a6TS9KtNESFLKM+Qw2OVPLORy2SPu+tAtXsZVnZa9qYMt06WFqy4WOLDknGDz1q+vhlQC1zd3UsmM7DKeOM57Y7V0O5S+c/Mv8XGEHPA96QkbcZYDGdpJyeBy3tRcrkRjppsluQVnlZVOOXIC9uD3706Lck7LG7jePmH17Y/rWq7FQWLdAcEdcYPQdh71TuV3DcFwRkg557Dr+HegGuwjiVdwMgPJB49//AK1QTF3Qo5DAnnjmpEkDA78ggYIJ+lV7zUrazX95KqFuAN3J4P40xMljlmlBCSBcegx7daLeMs8hkd8A7ODjcO/P4VTjuTOS8UbKrE+wPPpVuJjtxx0Pf2oEtR0sKAZUAv1znP8AP6iqtwN7LjgAYxnpV0jGSx79j/tCqoGXJJ+Ue/fnigbKywqMke3ekMYyM8DjvVoLiBmPp6+9QswXZuPfFBJZtjtGO2PX60QIWuzJn2HsDxSRtnGDn6GrUAwAMEdO/wBKBodknBGOgP6A/wBP609UBcDqc9M5zye3fr1NAUAdecY/Q/5x+dEkgRSxIJPTLdTwfx/lSLK97KqoOVDEgHJBIGOufwo2AOEByw64/nj8aj2mSTewBI4ABxgGq1yl3BHK6fvAykbi/U4HJ9cYoJLrZJPztnGGOe/+RUkW5eFCMM9P/wBX1rMttThkhKs+yRcfK7fMST2HStldpTOeMZBdvYdhQNaiNMQMSqVHODkHtjp+FSgpI25WGc9T8x6+nSo3YoCArsOeVXHr60YVuQQCTn7xLdR2oGZ1/pFrchnkiEcuCPMRgrcj0FY0lrqWllBbsLu0X7+7O8c+vrXV5KKeCoweeFzxQ2x5CysFbP3tzMeoouS4o5/T9UhvlbyZGDpwyONrL68VdinaGdJUPzqc9etVdW0KO8CSIskUqHcrxgqayk1Sewn8nWQscJO1LkHCtzwGH8J/SgnVbnqFvMs8KSoflYZqSsHw1dAq1ux/205/Ot6rTujZO5yvjL/kY/An/Yak/wDTdeUab/yVPxD/ANgXTP8A0ff0eMv+Rj8Cf9hqT/03XlGm/wDJU/EP/YF0z/0ff0xnVUyVmUZVC49AeafRSYIyNS1WGCL94roT/DIhX9elc5qF3Y3UbCVBt9Vbrx27V3LAMCGAIPUGsjUPDel32TJarG5/jhJjP6U4Plep20K1KGkk/wCvuPN7zTLHeDZXUsUx5BUbP1U5/Gs2fWfEemlha6tdfL08xhKv/jwNdZrfgT7OrT2Wt+QOy3uCo/4EMH+decT6k0FzdWs0scyxMVM0T7o2xxlW7ivUoctTTc7ounVXuu/qiaHxxruua9baJqs1rNBHG900iQ7Gyo2qODjq3pWJDdmW5chjhpXIP/AjVPwjKs/i/W7tv9XaWoTOeOSW/pVHRbvLwknO87uSTyea9WjRjGbUF2OmVNU6SR7bpkhbwbc7Th45lMvqVIwP1ryzxddFbhh1HT616JaT+V4PduVa6n2jnqqDJ/U15Z4rlRpW3c8/lWuFh78vU82mvdkzP0OTN1IobkEcfjU3gjxp4o1jxLLolzq0h0C0SQfZhGgBQHCqSBnv69qz9BI852APHPWrXwotIzqer3K5G6GMlj3LEsavHKKjK6voduV0VUqLm6O/3HR6pqEUmsyoACI8J9D3/nXZ6BP/AMSTUJFPCxr83tXkIuTNdySB8b5GbIOep7/pXo8c7L4BhELYaS4ZJOcEkdB9OlefTVonu4zVxh3aMrWbhZVYlh7YPSvPtbn2ghm+hFbur3MkUZEq7R6k81xF5ctczMx+ZV5wayk+aR7lJ8kDI1a9jtIGnuScE4AHVj6AVyxv72+mC2dqpzwB94/nV6e3l17xGlpEf3aHZnsAPvNXqmh+HILW3EVrEqoBwe59z71108sp1lz4h2j+LPicfmeIxVaUMO7RWnqeXJoes3KZGnOSAciMgn/vnOfyrnr+Oa2kaOeKWF/SRSp/I19Hx6MY0DBTnOeuaW609riExXcMVxGf4ZkDge2DWNXJcLJ/uJNeuv8AkeZXrYi1qup8xGQk8nPvQ7k8Z4r32/8AAnh68+aTS1gfubaRk/TkfpWPL8LNEkbMd1qMY9NyN/7LXJPJa8fhaZx88meMLnt2r1n9nLWzovxS0GSV9sdxMbRs9MSKVH/jxWtWz+FOiI2ZJ9RuAP4dyp/IV1Gj/DzQ7KeOe00+UTRkOkjXDkqwOQRyOQaKeV1k/etY3o+7ufWl3d29lAZryeK3hHV5XCqPxNcle/EDTsFdKjlvj2lwY4v++iMn8Aa81i02e6lL3bSTyFtxeeQyNn1BbOD9K6S10gxpvmIjHUtK2P8A69VHLoU/4juSo047u5YvNZ1DVHxcynyieIovlUexHVvxpXD2qg3AMK+jcE+wFVb/AFOz02HFoxeY8NKwwB/uj+tcJrXipfNceYXYdec/rXVTwl9lodUKspe7FWR2NzrCKzbSQOcZPbNVIfEI3hUbzHzjCmuFsm1LX7tLa1jkkdxkRxAsxHqR2+pwK9h8FfDsWQS51vaZBgi2Q5H/AANu/wBBx9axxXs6Ks9zWUo09Zs0vDwv9RhWRVKRdm6D8+/4V1lratEmGkz67RirKKEUKoCqBgADAAp1eJJ3dzgq4h1NlZCAYpaKKRznK6l/yVPw9/2BdT/9H2FdVXK6l/yVPw9/2BdT/wDR9hXVUAcr4y/5GPwJ/wBhqT/03XldDqH/AB6P+H8657xl/wAjH4E/7DUn/puvK6O+GbV+cdP50nsBzzgbTyvX0P8AOmqvGSfpk8VYcNtOd/Xrn+lc34q1d9Phit7JFmv7k7IYy20EnjJ/HFQZvQi8Ra+bJ4rOygkub+YApFGCTjkbj6D+dQ6P4XNzcrqPiJkvLgf6uHy2CRnGdoHqCOTVrwpoC6YrXd0zyavcf62ZpCSo6lQPQHOMV0x6DGBkfKSTjbyN3Pc5oJSvqyuVDahGCT+7JygJ4JH3RVuRQ0RVyBldrEZO35ei89aq2jEXVwwBRAE+bqQPT61YB4UoO20AZ9Og9/ekWhkMpRzC74ZDhCT1HPPu1Shj0Vu/POTn5fzPtUciHOYyBKpwhA6HPIHr7mkt5fNQbeCPlCgnI6dP8aYyQjGSSC31zg4/U012Pzc4OT3+v+c04429OgIyCfQ8D29TUF3KsUMsjk+WiljgHsCaBMwPEur2+iWbySEmUnbBEv3pG44H07+lY/h3Sbm5capr+TLJwseCAg7EetQ6Fbv4r8RXGp3pb7DbNst4iD8ucfKoPX1JrvJJpol2vAzELhdp4TjHSgztfUqx+WZHEGVKn5AeSc/yFSkxODhCSOCQTwfcmnRyQxRCP52bGC4Ukucg8HtSoZlYrDtXJ3bmPCc46HrQVYglzGQuP3h6IDyO4yO340XKrDbDzWCsWB5bkDPP0q5bWywqW3HJGdzZye/FVp0F7fpEiExoSCcnOCc5JouOwwfLYkEHuOePesbXElfSHe1DF1G8YzzjPb/Gt3UU2xeYrHDKEYHqT6/QVSs1821EDhmzhSpJBfPqcdKCWuhR8I3j3+lRSjmZPlkVWzg89+lb8Ts/MY3cdjyOnWuC+Hdw1re3tk+11hYM0aZVUGT/AJzXoPlCQb4nwxUZKkhAMdD6mmEdUM/fOcABexZjwOTUU0WwK0rlmOMLnnGO/oKsiWdBlkMm0gLIDkdewqBlaZwVQ7sAbSTk9eTSKJITGVWeTbsT5l67QO5PrT4A0haZxjAKqzcADHBFPjgIkBnfzpEOQBxGh45xUpIPOQ5H8RyEXr0pDsZeuaVHeRtKhaOf5jG2cNI3HXjjrWZo+pPa3P2C9BjlX5EIG8vgc811BOQ7hiqkHLnhm6cAdqwdY0lb0Tx7vKkLFoGIZmB7+4/CmJq2qNhxu+aQBc5w0rZPftQpPQF3X1X5R271znh3VnNxJp18vl3cILGabP7xcgZGe9dBu3jpJKAO5Kr2/wAKQ07jsqDyY1P4u3enbXJxiU8922DqKaJduQsgA/uxgk9+9IVJ5MbEZJzI5Pf/AOtQMjYbTgqg4zgymszVoILgNDPErxuMFd27JJPXNaU7LGpOYB7DJzzVGVcxpgxkk+/HPeglmFo1xceHtWht7t86YzBbeRjzEc48tj3z2P4V6kDkAjoa4HU9PivrOSGaMlCOCrE4PYj3rpvCl293oduZQRNFmGTPXK8fywaqO4Q7Gb4y/wCRj8Cf9hqT/wBN15Rpv/JU/EP/AGBdM/8AR9/R4y/5GPwJ/wBhqT/03XlGm/8AJU/EP/YF0z/0ff1ZodVTXfaucFvYDNONZ+rXJhhAVtpPvyaaV3YqEeeSSKmo6tcQAiKGNCO8pz+g/wAa4zWNR1G5yLnXHtYz2txtP/jvP61fvrLWL5z9nicq3QtwP1rJn+Hur3pzLewRLz95mdv0GK6acKcXeTPUVOhTVm1c5W5Xw/CDJd+fqdwejTyEL9TkkmuV8QapaqpS2ijiQD7qk7envzivTz8H2mH7/Wyp/wCmdvn+bVBcfA2zmyW16+BPBxCmP1r0aWJw8HrL8BKtSg7qX5nkfhSUQeEfFmpr8hlcwxnPooX+bVS0SVEuIgSBt9/auk8V6XD4c8CXGmWk7zxS6g0ayuMNIPMJJIH+7XGaIS10zE8dT616+G5anNNbNnq1k/Zr0PW5dV83RrSBcKsCMowT8xLZJ/kPwrgdf2zM5VsvngZ71tW8u6IKSeO1c/rEW1ywYnr061ULQnZHD7JxpbFLSmMdvdyZHyRknnpwam+EzlfD2tzL1zjPphCar6ejyafeKnEkriFOwLMQv8zXW6T4H1HwBp+qaZrE1rLNcRG5RrZ2ZQpUrg5A5yPSufMakUnFvVnXk75aiXe/4WPM9Omk3QbAWHc5r1SW9A8D6QEOWe4mLAdeMD+teHWdyxCYPHpXd2GpbLGLLsyqPlUtwvrj61w0p80D26kPa1IyXRkOtagSjZY4Pr3rl7WVWS5dzhUIGPXAJqz4mvy0jKcHvkVy0N27W88MaPJPKwWONeWdiCAAPWsJT5ZI1xWMjRtH1Oh+FVkZxeXzKCzOI1P6n+le6+FrCWSa3W2U+fuHlkHofWvOvBelNoujWllMF+0g7pdnI3HqM+3SvfvAsNvpekxXk22W7uV/dxA5Kr7+nPXvXsYqrKFCK622Piad6MbW1ZvXeg6R9mjOoQpFO6jMkOUye5C9OtYF74XsVQtbXgkz/CyEGtZpTvaWd90jcsef84rK1DU1iyA3I968ukqkX8TNI0ZNbmenha3lXme3iPpIxGf0qVfCdnGC019aKP8AZJYmsu711xkBu9Y1zr8pJ2tivRh7aW0rHJWoNPVnXx6Hp8Z4vICP9oEVZWHSrUEyXkJx0WPJNeY3fiCTndKB7VkXXiIITum9cZbvXQsHVqbyZyOKT1Z7GNUsISfIuDGfcdqqXN/bsSRcRuzZGQ/P45rxmXxNztD5Ht1pyeJs4JJH8qf1CUdTWDitj0rU7MXaNliAR1BrmZ/CmZNySZHXnmsi28SoTncB681q2PiaNyuZCuT/ABfyq3GcY2N41OV3ub+g32t6Cpj068aGItuKFFZSfcEZ/Wu80fx9d5CapZRv/wBNLclTj1Kn/GuM03U4bhAeCPXNb9jDay43q/8AvIcV4mKpQbbktTrjKlV0nG56HZeINOulBWYxk9pFKn/CtOOWOQZjdWHqpzXD2VpAACrSYPYrXQafaxZGNrfVSDXjzhFbMwr4anDWLZt5opiRqgwox+NPrI4DldS/5Kn4e/7Aup/+j7CuqrldS/5Kn4e/7Aup/wDo+wrqqAOV8Zf8jH4E/wCw1J/6bryulul3QOB1xXNeMv8AkY/An/Yak/8ATdeV1LDKke1DAwJwi9Svqeufz/pXHeH7f+0vE2p6tdRwFYmFtbsxLED+Ljtng8c8c11uruYtPnYGT5U/gHT/AOvWX4YtRaaVHGqLGWfcVTJPJzyayRm9zWUEbuSvITglcDv7+v50oOBkgYb5iMEbgPuj17Ug4UgDtk4yT19T9KD8vzcbSevOCQOAT1oGQWe52dmOWLnYQTnGOWP06VZbHfcMjjGeF547nJzUNlk267iwXPzBjyvcgY5PSrAZh0wDkHGDgntwPp3oGhoUjqh6gEZII6fKP61FKhRxIgz2dUP3gAOBiplCpxuK4+UHIXbjG49z2obaRyWVdvQZOFx2zjk4oCwzeGQMp4YZzz0wf0H61w3xC1GW9urbw7p5LXM5Ek7IMlEyeDz1PU+1dJrl+NGsLu8xuiwxCYyPMwdq/T2rA+HGmu7T+INRAfUb2UvEzAIQTw2Mdj/IUES10Or0Wwh0nTrayttoSFCEwciMcEk8d+amAjmu8LysRKbegkYnqfX61JK/lwuC5OB87B87jjpS2aPFEPNZfPYZkYHATkHIBoKt0HMEAZvlBx8zjovHQc9eKY6Os4dEywJITPTkfeqbsNuCeka7uo5+Y8U0lXDZJMY+82QTIcjigZVuLh8bYFkaQgZkOQAOhANTWdt9mhCuCzNjIAI34I6jkAVOqneFx83pg7Yxk9cHrTcjYW5VCOWOdznjimFhWGcqTxwrMueOSNo4rG0UboEZ9y4bEjEEEYbGOM4NbYDBl+UBuw5xGNx5PPWqc0JREkhjI2neFCEB+Bkn09aBNHAeG4hZ/EHU7OSMqksZaOFcgk5zk4P8xXepBLHlbdxImdzIwJVTz1PrivPtckW0+JumTRBik8cYlfGS+SQcZ+b+lekTSCKLLrtAICw5OT1HPegmK3I4pZHJEgRX43OCSF/3asRDZHgbgrdgcs/B/Smxp5QJch5/4nOdq9McdKUFQpYsVQ9X5DNwenXigtIdyTswpxzsXIA4HU96Q/N3WRgfcIvWhwFQBlIXnbEucngdSKSUjIDLubPEa8BeT17UgHZ3KzId52nLt90fKOlVrni5gmQsQrNvmYHFSn5xjiV8cDkIvygfj1qK8QzQyBT5kg5LEHanJJGOvagGYXijSTqFqLm3Li8tT50Uj5wSoyFx6UnhXWjrdo3noft8Hy3EbMQI364x1Fb0Z+0KrorSk8guCFHQdP8ACvPfGYPhrXbXxFHNC1tK4hu4pFIUlzwQw6H/ACaCHpqeheZuyrP/AMBhU/lmk2/MT5QUH+KRie9Qw3KywRyrKixSDcqw8kqehzSFfOf5EJUfxOTzQUAIlYOXjjHYAdeetRzNkqPMVueykVYPytgvCv0BqOQksB5qN+FAEZXAB2ke6k1f8J5Rr6MvuG9XHtkf/WqmFwR/AfUZwa0fDq4nvDjBO3P601uC3KPjL/kY/An/AGGpP/TdeUab/wAlT8Q/9gXTP/R9/R4y/wCRj8Cf9hqT/wBN15Rpv/JU/EP/AGBdM/8AR9/WhZ1VMWNFJIUA+ven1Wvb62sk33UyRjtk8n6DqaBxTk7RLNFc9ceJP3TSWWn3UyL1kkXykH4tz+lc/feK9Qwc3NpajqBGhkJ/E8fpVxpylsjtpZdXq7K39dld/geg1V1K7Sx066u5CAkETSEn0AJrx3WfFk8MTtNq9zIx/hSTYv8A47ivNNd1p9a13TdLinmYXdzGjjzGPy7gTnJ9BWscNLdnp08gnvUnZen/AAxofEyRxpGgwElZHLTsOc52j+rGuV0PTpTPufIzyf8ACvWPE3h/+1NVgubuQRWsERC8ZLEnJI9AMDk1knThIMaLaNOo484nC/8AfRwPyr6jCzjSpK7KxGI9pJ0oK5QtrR0TAPbPNYWvWs0KSSOjMP8AZBIIrt49M1SNQHtQ2OyODVe5uPs++G5jww6ow5xUKtFzumXOjOVK3U4DQ5FSzM8pJSK8ikc4PCiRCf0Br2H4sXtvc+J7Y29xDPBLpbgNE4YZEmO3+9XM2VvpN+JIAqRtNkFTwGzwR+XFecQ2X/CMeL5rGX5ZvKkjyRgSx5Uo4/DIPoVNc+YU+eSqLp+oZfy+2i27NX+d1Y8ztbpkYISMCuu02+RLHa4yOuCeBXn887RXc8YH3XZf1NasOorFbFpHwBXj4TEKK5ZndhsXG75nsaGqzm7lSOGEyzzOEjiQZZ2PQCu/8LeE4vD8AuL0rPrEq4Zl5WIHqkf9W7/TrV8D6TFoen/8JDrCY1C5XFpA3BijPQD0dhyT2X611Ph62uNW1CJS4Ms7YU5O0f4AV62Hof8AL2RhiK/tJe1l8vTu/Pt2XmbHhTQptVvgECjyxu+YkDA969K0+NLO3HTOO1Jplpa6VYta2eXkOBLOQRu9QPasnWdSWBCu4DFaSnKq7dDzFerK/Qk1TV9gIDD61yOo6tuBLPz7k1matq4O47stz0ya5W8v5JWOScHqM9v6V10MLfVhiK6guWBrX+tYdtpb6nNYs2oyyk7SQfYmmxWzOcFck8jByKwdY8S6ZpZaCAG/uwcFImwi+zN0/AZrrnWo4aPNLQ8uSlUepqD7TKxKiRCe46VnaksFpua+1CGDPZic/lXLXmu61qEbma6FladCkAKZ9Bu6morDSI7jEgV5XP8AE2c5ryavESvy0Y3f3Ho4XJq9d7W9d/uNSXXdHgGIzNdN22hsGi01/wAyZRFpikHgCacqCT3zirNn4fZgCIQPqK2Lfw4MhinI9RU082r1Pjsj1Vw9KGspmvpOiavfTxLPp9laQOfmnLySbR67VGTXoVr8Jdans0u9PudHvYm6CGeRM/gynB/Gud8LX9xo5WN1M1sOsTHGP909q9k8KaosQS6sH3wy/eTkbvYjsRWVbGYqHW69DjxWWcsbw0Z5zd+DPEeikTT6fcIg5aS3bzVA9wuT+lbPh/Up49qzKJAOGKk17pazx3MCyxHKt+ntVDU9A07UX8y4t1E//PaP5X/MdfxrgqY+VRWqI8qlWjB2qIwNInhnjXBIPoO1dNYoAAQcj2rnzoM9hJvhInhHdRhx9R3/AArd0p9ydckcV585am2JcXG8HdF9CT14PpTqKKR5xyupf8lT8Pf9gXU//R9hXVVyupf8lT8Pf9gXU/8A0fYV1VAHK+Mv+Rj8Cf8AYak/9N15XVVyvjL/AJGPwJ/2GpP/AE3XldVQBzfiSP8A0G46g9MgkED296oaRvitoRMqqrYOMnAHYH3rZ8RReZAygZLY7dKydPXzLCEFSrAbeeo561mQ9y9gkLkccAZBx17UkhYRs4PzbSGyCSPUn2pICWGzBJTGeCfz9KSVj5YAB6YGAfx+tADrUAQIQCMDgAEc+uakbCg56EnjBVTgfmTQgIiQEZyAEBGfyHamkMzYA+f+I4yfxNAxVDhcAbF+5uxtwMc570Es2W4Zup+UnB7DJ7c0hUNngk4PYsR9e1NbCsR5fPbcCSOMdKAPNPi9fXV9quieGtNW0nuL2TcyvPtbIORx1ORuPA/hr0DSEWytYrC3Ur5MZWKLb92PjDc/SvLtKSDV/j9qUmYC+mWxbAhIkWQAIN0nYhScKvrXrFzGFdHTZwDGCgJyB60iV3FuP3lxFbbGe3UkyL0bcDxjHuauuGw28t03M/HPHT9Ko2yoZ5Zs8YCqpU4BGOn1q4FC5UqpCnLARk7myf8AGgpDn3l9uWQsfmO4fIM9P1pvzFVIRsYxGpUHBwMml2HOGXj7znyjyOOKGjY/wAOy7f8AVnIXn9aBgUXkFWMat8xEfLncemKPmB52iXbnkMFjGOv1oVcEOqJwcRrtYZORShcRlSSUHLMGPJx05oAQbGBP3oyc5wC0h3UxkPPmrjIG9ihwF44GDUzLIXyUbeTlRsDCMZqPYoVcIu0EbF2spY8UCPH/AImyNpfi7wxdSSARG6jQboCyrl/lHtx68cV6pEd07OHIRSVMm3G4nPQH+VeWftEAw6XoM6QtNeC/CxA3HlljsJ4J4OMfdPFepaOsjaZZymL5pIUYRqcjJX7xFBKWpd2hCgZNoz8kWCpPI6kcUhDBs8GTbnJB2qMHjIpyAqzAEqxOHkGRjk9AfpUfGAqgqh4ChSrOcAHNBQYA3EHC/wAUzAnPToRSNwueY1bp13Oceo+velwS4IAaTqFxtCg/oe1PVCC5UkMBhpCvPHt0I4FADCAo2MnXkQoOSPfselJKmU2SfM2CqxrkAcAde3frUmAqHaNkR6tgkt2PuOhpcFQzMPKB5JIy57c+o5/SgZRgz5GyVWGwlFjBJyOxJ/Lmq2uWJv8AR7yzdo4RNGyLuj3gMeAWXuOO1WkUxTzBV8sH5gepwOgA9TxxSOxGRGpDENiQjkDHJHp34oJ6HGfDK8mk0B7KR7Yy2chjeaI5QrnAx6dDx2rslAYYVXl9yCBXGeHbZrLxlrMAtYlSU+apjzskPHzYzwQM5Hr9a7TbuOGLSEfwoMAc0hR2EIZeMQp7YJppXLf8sn+gPrU4hbqIUUf7VNeI87olb/dBFMZGBjIC/VCD+lanh9MRTt1BfAPrgVmHhcgkgfdJHIPpW9pUXlWESngkbj+PNOO40jA8Zf8AIx+BP+w1J/6bryjTf+Sp+If+wLpn/o+/o8Zf8jH4E/7DUn/puvKNN/5Kn4h/7Aumf+j7+tCjpbiRYoyzkge1cXrniCO0lZbRFSX1C7pG/GutvLMXfEkjKnonBP40WWm2VlzbW8aMerYyx/E81cJRjra52YarRo+9NOT7dDzV7PxNrsm9bWVUPSS5bYB9Aef0qWL4Z31zuOpayqZ5IgiLfhlj/SvS7i4htYjJcSxxRjqzsAP1rnr3xrpcBK23n3jj/niny/8AfRwKv203oj0qeZYyquXCwUV5K/4v/gGAnwh8PMF+2y6jdEdQ0+wH8FArC8UeCvCnhS/0e40zTFhvDM8vntLI7YVMY5J6lh2rS8TfEm707T5bqK1tbaJB1nYyMT2AAwM/jXL2GoazrZTUvETI126lYIViCC3jznBH94nBOenStqCm5py2O3DYfHymqmJm+Xtf/LQuXUR1K9afUP3i4AjtgMIoA7jufrxXMeJfiPoug3DWqmS/uo+DHakbIz6Fzxn2GcVzfxA8YvJ5mk6NMVj5W4uY+DJ/sKey+p7/AE6+ZmxJ7fpWeLxdW/LSV/66HvYfKvdvayZ6tYfGOzlnVbvR7mCInBeOYSEfgQM/nXoNpc6P4r0tZoHjvLboHXKyRN6eqn/PNfNkNkcjCkkV03hO/wBS8P6j9r07rjbLEw+WVf7pH9eorHD18Qnep/wTpqZSpRvTdmbvxL0TUfDjRXVtK8unyvtS5Xgo3XY47H0PQ/gRXE+KfEEupwaVeXUga8tZHtpHPVkdcqT+I5r6MiNh4x8LyxEZtL6MxyI3LQyDpn3VsEf/AF6+SvF8Fxpc9zY3SlLm3mKOD/eU17n1tzoyjLsfPVn7ODc1aUX+RzWqTbNQuSo5dt2frzXX/Crwyde1NtQ1Mf8AEosG3Pu+7JJjIX6DqfbjvXFwwT6pqcNtaoXuJ5FiRR/EScCvbfFaxeFfDOn+F7CQB3TMzjq4Jyx/4E36CvPwOHVatzHi4aDxFWU38Ce3fsinqWov4h1pplc/Z0YpEvTj19if5cV698PtMk0+zS6G0PKCkYYHOP4nH8hXnfw78FalqM0DrZXItnYbpmTYqjuRuxk179YeHbvy4w5gt4o1EcaLlyqjoM9z3PvXv4qtCCUE9DetUi3Z/wCZnaheJaWxGccV55r2rK5bls9cV6vdeFbOUH7Zc3MvqFOwfpWTN4O8OKwd9Limx3lLv/M1hSr01q7nLPFRgrR1PB7i7E0pzIAoOG5qSKJGQySMqxqCWcnAA69+w9a9rm0vw9CCsenaerDptgWuPs9I/wCEg8aQ28emEaPaSZkXyPluJB2IPGwenQn6V2PHJqyVjirYqNOPPJHhvifxNJqDPY6M7R2fR5E4eb6ei/zqro2gvtDSR/N1C4+6P8a+0l8E+E7pALzwhpuf7yWSq35gCqk3ws8GStm0gutObsIp2xn6PuFfNVpyrVHKtqeplWY4GlLnrxd/kz5bbwTql5qtlAlpI8LxiWMqpK89ye2K7vSvCkNjGsYAZlHJ969mf4cX9vamDSte8y3JP7qePaMfVD/SsefwjrOn5M1g0q/3rciT9OD+lOnGipOUXqz6mhmmDnd05q7+T/G33I4yLSI0/gUfhUp05QuQo46HFb5hCuEcFH/uupU/kaY8OBj+ldEY2Z1+2UjlriGJZjDuTzsbtmfmx64rS8MawdFvgJyTYyECQEfd/wBoVxOp2k0fxV0h1Ysbt3jYckBduPyrr9Ts9iE+n613UmppwkctWKqNxaPdtDuRE64YNBKAcjpnswro68e+FGtG6tJdJuGJnthvhz/FFnkf8BP6GtHxR8QdY8N+KIdNn0y2ubG6j821uA7IzAYDIRyCwP6EV4+KouM7I+RxOAqTrunDf7rnqFN2Lu3YG71rj7fxnIVX7TpUqMRkhJAf5gVqW3iixmYK8dzCe++I4H5ZrkcWtzkngMRT3j91n+RvUVXgvLe4UGKZGz71YpHI01ozldS/5Kn4e/7Aup/+j7CuqrldS/5Kn4e/7Aup/wDo+wrqqBHK+Mv+Rj8Cf9hqT/03XldVXK+Mv+Rj8Cf9hqT/ANN15XVUAUNWTdCpxn5gK5+1QQTzQnaFZt6jB5z1Oe1dTeJvt2H41zuoRMhSVFyykZ5x+dZvcmQ9snDAcg88YNE21gq4LDODxgf/AFqWMrgEYZfpwfeovKLhRtU4YMoPb3+tAi4ACvHsDx29z3prgYXptGOq8fgO4qTjGSPZeOB9BSBCWAUNu9hk/X2+lBRGqvsG7henIwPWlEbFCyh2UDJ2rtHT1NWY4Fj6hN47Y3npSakzJYXEjJu2xsR5rYHT0H8qBWPPfhRZTPc+ItQuLqWY3V3hPMhACbcj5PUEck98V31/ar9mcosh28HIwD2JrC8DW9xZS3ML5ktWjSdXXg7iMbTnpx2ro7woALdhtZ43bcSTg/40LYUVoV9A3GyWRo8ZJJEZypPTqea0wrAjPmcfMeRyeOKoaYyG0GQmFOclSM1dCrkhhFz8zcH8P50IqOw4qduGD/3j8/6UmGZujgscn5+gzRtXOSE5+ZvkowCPm8vLct8pHFAxSXJyBICeBwDgcc0w5wOCVXgBo85PrSgA/wDPMMR7jC0KBwEAyeFAfoPWgBm1Mtv8s85c4Kknnin4bd8u4N7NuCj6GlG7AI8wqOAOGyeeabtBz5m0gfeLLtLHmgDyP9o61nm8G2ptpYbeIXB8+Saz81RHsO4v3Ve24DPIHevS9CjWPRrCMOjBbaIM7JtwuwYANcX8bNPm1XQI4N97H5ciyj7JKEkBHQA9CD3zXa6JIJtGsZI4pEjaJDs7lsc5HbGOlLqQviZeK71RQh2fwoRuH1P50m0bSy4wPvOBuH0A696UAZYZG/o7j5ST2ApSPnXKjzByqtxsH170yyJoI9oAXah6KATu46nuO1NaEkjBVmXpkZjXHvU2MknJGeC54d/TBpMY+UKR3EajBP8AvDvQBCY2yxA3MAQZCOg9h371EecN0U9JGHqOdvp34q1tyR9x9vTtGpH8jS7N2SR5jd2cYX8vX3pWEZE/y3CygDDDl2GCT6kdvaiJNxMmwu5IGWGOB/8AXqfUkUyx7fnYEhn/AJKRSyW+xABJv/2UHbNBJxVvtHjW4mEM3lSDyWdB8hIAOR9e/wBK7DooDYiXpsVeawoLcR6m85cwbpmAHXsMqP51uqoUZ4jU9yMsaQogUVukMjepakwu7ChomPQkcU47TzumPvj3pGGYzhtyHjJHK0xgkXnzxx4ALMNwx6dTXSDjpWVo0W55J2A4+RTitWriupSOV8Zf8jH4E/7DUn/puvKNN/5Kn4h/7Aumf+j7+jxl/wAjH4E/7DUn/puvKNN/5Kn4h/7Aumf+j7+qGdPNIsSFmzgdgMmue1HU72YMtq0dnEOssnzN+A//AF10E4BibIyMVw2qy3d1O9vpNs08wOCQPlT6t0FXBK+p34GlGpLW2nfZfp95nXv2GKQzXbPey9TLdEn8l7VzXiDxZBaW5SJIVZvuxooUH09zXY2fw/ku5Fm12/djnd5NudvPux/oBXUab4d0XRVaWy0+3hZRuaUrufjuWPNbe1Udj2ZZhhKFlrUa+S/r0R866Taah4g1tb7WoJYbG1Ikt7eVCvmOejkHsOtX/G2qm2tvsFs5FxcLmRl4KIe2fU/yrqtc1Jd99q16x2fNMfZR91R+GBXjstzNqV7PdXH+tmcsQOi57fgMD8K6lpHzZ9NhU68lKSsl08yvFpaEklAB9M4q7BpUe7bsBH0rSsbRio3ZB+nFblrYg/w/pRGnc9adRQWph22jRKoIXJA9OlX4tNij5CjP0roY7DGeOaV7IA+9aOlocrxSvuUfCNyNJ19YM7bS+PluMcLJ/A39Pxrzb9o7QZE8Y2VxZQPI+rRY2RqWZpU+U4A7kba9Qm0C4vraSWENFBGQWuAudpByNo7n26etP+JeotBpenXmnos16ZVhjJHLGb5R/wCPbSQKyhBrR7M+Zz2vRqtxpSvO2q/rvt/w55n8BPhpMbufxFrEiQpaFoYYx8zCTGHJPQFRkfU+1esWWk6La6hLqL20JunIzcTAOwHQAFumPbFcr8QfFreC/D+naFo0MZldSDI64GAcs+B1LOT+teeaFLqGv6kkuqXk1xtPyoT8q/RelduGoWjo7I8Olg6s4qk9Et/U+kbXxJp0O3yZvtDEdIhu/M9Krar43mt1xb28a8dXJP8AKuV0m3W2tBtGMD0rG1q+2hwwIzyRQqcZS7noQwVKmtSbWvG+t3TMIr9oFx0iQJ+vJrkLm+1C8cebe3k8jMAA0zHJ596bdTK7MVX5STycdKW3kj0zS7jWryFpAn7q1hPHmyE4AH1OeewBNeguSlC9ilhqcU5NJJGD8QtbHhzSY9OtJSdUuk3SOGO6JDwT9TyB+fpXn9i8izqWdyjAEEsT7V6v4ZuPDdneNeeIrjSL3VpXLSu8X2g5PUAAMNo6Aeldp/Ynw98ZwN9nt7TTrmNeL7RxtWI/9NYDxj3wPqK8PFxqVZOT1OCnWTqe1e3bql6HOeEJJI40Md3co4HGyZl/ka7KbxL4wh8R6da6bq10tgLXfJ9ojWdZSWOeWBPAAGAa5HU/C+r+Cb6J77ZPp8xxDe25zFL9f7rY/hP4ZrrdI1Z3swkMp8luSBUwjGUbSR9xWhh8bTjVhFSj/X5dmegaf4vu02i8tLaZgMFoS0LZ+nIro7HxXauBummtz6Tx7lH/AAJf8K8zt5xkZANaUMoxnPQcVUqcZHz+JyfDS1UeX0/qx6i09jqsGLiC3vYsfejxIB/UVjXng3Sb0FtOuJLRx/CDvUf8Bbkfga4rIDb0JV+oZCVI/Ec1et/EupW5Akkju0Ha4XLfgwwR+tSsPOOsGcMctxNDXC1Pk/6s/wACG6+HcmnawNZ+xm+vI0Ko0D8DPGdh5zj0JrntQiADxyKVlX7yMpDD6g812OjfFfSZ/EJ0S8S6sL35innL5kLgc5DryOP7w/GuyvotI1u1U6hbQXMB+7KMMPwcdPzrSniZ0nacQWa4jDS5cXD5/wBafdY+dbTV5PD/AIgtNSiAKwSZkGPvRnhx+WfyFev+PvDkXi/w8kFtOkN3Ey3VjdEHar44zjnaynBx7HtXl3xk0jSfDWqWVvp9/Mz3KNKYZjkRrnAw/fJz8p5wKreFPivdaFoFlpd5p4vpEIgtW8xldlLfKm0AliMgDFa1orEJTh/kdleP1qEMVh3qu9l+Z2OheHvHdjEkFzquixwrxkmW4P4AgY/OuhaTVtIRZNSlt7y24DTRIR5fuynJA9waw7m+8SmEXOtzPYvL/q9O09R+5GePMlOWZvUDAHTmtHw34glnkiivtxE3EUjKA27GSjY4JxyD36dazWGnKHM2eb/aCqT5ZWfyX5nb+H9QtrxQAqE+3NdGqqv3RisjSVtLyLe1vCLiPhmVACfQ5FbCjAAHavMqLllY8nFNObsrHLal/wAlT8Pf9gXU/wD0fYV1VcrqX/JU/D3/AGBdT/8AR9hXVVBzHK+Mv+Rj8Cf9hqT/ANN15XVVyvjL/kY/An/Yak/9N15XVUAIwyCPWse4hWRGRgGHQ4HH5Vs1RuFzKw+Y/QDAqZAYtvvV2ikH3MbW45//AFUsUbG4jyNwyBg8YHqfWpLyLYwnVCWUc4AyRVm42uImC+m1Tjj05qSLE6oqg4GWPG7HJ9h/jTscYVflHUA4A47nuaUHcM9c8fLjn2Ht60cYGduO3HH/AAEd/rQWKoJGFyV9IwFX86o6tsNhKpCZddoVfmck+hq6+MZcA+8px+QFVLpWuLi3hXLRK3mOMBAAOhH40MTKtigs9ae2ZMLcQK67zwSnDfzq1rS7YI7kcNE+Q2Nqjd8v+FGsAw+TeRYzBJubaMkqeDkn86vfu54v4XRxgFjnI69KAt0Mzw0scVpJbQAIsTlisbZA3fMevqc1scnrvGeTyKw9OYWuoy2w3vAS37yTBwS2QuOvQ8ewrcwD1A56/J2/yKaCOwHJ4O/nk/MKU5Od28A8n5h0owMcgc8n5O1BX1HucJ+lAxOTn7/PJ6cD0ppBI+bIz1ygOB6U8gdGAI6n5f0pp2jO7aecntz2FACKq5GQgOOOCNopRnaMBsdFHDD60ozjB3HucEH8KQkDqVDY5OMYHpSA4zxdALu6itXI2OcnC43Ht/Xitzw7n+x7PzSu8RAFmH3V9m7modQWS51NQNypEAM8ELnpmrGg4SwSFQN0bspVCOTk8kHtjBpdSFuaQBAXgjj5QfmC+5poA2gAEqecDnf9Qe1HAAJAJJ7jaXI/pQ3zctkgnBOAd3sCO1MsTk8gj5eCQMquPQetLt42hSFOcLnJP49qcuScnaAvc4wv0PrRkYJG4A9ePnf8PSgBGUDgjcem3HC8fxeo96acvn+M46fwKMd/UUpB4UAn0jU9Px/pRjPy4346KnCj/PcUAZupYeaMH94UyAFH3ScDHuO1TalcPZ2UjrtEnREjXcSxOBx6ev0qLe0t9gq21chVixwMcEH0/rURAu9RSRWSKG1JwMBi0h7g+wpEkDWS2ljBsQRlSGaRhks3fAPbmrSqcblAGf45Opqa9TNuxxtP95yCx+gqOIF1DiIuf70mBSCwDexwkqE+mBzTJOeAmHPylcdeetSOBn99EFH95cetS6fCZbrc/ITj60wNO0iEFukY7Dn61NRRWq0KOV8Zf8jH4E/7DUn/AKbryjTf+Sp+If8AsC6Z/wCj7+jxl/yMfgT/ALDUn/puvKNN/wCSp+If+wLpn/o+/oA6eWNZUKtnaeoBxmiKNIkCRqqKOgUYFPooHd2sFY/i2Yw+H7wqcM6+WP8AgRx/LNbFcx4/k26PEg6vMvHrgE1dNXmkdGDhz14R80eHfEy8MOm21hFnNzJvcDsi/wCJI/Kua0Wy4BIJ5P4fWtfxr/pHiWNDgiGFQB9cmrOm2+yIfLivR+0fpeFtCkmWrS0HAAxn0rds7QADI56Cq1inPT8q37OPC5I49hWqlZHLiq7EW2+TJXt3FamieGm1RxcXWYtPXqejS/T0Hqfy9a0fDujjUZTNOP8AQ4zgj/no3p9PX8qu+L/Edro9j8w3Z+WGBCFMpHv/AAqO5/LmsKtdv3YnzeJx1VzWHw2s3/X9PoU/E1xbWmjyRpH5Vig8oLGoy3+yo/z714L9tGoeLvDtmxcW9jNPM8bEyMzR8RdPvMWkHAHX6V3GlapdazbeILu9cuwmhiRVGEQYJ2oOw/n3rK+C1rA3xK8VX7qpmt44Le3kIz5XmAtIR6E7AM1DqcsF2CeXLLaM6s/eqXSfbXW3/B3fkM1T4R6l4q8Qz6p4h1BNKssLFb2oTzrgRqONwB2qSSTjJPPNbOn/AAr0bR0/0bUr8yKcgvEld1EtxoR/0m7mutMnfNvdSnMkJLf6qRu4z91j/unsanbWoI2/eBZWBx86jcKzeMrP3eay8jy3jp/za/I4O70qeCALbz28pAwpcmP8+oFcL4gWa3l23COkhAPIHI9Qe49xXrXiDUdLv4mDgWs+OJVA257bv8a87WMajM9lLukjcn5o+djf30PQEdfQ9+DWtHEuDvLVF0c0qKVqvvL7n/kcPDYveXEFmmczvjJ52r3P5VW8XW39v+NLHw/b4TT9NUI+O8pA3cd9q4H1JrrYY5PC2l63qmqIr3dixtoo06SvxswPRyyn6Z9K57wrYtaJbXt8rA3j7jfbSyiYnJDt2VieD0B4PrXfiK3N8PQ3znGxVGNKm/i1+X9fkeyeE/h14f0exjFwiG6aMEjblgpHHA4Gam1fwVo13sWwjNjfJ/x73UOFkhfswP8AMHII4INRW+pX8js93DtmJCsNu3BAxjFb2jrJ/aFsLpX3sd3lY+baOrN/dX3P4ZryZNt3ueDTklsjC8IXLXWlx6drttF5F9Ay3FswATzVYo4UHpyu9fTOK5u/8HXGnajdR6Mdk8Jy1q7fupUPKtG5Pykj+FuM5APaqHwh17/hMdL8QpdNm8tNUe6TafupOSRj2Dpj8a9Vyl9aWl/KoMsObS7XjBU9CfYN/wChVtCspWZ9BSxFXCS56Mt9+z9TzC1vQJWhnDwXKHa8Uq7HQ+hB6Vpx3BHQ5rv5tGs74eRqdlb3gjX5DIg81Y+2D1IGcYzxWbeeANMeHzNMv7mzZvuoxEkfT35H510wnBfEe3DOaM/4sWn96OaW54Gad5oZsZxmq2paNqumliVivY0yS1u2WA9Sh5H61kjU8Hbghx27/lXXCKeqZ6FOdKquam7jvD2gXcPia/17WI0R1ia2tFDBt+48yewC8fU1svqM2ms09hcSW03cxtjd7MOh/EVjSauNud3GPzrD1nWFdVVQxdztCqMlifQdz7Cr9luROmpX59bmR43vTq+q3N/fOGu5FVXdAFGFGFXb90gdgRXU/CrSLPwxNHqF+iLrdyp8hOf9Hj455+67Ag+wPqaqXfwx1d9FXWtUmit1idZX08584R5xknoG5Hy+mQeal8OmbUprK5jMT3MayiQyKRvby1PIycE5qadOE7tbI+XzPFRclQw+y3t2vay/rbQ9VCx6hbzbwd0bgYx64OfyrBvHttNtpF1K5ht1O10YsQzAEfMoIySDj8e9ZOreObTw3qUGlXHk/bbwD7KshDKV5G6T+6CcqB3PtXmOvJo+rnVtNlv501l5fNkmvpj5qS/w7c4Hl9BtXjH0FJzcW1Fr7/wOfLculOTqqXupvTq3roj6H8D+Jk1CD7XGf31u3k3UWMH1DAehHzD8R2NelxusiK6EMrAEEdxXzF8Lb9117T5Fcn7TG9rcAdGdQTg/R1J/4EfWvobwzOZLaaA9IXwv0IyB/OvMxtK3vorNMMqcrxd9te6exnal/wAlT8Pf9gXU/wD0fYV1VcrqX/JU/D3/AGBdT/8AR9hXVV5545yvjL/kY/An/Yak/wDTdeV1Vcr4y/5GPwJ/2GpP/TdeV1VABVO6A88DGcgHGcY96uVk3LSrqTh1/clVKnoPxqZCEYBuCAQeOoOapJmGRomLMpwQOOnoPWr7EHHKnOOgxUNzHvjDJy68jpn8KkTLEGCgwAc4HHfjoP8AGpBnPBO49xjJ+noKq2koIXtnjHH/AHz/AI1b7cDOevPX6+386CkRzMqo7Z24BLFAGPT1NM06L5Xlcq0kp3bj8zY7Zpkh+0TpGsi7V+ZgeFI9AO9Xx8uB0H4KKBBKqyIY5gGRhgq5GCPpWZYt9huGsmLDezNAVUAEHnaD7VqYwDjI9wAP51W1C1F3FhX2SoSySKNxU47UDZVuYYVvnxEu+SPcWPUlfU+uK0o3WRVYEYcZ+92rOsbp5ZVikR0mSPDrhQd3HP4jmrttvCMjE5DFRjHTNAkTZBznGDyfm7UcZJOD3PJ/CjcSDyfXqOlLk+p9fvDrTGJnHccf7XU0DPbcccDBByaX5uxY49weaTABGCM9BkY+poAQADHQ88ZGMn1qG4nWGFpGJKr0+YHcfxqUsAOGwuOz9B61mSbr2cuFLW8WCMhSHbPSkDFtI3KCaaMbppQxGMHpx+Aprr9m1IyOMwXPDnAPzjsMetaEgAQLwAMZw2MD0FR3cQuICMhWGCrYzsPbGO9IVh24k4zz0Oxgcf7IBp+3Gf4exIG0j2FVrOUyqVfIeH5HzhghH65NWeuAuAqjpwQg9SOuaYw6naFAHXZ2A9WFJwRuyeeA3c+y+lKcHAAyvUKT19yeooJ6tu+shHb0A7/WgBGwPl2nn+Bep4/i9DTJ5FVSHYgHgJH1z/j7VIeBg5XP8Ofmb6ms3UptrbSMAdEUjJY+p9aBMzzITiG3bdJOSDsGQq9zkcjOPzFa9tAlrGI4U2AA5wAXJ9Se1Q6fZtbK7Syb5XJZljwAue2e30q3/CQucc8J/U0hJEcyhVYtsTPdsM1U4fKwQ/mtjOM/WrzKVBI8pOvU5NVIy3mMEnUnPTikNgcKh8tiVPBU9q1NPj2R47gYrOQeZcgEAFR83Iwea1bX+L0prcET0UUVqM5Xxl/yMfgT/sNSf+m68o03/kqfiH/sC6Z/6Pv6PGX/ACMfgT/sNSf+m68o03/kqfiH/sC6Z/6Pv6AOqooooAK5L4jA/wBn2ZHTzj/6Ca62uS+JKn+w4XH8FymfxBH8yK0pfGjty5/7TD1PB9cTzPFVwSAcKg56fdrWgTagxWd4gAj18SM3+tiUg49ODWhBKrRgg12yfvH6ND4EalmcNXUeH7N9SvEt4iQoBaRx/Avr9T0FcdDNs5zwK9f8O2X9iaFHvUfbbjDyA9Qx6L+A/rRUlaOm7PDznEfVqd+r2J9YvrfS9PMUY2QQqFKp1Pog9z/ia8G8Za0817cXN66hhwFHRFHRV9h/9eu913VBf3TBG3W8TEJ/tnu/49vauW1Tw1o2r30d7f3FxGicyW0eNspH8s96FRcafu7iyLDwwf76unzP528vn1Knh9jpfw7F3c/LJfzSXpB67Bwv6DP41c8PQy+HfEel25QLPqOlFZRgA/aUZp8H3MbuP+A1bZB4j8TabpqqqWm4PJGvAjt4/mI9gcAfjWR4/iu9V0TXbjTZnTWIP+JtZSRD5o5IGLYX3KlxWdVcsVA4uIMRJxjSejk3J+XRL8z1XTtasZ7Zre72PbTfK6NhgpPByO4rhfGbxaNc20K2Nxqe66FjHbwzLFcwuULrhm+WSPap+9hl9SK8o8O/FfSfEaxrrLLous4w0gB+yzH1GOYz3wePcDiunubeVY7TULS/ju3XzZFkguFlO5k2jbgknjPPaooxVrnx9dt7o7fTfDV3fxidPDYtuMq1/qAkx77YwB+ZrG8R+G4LeyddXvo7yTcuLKJtsIIOQWRCAcY/iY5qlb+L9auNJig+yztFCmA2MLgdznA/OuK8Q+P9M0YSG4uItT1Ij93aW0geJG9ZnHGB/dXJPqOtEvc12FRfNpDW5N4+ubjWNdghZJY7WCITSgnCSXKKq7R/uq659Cwr1bwtp1tLoXh60WOJkeLbLGwDK25j5it6gjOfauD1Cxk/4RbwJPdvvubq1u7u4YALvkl2Stx+I/ACthNW+z6HYW0jmIXO6KV4uscXSQjHQ7TtHu9dE9IqKNK0XGS5+x3vgLQZ5vD9td3uvakNPJdbSEMikQB2EeX27j8gUZznHeq/xK8V2Hhfwjrc2nbYzFbMC2ctJIw2RqSeTy2fwNc/rPxBjNnJb6OqWmnWcSxLLIQsUCAYBY9B7Dr7GvnL4leOT4omjsLBn/sqCTzDJIMNcyYxvI7KOdq+5J5PHLVfKuaXyKoR9rNKB0P7L2pNZfEj+z5G/daraS22OxdR5iH80I/GvqDT0WO6vYJUH2a4G11xxgjr/Kvi3wJqJ0TxbomqI237JeRSk/7IYZH5Zr688SeIZ9M+Jvhjw4sEDadrP2pXlK5kSRVDRlT2HTI75rmoVLpnvTp+xWuzOx2tcaYs9rtF/aHcn+2o6qfqM1Qu7h7pHi0kmSK5AZcYHl9c9eg9c/zrK8P+LLL/AIWHJ4YRJ11CPT/7QllJUxFN4GzHUEZBz9RTdYafSLq7trWXbDNJv2rgHBPr6e1dUG2Zq3PKK/r+ug8WGi6Wy/2jM2oXuCSWJ8sfRAeR7kmojqGlX0M4n0KwliDLGreWqbnYgIu7ruJ9DXOB7I6iLG5vNupXSTSWtqASZkiXc7E4wMD164I7Vy41SW8+PHhDwmJdtrosb6hcxDo940LPk+pVSgHpzTegnUjS2bv6nrCeCvDv2XyZdJtpmY5Z3yzEnsGznA6D2qbTPDGi6Jc/aNN0m2trhR8su0s4/wB0sSR+FYnxD1e6tLm002yleFZYzLKY/lZ/mwqg9QOCTjrXJ6frWqadcBrS9mbactBI5kjkHowOcfUYrd1ZpdWvU9mhl2IxNH2vPv0bevqesXES3dtNbyfdlUqfx7/1rw3WtJOlRNcSXNxay20xmuACu35VfGe46DB56jNe66Hcwa1Z2txbM0cM6E44LI390+4Oa5D4t+EZ/EXhu/sbUmLUGjVWKkDz4wwO0E8ZyOM/7p4Nb0cTyXS6ng1qSlJwlo/y1/Q+ZbbXn8XarAvibQ0uZJZFSO7jfYY1zwp9R9OvPGam8e6Q2qXyW0TQvqNoAItzBZJYGxs3E9cHKhvbBweuDeaZrHh1rhWRZkiJDbgUbg9wcMjD6YrWu7+bxpp1td6VbGHXNJ/1m+VT5qEcqF6kH8uSD1rBN1IOnU1k/LVo9vmpuioauemlt15NKz7rqd98CtNvhqdit0phW1855Y5BhxKuVUAemHyT7CvpLwxcBL2SI9J1yP8AeX/638q+T/DU2q2V9JFeQyxWGFmifcd0bHrHuzknPb2r6U8HSXTrpT3mftRC+ZwM5wc598V01aS9j8ra+ROPwqVFu/S33fobWo/8lT8Pf9gbU/8A0fYV1VcrqP8AyVPw9/2BtT/9H2FdVXinyhyvjL/kY/An/Yak/wDTdeV1Vcr4y/5GPwJ/2GpP/TdeV1VABVLVyy2okX/lm4YjHartc74i1K40iSae92toske1plX5rV/V8dUPHPY+x4T2E9jSijd4m3OSysQw9CP/AK1RDp1Bz71NYXCzrDPGVMdzGHBBzkgdvw/lSzxFHyoJQ+h6VDQLYz8FJjnDK/Q5H5GrKyZhySCQOdx9u/8AQU2ddyjB57DPB9qr7hIqKzMpYgcHkUg2L1krCMu4xK/zHGM9P0FWFOeR267f6k00fdxgDHUE/wAz3NLnB5PHYt/QUxjwd3ufbmgnqCR6ct/QUZx97OP9o/0FBJA6kD6haYGbeRSC8a6gUs0YBZAv+s9s+1TRyhzBJEFMcvysQB8px+vPFWIiN7tkHnsSelZ9zD9kkaRMC3cjeMH92cff/wAaQjVxk9MD/dHSjB64Pr90VBayiWFWIVSRyPQCpt3+769T1pjFxjkfQZX8zTSwxwcD2btSsR0Uj04bH1qlezyFlggUtK/Jzj5VzjNACXO+7byIycZzKy4O30WrEcaxlI4wAqDPTH40tvCsESoDnaMFivJ9SadGMc45OO2PoPwqQB8bcE4GO56D1+tNizsBbAI6kdF+nvTyeRg+/Jx+NNXjgHpzk/zOKYFO6Ro5luk3nYMMg5GP7x9xVmNtyKeT3G45/wCBE1Jj5Rj6jJ/UmqUKC0lEKK5ic7kO4ZY+hPp9aALZPTBJ3d8jL/8A1qXPPBXI4z2T6e/tSA5DfNxnBYdz/dA7fWgnb1xuHYnhfr70AR3DiKFndiowT1+Zh/h7Vm2sQu5/PLEoM7EBGPxNSTGO+uTb7maND+855c+ntV1FVQQoUKP4QflX/GkxbjuNvbA+gUf40dc43uOfu4ApGYfe3A/7THj8BRncMnzm69OKBjJFI6Qr+LCqcoAk/eRhF9QRxVuQoM7jKv1aqkzfMCkvmKeoz70hMntlYRFh8zMcDkZIzWrEmxAO/eqWniN53aOZHES+WFVwdpzznHQ9vwrQrSK6ggoooqhnK+Mv+Rj8Cf8AYak/9N15Rpv/ACVPxD/2BdM/9H39HjL/AJGPwJ/2GpP/AE3XlGm/8lT8Q/8AYF0z/wBH39AHVUUUUAFYnjSzkvvC+pQwczeUXj92X5gPzGK26DTTs7l05unNTW6dz5f8ZP5mjwalABtiw/HXY47/AEOKxNL1xAmx5BkAAZPWvQ/FOixaVrGpaLKoNnMrTwJ/0wkJyo/3HyPptrwfV7e50TU57Ocneh4bs69mH1Fb16yglPoz9Ry+tTr07rrqj3f4aWqa54lTKhrWzX7RLnoTnCL+J5+i123xC18Wdt5MT4nuS0EeDjC4+d/yOB7tXMfAyAab8O5NSkJ+06lOzAk87V+Rf5Mfxrzz4l+JvO8cXlsr5gsFW0BDcbhzIR/wIn/vkU1UVlOXXY+ZcP7Vzh01rCn+n+b/AAR1KXK7euF6Cqd/qAjAGSzscBVGSx7ADqT7Cs7wXbat4tuTbaHEGSP/AF15LkRRD0J7t7Dn6V6z/wAIlaeFLAXFszXOpSZV72ThwP7sY6IPpz71s8SmtD2MZjsPgpcktZ9v8+35+Rz3gvSrzTfD2vavdoyaleMtjFER80KnGQfclhn0xRYWh027jlMizSWrBh82QyHIwf14966nRmeDwvYOVcIk32yV/YyMD+QINc3qNzLE15fzRN/Z1payziGKRTPIih3VcH7u7aQC3XBrBu+rPjcRXliqsq1Xd/0l8j5F+LPhk+D/AB3e2lspSxlb7VZN/wBMX5A/4Ccr/wABp/hvTrXVYBLb/JcD7yrwQ3t9a9j+L2nWHxE+F1l4q8NEz/YNzqCP3ipwZoZB2dDh/QjJHBr578Nao+k6pFMGIiYgOPb1opyUZWlsx5fWpUMQvaq8H+HmdHfWEwVo5Jp3UjG1nJH5VkC1SMkCMDHfFeparp0N/p0Wo2oBVwBKB/A/r9DXHXlntk6AGubFYeUJ76H2VXK6XLz0opH0jrOjXepeCNAOmbG1TTbeCe3idtqTDygrxE9tynr6gV4XP8YL3S0udO/4RawWaN2Vl1B5JWicHkFQVHB7EV75p17K/h3w/cxSbA9pGSeoJCgYPr0NcN8WvhvF45gbWdCSOHxFEoEsJIC3YA4Gez9gx69D2NejVi2vdep8xmOWOcPaxV+588+KfFmseJ5w+q3QaJDmO3hQRQx/7qKAB9evvVGxjJHPWq9xaT2l7Ja3kMkFxExSSORSrIw6gg9KvpJ5EQZRnFeXWk3p1PNwNOKlzS0SNCBMjHfpX1FqN2dW1r4NayWzJPIm8/7WxFb9VNfMdoA4R1+4ec19FeA2/tDwx8MmJ3Gx12S368AffH6GssMm3JH0teipU4y9fyb/AER0Hgm2E3xm8balIB/otnb2O4nGA7KT+iE0njD4gF/Cmk+MfDvlz6bPqC296LiEFmhWR1ZMH7uflORz0qvfXq6N4T+JWuLIY5rvUms4mJ7rGIx+sp/KuL+GFsL/AMFeLPB90AWkt/7Rs0z/ABx43Ae5AU/hXck17q631/I4Xg3UlKs/hi0n87Xfy3O+k05D+0D4Zi3Zghsr0Lnn5CrY/RhXj/hC4v8AVP2iBrFow+03OryMMjKiDLBh9PLB/SvZtNuFvvHXg3VlODP4cmlDZ/iEYB/lXh/hjUD4e1XT9aRgJorlZGY9NhOGB+oJq1SdWVk9N/wNcJl6qc85bxj+PvL9D3H4m5n8YRLauoENmonZmACFmYoPckZ49K50u9vEyySDb1+Q8MPX3rf8dJGviSW4UjbPCj7s9SMrn8gKx7eOD/W3Enm7c7IgOCexb29u9bW1sfSYF8uFprfRHR/DHW/s2pTaZI2EnBurcE/xKRvA/Ag/hXsF5ax39uoLFT95HHUf/W9q+fLaa0stbsNRECQzQSj97GMEqx2sreqkH8MV79oU3nacnOShKH8KymmlzJ7M+Y4hoOnWWIirX/M5fW/D7TDN7YQXqKOHMayYH0IyPwzXkPj7wjYWuqQa7pVqkF1Ipt5vJ+VXHUHaOM8YzX0ua4zxLoBeWVkgE1pK25kAzsb6emeciurC4pOSVQ5cux8VUSqL+v8AM8f8BeHhdzjUr9cwRPmGNujsP4j7D+de6eGNOMMX2qbO+QfID1C+v41n+HNE3FJJ4THbx42RkY3Ee3p/OuvpY7Fc75IizbMPbScI/wBeX+Zyuo/8lT8Pf9gbU/8A0fYV1VcrqX/JU/D3/YF1P/0fYV1VeaeGcr4y/wCRj8Cf9hqT/wBN15XVVyvjL/kY/An/AGGpP/TdeV1VABTZY1ljaORVdGBVlYZBB6ginUUAcUr2nga3jtb66SLRjOq6e8jY8lmP+pLHtydvtx2FdopDAEHIPIIrI8R+HdO8RxQwaxD9ptIm3/Z2PyO2MAsO+OcVFpKJolzBo+4/ZHQ/YyzEkbRzHk8nA5Htn0qVoQrp+RqXNuWRzH94j7ucZ4rnNBnnlxHdAxzjh4wfut0IHt711lcPoWmrB481y6kuZSLkr/o5c7FODyB6kCk0TNtSidahzgDHBxjPQ+g9frSg9dp59jkn8aS6HklJMkRD5ZOeg7GpjCNp2k+2TxRY1IweODz32nJ/E0cMDjH4c/qaGyv3uPr0H0FJI3ytzkgHjP8ASkAkZOzlvzkz/KlcBkZTtKkEYJPfilBwgGcceoFBcDPzdP8AaNAFC1H2a6eDeSjklDvxgD+GtEFjz83rwwNVb2LzotoOWBBX94OCOaLa4WSBWYxB+rDOMHpQCH3s3kwkgszt8iAj7xpIYvKTLnMjEFmZe57celMgKTP5uU2DKqNxGMHk/jVgn3GfUSfnRuAjMpwoKc9gx6dqeOff86jRizFiSOwywFKGHXIP/AjQA4ntx17Hr+famH5ZVI53DucZ96fnH1PbJH4c0yXBAPBIIbk4zj29KBj89AOSemTgt7n2qG5jEqMu4jody9SR7elTKwPTkH07+2PSm5+XOR6ZB/RfSgRDDKGU4YBkJVvSPHXHrUV3MI4gu7az8IM88/xH/ChyIrshmXLjIRjwpA6morYiW7eTltnQseAcdTSEWIIlt4Ao4Lcnn5nPr7U8nqflwO5Pyr9PWlZvlyM4b35b/AVHE4lmeJGR5owCyl/uA9Dj3wcUDAvg7t+M5+djyfoKfuB6SyZq1DAEO5yXc9z2+lTVSiwMyd5IomkLgxqCWLcYHrmueGo/b/FVhY2lvK6Rj7VNcDIiCYO3a38RzjI7Vr+LC89iLGFtrXDrGxB6AnH+NR6G8UMt6yJiMzCC3VTncqjHH45pWszGbbkoo2LGwtbETCzgjhE0hlk2DG5z1J96s0UVoapW2CiiigZyvjL/AJGPwJ/2GpP/AE3XlGm/8lT8Q/8AYF0z/wBH39HjL/kY/An/AGGpP/TdeUab/wAlT8Q/9gXTP/R9/QB1VFFFABRRRQB4r+0ZJcaQ/hvX7NNzQzSWkqk4EiuAQp/74PPY1wurabpnjDQIbiKTarAtb3AHzRN0ZWHcA8EV6z+0Jbfafh46gAlbyFgT2+bH9a+YPhzr1xo/jd9Gkc/2df3YhZHOdkhOA4988H1H0r16OHjXwl3urp+aPpctxsqNGCe12v1/U930rRfFttoOm2Wj3GlSWlnEkaq8pRkIHJYEfxHP5965fS/gdrt7q0t54mvIDFLI00kdjLvkkZiSRuYALyeuDXo3jWCSTR7ldM1GXTNThT9xcxYO08fKykYdD3U/hzXk+lfGTWPC2tro3xO00W6PzDqmmpgbem8p0dfXGCPTPFcWKpqooqa92Oxx0JVcA6lag7c+738/lue9aVbXOg6dBp+k6OLHToRgRoQ2PUkjkk9yeTWhql3BfWIjKnzQ3CjnNZOn+IYbqC1aO8hkgmCyw3VvJmOeInllPqO47V5f4C+Ll5rHxD1Pwl4ysoLHUluJYrOeDdGJMZxE2SfmK8q4xngdwazaSscvMubnlq31/wAzmf2gLDxD4b1XR/HGgXNzbyWCi1lQMSipuJUkdCjZKsPpnrTrLVrYePPDHjyw48OeLIf7H1WBjuFrcYC7Wz2DBSM/wj3o0fwVrvgDW9Ts9PDeJPBN8WS+0gv+/WNv4lQ9XAPDL94cEDjFbRvDUHhnVr7wZqk7TeDvFKLLpt8ylfKmH+qc5HyuDhGHHbNZyk10N4YaVWXNt1+7qv8AIjs7SX4Q+O7oOrSeB9Zl8m5jHzfYpQT190JOP7yEjk15l8ZPAb+FPE0yWaq2nXP+kWciHcjIedoPcDPHsRX0w9u+saRcPrwgjljiNnrUFw2IvNiwPMJPQMu1w3vXNX3htJvD9v4K16VTY3Lb/DWslhIiSHkWzyDgg/wnvnHoKqUG1oaewgtJr1/zXp+R5F8HNeiklOi6o4FtOuwMx4X0J+h4PsfatLxbokmm3kkMiEMp788duf61wup6Zd6Frc0cyPaanZSlZI2HIYevsf1Br2HSL238ZeEo0ZsajbxsbcluW2jLQk+oGSta0KyrwdOXxI+uy6vKlBQqO6tv3XR/LZ+R1Pgif7V8ObINjfYu0JA7AHP8mrT89okDwb1uFwfMZ/lx6be/4/hXOfB+5SSPV9IkI2uq3CDPUEbW/mpreMjiyNrGv71M+eQCSzgkZJ7KARjp1PeuiXRopwUKkqduv4PUw/HvgjTPiHZG4Ty7HxDCuEuOzccJJj7y+jdR+lfN2r6Ve6LqNxpurW7213Cdrxv29CD3B6gjrX1YjxWkayiVxeqxCBcbFUdQ/ds/pjNZ3jzwpafEDQcxGODWrUH7NO3Y9fKf1Q9j26juDy1aSrLT4vzPIxmBVNutSWnX+v6/U+ZdKLLbTxN/Cfl+le7/ALPN/wDatHjsnbJsPEVnOoPYSo6fzUV4Z5U9jfXNnewPbXtu5jmhcYZWFetfs73FnaeIdRjvJxCk0lncJ8pYs0U24gAD+6WPtXDRbVXl6mFRyeFi6eqX5f8AANr4v6qY/hfp1pFjdq+v3k5/2kSVgD+YWua0XXJfDHifS9bjyRaNG8qBvvRsMSL+Kk/jSfFySN08I6fDOJo9LgmiulwVaKdpS5JBHQgjBHXmvNr7Ubq+vt7TMIi4xGDxgHpWtSraUoP+nqd2CqqlQm6sW3NtW8n19NT7H0fwtHbal4fS2mZks49StLdx0aOX95Hn6Kwx9K+Wb6ObTxeabqI8uW3k2yDPQbuTXtfjHUbyw0bT7e3nYxSWMU7yL99ztAwD2CgAAD0rxrxgz6jBBeF8ySqYJmJzlhzk/hXdWgqMPaxe36/0jXB4arTpzm3fmTX4v9WfQnie0Da3ZXUkjGz+yG3SNTxK24MoJxxhcketYpigKu0LTxuvKhwNre3A4rN+EPii58S6XceHtSVJRZWqCO4BIZlB2ru9SpxhuvFXd6TMoklKkcgryDUwmppSXU7MC5crpvePb+v6/Knfu8yiGON33ZBbHAPrXunw21A32ko7HLvEkh+uMN+orxe7KtF80l0ypzlZzHn8F4Ar0H4MyrbxR2SuzKolRNxydobcAT7bqT2lHy/I5c/p+1wfNbY9XooFFcx+fBRRRQByupf8lT8Pf9gXU/8A0fYV1VcrqX/JU/D3/YF1P/0fYV1VAHK+Mv8AkY/An/Yak/8ATdeV1Vcr4y/5GPwJ/wBhqT/03XldVQAUUUUAFY/iqF30lrmBd1zZMLqIepTkj8V3D8a2KCARgjIpNXAhtLiO7tYbiBt0UyCRD6gjIrnIEnh8U6xNNC4hKRSRNnIYKuDj368VL4MIs4r/AETvpk5jjBOT5L/PH+hK/wDAasa+0lrPb3SZMTAwzDPQEHDfhz+FS9Vczna12bRCuhBwVIx9RVe0Yxs9s+cx8oT/ABL2/LpSaXMk1hC0UqyqF271OQSOKW+idlWaH/XRfMo/vDuv41XmWtdS1WT4pmlttCupLZzHOdqIwHILMFz+taVvKs8KSxnKMMis3xGu+GxiPIe8hBHsG3f0oewM0/LGMAkH1HWmvEcfIxz7salooshlSeF3iYdyDxwa5m7vZbG+msRFKBKu8SY/d9cYPcV2NcZrejjUvGtpeec4ksYsRxgkKxbOd3r0qWjKq2kuXudLbkiJFUy7QFAJUcj1p0hYqB83PUFAeppNPMNzapOibC33l/usOCPwOabkPqDW6KPLjiDM3oSeB+QNKzNRY+g4IB7hcfz9qeWO7knPuf8ACpRAM5JH5VKqqvQAUKLArKc4x0/EUHqVPXoQP5AVaprKrdQDVcoFWLmMZLHsT/QelOJxzu9gRz+A9ahsnJ1C+iclhGyMmewZen5g1auJorS2kmlIWONSxpJAc34q1GDTNP8AtE7bUiOQuM5OOgz1Jq14Whkk0GzneUzGZPNJkG0nPIz+FZXifTodR0qBdZiDvdXUcrRHkIq8hfw7++a7OJFjjVEUKigAAdAKErmMbuo+yI44QG3uS7+p6D2rntCA/wCE58UMBzstAT/wB/8AGunrmfDpD+LvFTjoJbeP8oQf/ZqbVrGx01NdwiFmOFAyadWdqF2qTRwLhpXOFT1PbPsOp/Cm3YGcxrmrMPFVjplvua8EL3ZXBKh2/dxKT7ZZv+A10+k6VDp6ArlpSioWJ7D09PWuB8DafqN1411DxE9xJd6XO0lonmYDGWJihmUDgIdrKBya9PFJa6mVNNtyYUUUVRqFFFFAHK+Mv+Rj8Cf9hqT/ANN15Rpv/JU/EP8A2BdM/wDR9/R4y/5GPwJ/2GpP/TdeUab/AMlT8Q/9gXTP/R9/QB1VFFFABRRRQBxXxfhE/gmdCMjz4T1/2xXx9pMCp8QLWQkK0N8ZM44G0k/0r7O+JS7vCV0MZ+eP/wBDFfM/wo043nxfgbarxq91MC3OcKwH8693K5ctCbfQ9ilrl0/Lm/JHpHizW1uvCttfQB5Y7lovmiJLKd3JH6/lXB+OvDjeOPDklgkkY1izczWpY48zjBQ+mRj8QO1egeINHXTtSvtMt1CWE8j3FpGP4Gz8yj2B5HoDXH6fABfPJv8AJu4SSMNjcfXB6+hFebWfLPyZ7eVRhjcDyz67+u36HkHwy8d6t4B1KbSNWguJtH87/SbB/lkt5B1kiJ+649OjDg9iPZfif4Mt/GekWXjPwfcrcahDGsiy24KmdFOQQOqyIe3UdPSvN/j5Y3B8Rafqi2Dm2lsVE1zFESvmKTncfYY69qh+Efj668GajtJe40e4YG4t1PT/AKaJ6MPyI4PYjlnUUJOnU+F9TzKeBcJONJ3lHo+p7n4f8S33inwVJqmkyLB4hktmtZDsBKXSYYYBBADgHH1I7Vi+HPGOj/E6yk8N+IY1sNfPzRY+VJXHR4s/dkHdOjc49K2Lq0s9H1FPGHhubzfDWqhf7REA4h+b5blR1G1vvDqBu968y+NHgtrbxAutadiAXjtJmInak45YewOQ4Poa0kqiScNf1O3CU1Vly0dJbrumt1/X5s9Z0jd4k0rXNA1/Nv4hht1tL6QH/XRjIhul/vDnB/XrXkXhjxLe+G7rUvC/iK0F9p8crQ3+lyk4yD/rIj/A3RgR149iOl8EeLrzxXNZWl86WvxB0xGOnXUpxHq0QHz20p6FiO/49Qc6HxE0a08T6HB498P2FxJdQIbPUbfafPhKHBWRP78Zyjeq7T0qqdTv/X/BRphqkI4n6rXSUZPVPo+lu3l93Qk+J3hPSfGXgGy8R6bqiy6pC6WcN1MP3l6pOFhmA581c43Ec45yDkeYXPhjWPhfq0i3epWsyzQrMY49xKS5+X26ZB9j9KzND8X3Gk3nllpvsZnWWa1Y4yy5w2OzDJr3LX00zx7ocWq6MsdzcInmPbnliB97A7kHNKi6c7zh8SOqlg4YapFOV4Juz7dk/Le/6HmPgfW/7K13TNUfKW0hMcwHTy24P5cH8K9b13zrLVmjgyy32HByRGHQcsxH8IXnv7cmvEtRtFttyRD9x6HPyGvUfA+rN4l8H/ZWbdqulYAyeZI8YX65GVPuBWkZ3XI9z2MdS5XGv02f6P5MvywRPOFhJdAAu9xjPq2O3riq8NxNpl8dkc0w3FBGiks/PK49ep9qfagzeZKrgIE+XcdoXPALHtzx61PeGVZnaKaPzZVCOlu5dVzwE3Y+YnGTiok9LrczvryPVWOR+MnghfEemL4l0GMPqttDmaNB/wAfcAH6uo6dyOOwrlvh6kmm/DTV9YjVlvdRY2luwGCsf8bA/QEfjXqmjX8+l3TR3UsQtHbCYc+ZG/diOgUnj68+tReMtHRNLjSyhjhtELnykGFRm68dOaUoRqXqr4v61OClhPY4jlb92X3P+tmfPDbtk8OT80ZAB/Suct2UFF7gg11uqQG01EhgQA+MH0rkLlfsmoXEb8NG5HPp2rxqSesX0Lzf93KE+l7fqfRmtOL3wX4dugx3C08hh9MEf1ryW+jeeyvrFSQzZeIZxhhz+vIr1bRgJ/htopcghwGGfoRXnHiGNrLVPOQkfNkE/nXu1Z2pqT2srnpU6aqUJR6Xf3P/AIcd+zpf3MfxFt7ZGwklnMJQ38QA3D8iBXs+oGKGa6iYI8aOyIcDgZNeW/DnQ2j+MGhatpQAsLlZpJVXnyWER3xkfUgr6gjuDXqmoQWb6rfrO0rxrcyKhiAwoz69+c/lSowcIuJ4eUKVOpOnVvp+ljCnuDJDthVmByucYNd78J5WXV40fhgw4+sf/wBaucD/AGJAsAhkRvm8xowSw9CD0x0wK2/hs+/xN5yqqB5UO1M7QcEHFJ6Stc9PM37TCVNNLM9xFFFFc5+ZhRRRQByupf8AJU/D3/YF1P8A9H2FdVXK6l/yVPw9/wBgXU//AEfYV1VAHK+Mv+Rj8Cf9hqT/ANN15XVVyvjL/kY/An/Yak/9N15XVUAFFFFABRRRQBzGrM2l+MdKvgD9m1BDYTkdA4y8RP471/EUnxHS5fwrP9hbZceZGqv/AHdzBc/hurR8W6a+q+H7u2tztugvmW7f3ZVO5D+YFZmoXI8R/Due5jBSSazMu0dUkUZ2/UMuKh6XIlFSTi+pN4c0mHwppVrYwbmgVB5rsSWZ8fMxP1/zxXSA5GRyKo286X1lZXIAMc6K+PZlz/WmaVLsaaxcnzLYgDPeM/dP8x+FNMcUkrIUH7DfbDxbXLZX/Yk9Pof5/Wo9d66acdLyP+RH9avXUCXVu8MoOxxjjqPcVhahcytpdxHcf8fti6THA/1iqwO8fUA59Dmh6DZ0dFIpDKGU5B5BpaoYGsC4bydbnlA3sNnyjrjBrfrjvEurLpviewsto87U0ZYHK7gjoCSGA5wVzgjuKUjOo0rNm7Zn7Nq9xbjiO4X7TH9ejj/0E/iam00b5Lycjl5ioPsvyj+Rqtqx8ibSZV5YXAiz/sspB/kPyqbQWLacA331kkVh6EOaS3LNGiiiqGFFFFAGfD8uuXI/vQRn9WFRzD+0NREXW1tGDP6PJ1A+i9frj0qCa6Md/fvF80uI7aL0MhBP6ZBP0q/BCLGwEUbBnA+838TnufqakRh+IbqP+04t4JS1DOwH8RwOB+JA/Gt7TY5Utt1wxM0hMjjPCk/wj2HSuV8ES3Go6nrkmrQEXFvdeTExjKI8YAIdQfU5yfUV2goXcypa3l3Cua8HfvLzxHcnH7zU3QEdwiIn8wa6KeVYYZJZDhEUsx9AKyvCkBt9At2k4km3XEh93Ytz+dD3Rqak0nlpwMueFHqa4G51dk03XfEyAskMb22ncZEhDbA2P9uU8eyitbxle3DWMNjp7mPUdVk+yWrDrEhGZJv+AoCfrt9ap6zawvrfhjwzZpttbdheyoP4YbcARg/WRl/75NKTEzpPC+lronh7TtNUgm2gWNm/vNj5j+JyfxrUooqloUFFFFMAooooA5Xxl/yMfgT/ALDUn/puvKNN/wCSp+If+wLpn/o+/o8Zf8jH4E/7DUn/AKbryjTf+Sp+If8AsC6Z/wCj7+gDqqKKKACiiigDl/iQQPCk+SAPMj6/7wrxX4GWBPxIuZmyRHBcHJ93Uf1r2r4j8+GmX1mjH61wXwYt408S6g6jB+zH8cyD/CvUws+XC1D16LtgJ/P9B/xineyk0S8jTcYb2aRgOpXywpH4gn8cVw3iCwWS/hubSYCC9TKSDgZIz+o5/OvSvilbC6ghDDO0SMPbla8s8L3YvEu/D14wRwzSWj91Yc4HuD8wHpkU6mH9rhlOO6PYyCfsqEX63+86Kzv5rAwxR3SXSn5ZYWQqAO5Rs8j2Yc9sV4X8T/COqeGPE93qVnaCTw7ezmSGWEfJFu52Efw4OcdiOle0W9/AkPmS6fE13bkxzRSlmQyDAzt/UDpzVHxba32s/D7xDpVrbMb1dk0VpGv91wWRB7EEgV57/eQcfuPSx2H0VaN049dNfuOM+Enj5vDF21nfZuNDuj+/h+95ZPG9R646juPwr3DXNCtdT8KJZaZKlxBNGHsZAdy5XmLB9CCU/IHpXxfILm3uWUCWC4ThonBVlP0PSvUfhN8Up9BYaTrpc6TK2d2MmBj1dR6eo79Rz1nD10nyy0PPrVI1ZqtS92a+52/X8ygdUiN0GtZWgvLaTdj7skUinr6ggivXfCPxBm8Sprb/AGNYLiPT1ku7eB9gv7hSEMrEcgYIyByQACcCsT41fCk6hd23i3wxeWTPqUYkuIFkC+fLgHzYvUMOSPXnua8y8GazeeFfGVvJfRmGaNvKmjk4EiHghvUEHB/A1pOu41FKS02/r0O+GJ/tKEalWFpLRPpvt5Xtp23Wps63HaayWh1mMWt10iuo0wV9Aw/iFcZHqPiD4f6vE+6RImYSRyRsfLlx/EjdmH/1jXtnjDQLdplktsvZzp5tu5HO09j7g8VwU0UlnazWep2y3+lyH54Jc/8AfSkcq3uKK0OWd5ff/mevjMCsbTVfCy5Zr+rNfh+Z0B1yw+IGjSapYrHDrcOPtduny+aP+eir2b1A+orE8I62/hbxba3jlhbE+TcDpmNup+o4P4VyJ0S78Oagmu+D7lr60hO6W3Yfvol7q6/xL/tL+Qrs9btrXVtKtNa0rmzvkMm3H+pkHEkZ9wfzBrGpGclzR3Wv9fqceBxDqReExMeWXbp8n2/L7j1jxFbS2k5+zEGyuG85Bn5Q5HJ/Ecj2Jqra3ax2bXFqsxjX5YpzGcOx4Zw/TgcA+pqj8PbuPxb4Gm0W/O67sdsXzEglOsbfTgqfb61NJfSm6f7TIwlA8sqx+UAcbcdAB6VU5qyqLZ/0y6KcoulJaxevn2+/+t9EeJZ2VlKhNvJYkEY7Y7mtTw9qEV1G+mXhDK2UjLdSuM7c9yOoPpVWL7MQ6h4pFHJUhlJ9Tnpj/PFVL21G2OZ1eKRCJbeGJivk45Dvjqx7DoB9azjJ03zo1nFVVyO/l5f1/Wpw3xK8PSWd/IxBfKghx/EOx/KvMvG+mNPpNrrduCfmFreAD7rgfIx9iBjPqtfT2rQx+I/DnnLGrTR5zGOoOPmUexHIrx/UNMfT31CMW32jS7hPJuEYfeU8hh6EEAg9iBW/1ZOftIbM5sVQeY4SVF6TX5o6/wAFky/Dbw4COPJJ/Uiuf8b6X5tg8y53RjPSuv8AClo0Hg7w/YwK8ri2LRr32liRn8O9Vdet5XguLW4jMcm3BB9D3/8Ar10Ol7SlbyOvBXjSVOW5d+EmnrovgefXJFH2+8ykLkfdUHaoH1bLH/dFWUt0kQxvN5Yx8rE4yfWruo2c1n4Y8NWkFwYEgiLFggO5io4KngrhjkVQuImdd9uwEn8Y/gb3A6iskuRcvYwwqvzVL6yf5aIrGOWwj8q6YnGTk9vTHtXU/Cgs2p2xbGTIn/s1c1NKstsqO8SOgIxIpKMCc9RyD+GK6j4QM1xq2425hEdw0YUtuB2LyQR1GTWN1z3XYeZyf1Opzb2PcqKKKg/MAooooA5XUv8Akqfh7/sC6n/6PsK6quV1L/kqfh7/ALAup/8Ao+wrqqAOV8Zf8jH4E/7DUn/puvK6quV8Zf8AIx+BP+w1J/6bryuqoAKKKKACiiigArlNBT+yfEesaS4/0S4b7fbg9AshxIv0D84/266uue8XILVLTWApb7A584AZJgf5ZB+HDf8AAal9xMr+D5RFY3OkPu87Sbo22GHJjPzRt9CjAfga1NYJs54NSUZWL93Pj/nmT1/4CcH6ZrOuLN4PE9tfpKQssBgnX+CZQd0bf7yncPcGujkVJoWRwHjdcEdQQaS7AOByMjpWJ4sikTTmv7WLzbi0Us0f/PWL+NPxHI9wKm0NmtvM0yd2eS2/1bt1eI/dPvj7p+nvWtVboNzE8L38dxaLbrIJPLRXicH78RHyH69j7ituqdnptnZzyzWtvHFJL98oMZq5QtgQVz0nhbTZPF7eIGiZtR+ymAMxJCj1UdjjI4roaigO/e/qcD6Chg4p7le8s4dTshFPvUEhgyMVZGHQg9jUmn2cVjarBCXKgklnbczEnJJPc0+P93O8fZvnH9RU1CHYKKKKYBSNnaduM9s0tFAHO6DYXfnRS38IhMO9sb9xllc/M/0xwPrW0P310f7kX6sf8KddSmKIlRlydqj1JpbaLyYVTOT3Pqe9TboJKwsH+qX6VJUcPAYejEU27uI7WBpZiQo7AZJPYAdzTWwzP8RMZbeKwjJEl6/lnHZBy5/Lj8asKwu28uIYtY/lYjo5HYew71zei3U3iPVL25QFLOIm380dwD80aHvz95vwHTNWvGVzKlnaaFpTeTf6oxt42Qf6iEDMsv8AwFeB/tMtTfqSnfUi8Mka5rt94hcZtIt1jp3p5at+9lH++4wD6IPWpfDdp9o8Ta7rUgyXZLGDI6RxZLY+rs35Cty2tIdO0yGzsYxHDDGsMSDooAwBU1nbpa2yQxjCqP16k/nTSGTUUUVQwooooAKKKKAOV8Zf8jH4E/7DUn/puvKNN/5Kn4h/7Aumf+j7+jxl/wAjH4E/7DUn/puvKNN/5Kn4h/7Aumf+j7+gDqqKKKACiiigDlfiNzokKAZLXCfoCa5z4T2fk6jfykHc0KjPplicV0Xj757ewjxnMrN+Sn/Gqnw8tmhlvHYEZRR+prspzth5I9SLSwT/AK6oreOIRKqqRg7H/D5q+fvEkMtlqqXNu3lzRuGWQHBDA9a+jPFcRYj02t2968O8UWh+1uGAOWOc969bBS/dpM9TKZctBG0Jlv7aDXLWJVuEIS6ixu2svRsd8dRnsfarui3ccMk93eQzzl22oqyGM88s+e5/TNHws0c6ne3yxOyn7IGIP3ZDvwu4fQEZqrr1ldaJqKlUdrUZQKeqHrsP0OSPUV4+JpqnUfKe5h68MRzYdv3l+Xa5zXxp0CTxX4QlvtPhebWtIkLhkjxLNbn7w4644OBnBB9a+fdMvw8A+0gHb1J7+9fW2lazcXKQxR4MaDdCZDgW4HGfZTyGHf64rh/i78NI/E9odY8KWkB1dMm7trcgC4X++o4+YH2BPfnrjVp+2jzLc8zEUauErOrD7uhX+GmuzeJfAepaNbX3+ladEDag4O2LduK+uM/yHpWLdz2muwNpXi2A215HxFfRLmSM/wDsw9RVD4I+HPEvhzxTb6rf6Pe22lzB7eWSWMgA/wC0p5A7ZIxzXdeM/DsNxcSlAA4yI5B/dzxXZSi5UUmr279T1sqqrEwcKseW/TbX+rP1IvCdxdxaQPD+usrXcH72xuUOY7uMcZRvXGMr1BANM1C3jdWDDaP4s964pdS1DRCbW5UXFqDzFICUz69cqf8AaGDV2K+ub4O+nXPmEjHkXMmJPosnRvo2D71PtIS/drddOv8AwT1sPTlhrpu/9f1+ZFdaLdeb5lqpjAPysTtH0B71c8KRytZ+INOmAWSNBqMagdHXh8f7yn9KzPEUM+t6NFaTLLa6zZZaKKYFVuF7gdt3p61W+HLwafqxlL/LPaSQypg5UkY5HbHNcko8leKitP6WwqteVaXIo7ap3/q/mb3hjV08P+KLW/Rl+zsojvY1OcRP/Fj2OD+FekeL9NEetwXpfNjcoQ4QDmYD5cH0defqK8R16A6brGmahGPMhlia3nUDhlU8/oQfwr2XwPcrrHhyfw/qMuLi3jRrebGd0J5ikH+6cD6U1FTcqXz+f/BOGvUlTrOta1nZ+a6Mbaz2luHTyWKsfuBuT7E45B74p9xKcu8qkM2W5BGTUOmmRJJXvoxb/Z5mgeJP9ZLIuM89FTkEdyDxirpngln5t9sr8IFkIQe5Bz/OuZLS0mbtrmulfzKWian/AGJO7XrBLedgCO65OA+PQd/xrH+IMeuQ+KrbSNPtrRtN1Zdkc3lnMRx+8y2ccD5h7EV0890sQMNv8quDvLKC0x6fN7dgOgp6J/bGjT6WjKl/bKHtnPPyjp+X3T7EV1Yaav7Fv+uqOaupOSrR93v6dGcH8RtQWzisNHsp1iN0BbqC20mGMAYB/wBo4/I10mhWs+r+HdGhYb7+3ElpISeqqeGJ9AK8h8Uafd+JvEU9zcwtGkZ8iJZDjykXjH1zkn3Neo/Bx7y3lOnXoaV/Ld4pm53rwCD79K6IVG6rai7bLsU41qcJTcbKOqfytr+Z2XjSSOI6dbqR+7QuR3Cnaq59M7Sa5nUbmOztZbnZdZjUlREqsM9snIOM47cVr6pKkmvai7AvFJKwIb2wAfbGKyr2JXtHEozEf3cntnvXPOW7RphIclKMX/V9Sh4gfY0iphWLKrDtnA3Y/HNeo/Ca02XVvhcCOAufx4/rXkk/+kalFHvZ5QQG/wBpsgZ/Hr+de+/DSyEdtc3O3AO2JeOwGT/MVhTd5SkcnEFX2OB5Or/4Y7YUUUVR+cBRRRQByupf8lT8Pf8AYF1P/wBH2FdVXK6l/wAlT8Pf9gXU/wD0fYV1VAHK+Mv+Rj8Cf9hqT/03XldVXK+Mv+Rj8Cf9hqT/ANN15XVUAFFFFABRRRQAUyaNJoXilUPG6lWU9CDwRT6KAOc0EtFYXOk3ZMlxpx8tWbq8R/1bf988H3U1zOg6/f8AhXWP7A8UI5tJZSLC/RGMbox+VSR93GcEHpx1B467xBZTebDqdgpa7t1KPEP+W8J+8h9x95fce5rUt2jntkYYdCAeRUWdybFHXIpESO/tIzJdWuWCDrIh+8n4jke4FaFtPHc28c0Lbo5FDKfUGpayLMf2bqLWZwLW5LSW/YK3Vk/9mH4+lVsxmvRRRTGR3DFYjt+8flH1NORQiKq9AMUz79xn+FB+pqWkBDcqSgdBl0O4e/tUkbh0DL0IzTqrRfuLgxY/dv8AMh9D3H9aNgLNFFFMAooqnfysSltCcSy9x/Avc0MBIP8ASrtpjzFFlY/c9z/SrtMhjWKJY0GFUYAp9JARoNs7j+8AaqaxpNprFukF+jPErh9quVyffFWpMiaIg8HKnj2qWi3QCvDFa6dYiOJIra0gToMKiKOT9BXN+DkfVbu78UXKMv21RFYo4wY7RTlTjsXPzn2KjtTfFjnW9Sh8MQMRBIouNUkB+5b54jz2MhGP90P7Vc+0LrwNppjAaUh8ua4j+7IBwY4yO3YkfQVLYrmjptydQkkuU/49VYpCf7+Or/TPT6Vo0yKNIY1jjUIijCqowAKfVIYUUUUwCiiigAooooA5Xxl/yMfgT/sNSf8ApuvKNN/5Kn4h/wCwLpn/AKPv6PGX/Ix+BP8AsNSf+m68o03/AJKn4h/7Aumf+j7+gDqqKKKACiiigDmvF6eZNYA9i56Z7CpvC8Wz7QcYztH86XX18y9txjOEY/qKtaEgVJSO5Hatv+XZ6Ep2wqj/AFuZPilRvIA/h6fia8c8TRA3oBHLHqBXtHiUBpXxgkKM15PrFv5l5mRRwxOPxr1cHL3Ed+CnyUUjqPglb7Z9Vlx0SJM4x3c12nivw/Fq9q5EatLtwynpIPT6+hrB+EVuYrDUZCPvyoOnov8A9eu/rzMRP99Jo4MRXnSxLqQeqt+R87anp11pM8kStIImyASMb+fut6MP/r1ILV4hamw1G3a7nby/3RZXtjjJf/aUAEnpyK9j8UeHItWiZ0VPOIwysOJB7+h9DXj93pVxoMt2CH8to3jVmHzRlsfK35Yz3FZqyV1t+R9fgczjjqdr2n27/wBfj+Bfm1qdbmBLWW6kULgNcymV5sdS/bn+6Bgdqbq+mR6zbtNoNxDFdp8zWkwIBHcZ7fUZHriuYsNUdbgy3G2N7cb23cAAH/I/GtS0kW1uTNJJIYoSZLfClG3/AMIbPYd/UDHerpYlrqdk8K6LvS0aXrfyZyGsaWl4ZY5IzDeRNseM4LIw6j3HfPcGuE1DTZbS4JB2sPToa9j8U6Bc+INRi1vwo9vcSmNY7ywMoSSN16MAfQHHuMYNc/rPhrW4oRNqOlOqAZJjIcgd84/wroqUo1VzQ3O3C46FWKhVdpdr2d/I4rTNWu4UETS74McxuodPyPSrso0S7uUnmsxDM4H762YxZPoQCRWfc2piYS2x346r3xWxpVjp1xciw85Df7BOYSMHaR1Hr+FOlFzXLNfedNaVNW5zRsrDQ5444vIknSBvM/0mdjGmR8xPT0rSe7hivrTVPD01rKtggi8i3bKiPnKH/eyeT3ritUtLvTtJ1u3nysnlYGONyZGW+mM1n/Dy+NnfTsQWhb5HTGcrznH86qUeWago7/ocVWUXVVNK91/n/ke565DFf2UOt2Ll4TGDMAPvR9A5H95Oh9vpWFFcRR3Dl0MkoxtAJAU9j71Z8Nah/ZmrQ2QYS6detuiJwRlhx+B5BFVr6weHWb2ySRILa3KhJNpaSRGG5Vx2UDgnrxXLjaHJJTXUjDPkvRnta69P6/qxcsWlUSzhj5gAXI5O49h+GaiglvJNeF/bs0stuoJOOD6hvbFOZ7qUopVMKCmxQFVD3247GnRq5RYyqRwx8iNORk9WPqTXDK62vp+Zq1u3bX8i/qHhux1m4bUbB0SK5G6VG6xydwQOn1/Glit18N6bLLC0Ump3C+XCikYT/a+g6k+uBWPJaw3MjSTRb9jEqdudpCnk46gVWSWKIbnSGJiMfLg8fh2/Sup4+bhytWIVCUo+zc7xVtLfhe/3k7h9wkDNEG++jkEg/UcGobmWSGQywCN/lKvDLkJKvXGR0PcGplu2jOx4NyP8rK4yjj69vrXN6vKYDBbQO5gmAkikYchOuCfUciuWc+WPMjtpw5nyyNXwzDbXPiBpLeO4jMKeZJFKo+QnhQGBw3cg19LeHLL+z9GtYCMOE3P/ALx5NeMfCDRWvJ7eSeM7ZW+0uCOiL9wfy/OvehV01aCv11PieKMVz1VQTvb+v8woooqz5UKKKKAOV1L/AJKn4e/7Aup/+j7CuqrldS/5Kn4e/wCwLqf/AKPsK6qgDlfGX/Ix+BP+w1J/6bryuqrlfGX/ACMfgT/sNSf+m68rqqACiiigAooooAKKKKACoHUw7niTPdkUdfp71PRQBXsryC9iMlu+4KxRhjBVh1BHY1Hqlmt9amPO2RWEkT90ccg/57VaVFVmZVAZupA606lutQK2n3P2q3DsuyVTskT+6w6ip5GCIWPYVVuFNtObmNco3EyjuOzfh/KppSshiUHKsd2R0IHNK4D4U2Jg9TyfrT6KKoAqK5i86PbnDAhlPoRUtFAEdvJ5sYYjDdCPQ1JVdv3VyG/gk+U+zdqsUkAyaRYomkkOFUZNVtPib57mcYnm5IP8C9lpJB9sugnWCE5b0Zuw/CrtG4BRRRTAjuPuBv7rA1R17VV0qxMoia4uZD5dvbofmmkPRR6e57DJp2tXy2druEUk8mQFhiGXc9gB/jVfSdOnN0dS1Yq9+42pGvKWyH+BT3Pq3f2GBU310EYy+CYr7Qp7PW7qeWe/l+0ak9vIY/tDYAEe4ciNQAoUY4H1rqrCzt9Ps4LSyhjgtoECRxIMKqjoAKnoppJDCiiimAUUUUAFFFFABRRRQByvjL/kY/An/Yak/wDTdeUab/yVPxD/ANgXTP8A0ff0eMv+Rj8Cf9hqT/03XlGm/wDJU/EP/YF0z/0ff0AdVRRRQAUUUUAZWpQGW8U4yAmM496s6dGY1kBGOR/KrHlqZGYgZ4FOVdpOMc1XNpY1lUvHlMTWodzSsByQBn8K831e0Zrlvl6k9hXrdzAJY5OMnNcne6UHn3EdeK78JVSVmduGqpx5exe+HsHkaNNxgtO2fwAFdRWX4cg+z6cVIxmRm/WtSuGo7ybOTEy5qsmu4Vla5otvqsR3gLPjAkxnj0I7itWipTad0Z06kqclKDszwTxf4Pu7C9t5IYg8UMomNrjiYryu1u4BwSh9KwEu7nUboy6lPJN5ZOdxO7Oc7Tn7tfSd5aQXkDQ3MYkQ9j29x6V5v4s8BBi11amQuBgTRAeao9GHRx9amUFLWOj7H2OW59CpaGI0l0f9f16nnk01tAipJHH9odhLPIi/OzkdN3UKq4AA4496v2Gp6jHcR/YbnzlWVRteYtFNDyWJJzj5RkEcgisq+sZbKfdqqM9ooOZIASkx7Bz1Qeo6HpmmWutvcapAkyl2VSiLwqlMEbRjgAgnGPWo9q4S101PelRVSD5VzK39f10J9c0DRdduHvtF1WLTrtzuktrpMIx7kY6H1I4PoK86+JPgzWLKXTNYtI3kjh/dG7sz5gBByDlenU13NtZ28lvFcwSN5cgeNGcY3AErkj25Ge5BrZS+bTLl5tHYQxbUhxgFZiiAZdem44PPBrp+t88HGp+G/qZVaDcfZRfMvPpZ7XX/AAThvCesN4usJ9KvoA+rQRGSKVY8iZRwysPcGuWvtL/4RPUm8wSR2cpwgkBDRt/cPt6HuK9fvdcv478fZRp1m7RyPc3FtajznWNd20FsjGTT4NYs/ENk0eu6ZBqMIGWzGEkjHuOh+oxXVTxsVFRm7yXUlKqn7RR28+/3aP1OR8ERtq2s2MFvIJoLaQXZdGBEacllPod2MD3rq9auFudZ1CaBDIkTJA+3kqVTknHbJ61esNRsdJtpbXQNJt7CFAG3YGN577QPmIHPJx0rnUhaCa3MFvvlALSzAlGeTcdzFgc5OQcdOaxxWJhVtGOxrTc6lT2lRW0sl+LL8E0UiEywh1XGPnIz7HHUVZhu1klQkIiRA7I0TAz/AJ7moZLpfMQSRqSTtZlAUv8AUjv71BdPGAZLZyqMNmJHyEbs2cdCeDXDz9maOPNui20zQ2QgtfkkZ8s/Qt6fhms77fcSO8NyxLBTgEAdfp9BVSC8uXlMdxGIZRzgVUnv0n10FG278pj14zn9M1n7Vtb+R0U8Pa9153HPrKC2cxXZt2IO9VxkY4PBH15rN0Qz6vLFptvh9NdiWaRdzwRA5IV89GPGD6msq40+bWPEM6W8TbGlYLH0zjAP0Hcmvevhb4MigjW4nQNCjbixXHnOP/ZR/nvU0+epLV+6jPMsXRwNB1Hudr4F0cabpYlkTZPOA2MfdT+Ef1rpaKK62flletKvUdSW7CiiigyCiiigDldS/wCSp+Hv+wLqf/o+wrqq5XUv+Sp+Hv8AsC6n/wCj7CuqoA5Xxl/yMfgT/sNSf+m68rqq5Xxl/wAjH4E/7DUn/puvK6qgAooooAKKKKACiiigAooooAKKKKAA1neVdQXyCFEksypP3sNG3pjup/StGik1cAooopgFFFFAEc6eZEynjuD6GoZJWdUji4ldQSf7o9atMAwIPQ1U0/T7fT45EtlYCR2kcs5Ylj15JP5dKTTAsQxrFGqIMKKfRRTAKbIu9GUMVJGMjqKdRQBXs7OK1jCR7iR1ZzuY/UmrFFFFgCiiigAooooAKKKKACiiigAooooA5Xxl/wAjH4E/7DUn/puvKNN/5Kn4h/7Aumf+j7+jxl/yMfgT/sNSf+m68o03/kqfiH/sC6Z/6Pv6AOqooooAKKKKACiiigAxUTQRs24qM1LRQnYabWxDax+XDt6ck/rU1AooBu7uFFFFAgooooAyNU0Cy1DLsnlTH/lpGMZ+o6GvOPEXw2eMSy6cDFIVIEtsoOCe5jPf6V69RTvdWlqj0cJmmIwj9yWnY+a7/QtTtoIIUQlbaJIUMBydqjHKHkHqT15NZkTT2witb37ssxWTcCvyAFs89DkcfWvpy+060vhi6gjkPqRyPx61gah4MtLhSIZmQf3JFDr+tZulFvmTsfR4fianKPJVjb+v66Hz3bXksl9bx3CGNznbNH1jbGNwP8weCOtX4dQa3u7JQgV5UUuQPlRtvIx6e3oa6j4jR6F4INj/AMJHsVL0usUkEJbG0DO4DkfeHrXHHX/AN3E3l6zHGCMEEyx8fiKx9jOOkZL7z2oZnha65ls0Nt9ZiSCJpkYPODL8pyihvuqPbGPrmp4dWgjhi847WkUMxHPHIH8qqPqPgXyYox4gjEUKCNFE7fdHQcr2zUYi8GX0vyeJozJtEYBulHHoMqKTpVFezX3mixeHas2XhrttdGaKN1WYKCkmASBkDJHfHpVC41ewh862M7Sqd8b7lALHPPHbntVm08LaDNcLBYa0J7icGNYop45XcHqABye/5V0CfDCe7kR/LvpJAAPNaJdzY4yzEcnHeplTrNWtqaLGYOm7uVkcQdaxaumkwLEHG2RwvLe5PX9aZ4f0m91GSd4YfndGRbhz+7iDcM2f4mx0A/SvYdG+EwVlN4i8HI+0SeZj/gK4WvQtI8Kadp4RmT7RIo4MgG1foo4FOGGk2nUl8kefjOJcLRi40febOC8BeBSEEs3meW+PNuZAA82OyjsP0+pr1qCGO3hSKFFSNBhVXoBTwAKWutJJWR8NjsfVxs+ep9wUUUUHEFFFFABRRRQByupf8lT8Pf8AYF1P/wBH2FdVXK6l/wAlT8Pf9gXU/wD0fYV1VAHK+Mv+Rj8Cf9hqT/03XldVXK+Mv+Rj8Cf9hqT/ANN15XVUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByvjL/kY/An/Yak/9N15Rpv8AyVPxD/2BdM/9H39HjL/kY/An/Yak/wDTdeUab/yVPxD/ANgXTP8A0ff0AdVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHhf7RmlLrOp6JC4DCCGVwCe7Mo/wDZa8Ru/BQBPlqoH0r6S+JMP2rxHGB/yyt1H5sTXNw6R5rKiqCznaM11whGUEmj73K506eDpqXb9bnzXq/hxrP/AFiLjpx61zstn8xC8fWvo/x1oSxxTx7MlSRzj0614xPpzCdhtPsBXDXwrUv3Z3yw1LEQU4o6P9mjTfO+MekNIn/HvFPN/wCQyB/6FX28K+X/ANmjSvL8fT3DDJh098H03Og/xr6hFaOHs/dPiM4pKliORdEFFFFI8oKKKKACiiigAooooAKKKKAOV1L/AJKn4e/7Aup/+j7CuqrldS/5Kn4e/wCwLqf/AKPsK6qgDlfGX/Ix+BP+w1J/6bryuqrlfGX/ACMfgT/sNSf+m68rqqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5Xxl/yMfgT/sNSf+m68o03/kqfiH/sC6Z/6Pv6PGX/ACMfgT/sNSf+m68o03/kqfiH/sC6Z/6Pv6AOqooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDiPEFp9o165fGQAi/wDjv/16LbTjFJE5U4Vga6j7Esk8sjj7zZ/TFTm1j2kY4NaQqWR6f1/lgoLorHmPjvTQ11MduVdQSPw/+tXk134eAmkYL15J719DeI7AzSM5XjGB9K4m40b5yNvP866FJNXZ9HlmYJUVFsrfAjSzaa1q87A5+zxoM9ssTj9K9orjvh5Yi0OpNtwWZE/Jf/r12Ncs3zO583m9RVcXKS8vyQUUUVJ5oUUUUAFFFFABRRRQAUUUUAcrqX/JU/D3/YF1P/0fYV1VcrqX/JU/D3/YF1P/ANH2FdVQByvjL/kY/An/AGGpP/TdeV1Vcr4y/wCRj8Cf9hqT/wBN15XVUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByvjL/kY/An/AGGpP/TdeUab/wAlT8Q/9gXTP/R9/R4y/wCRj8Cf9hqT/wBN15Rpv/JU/EP/AGBdM/8AR9/QB1VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADJY1kXDDNUZNKgcgkdK0aKC41JR+FlTT7dbcTADG6Qn9BVugUUkTKTk7sKKKKYgooooAKKKKACiiigAooooA5XUv+Sp+Hv+wLqf8A6PsK6quV1L/kqfh7/sC6n/6PsK6qgDK8Q6BYeIIbWPUluf8ARZvtED213LbSRybGTIeJlYfLI4xnBDGsr/hA9I/5/PEn/hR6j/8AH6KKAD/hA9I/5/PEn/hR6j/8fo/4QPSP+fzxJ/4Ueo//AB+iigA/4QPSP+fzxJ/4Ueo//H6P+ED0j/n88Sf+FHqP/wAfoooAP+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6KKAD/hA9I/5/PEn/hR6j/8fo/4QPSP+fzxJ/4Ueo//AB+iigA/4QPSP+fzxJ/4Ueo//H6P+ED0j/n88Sf+FHqP/wAfoooAP+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6KKAD/hA9I/5/PEn/hR6j/8fo/4QPSP+fzxJ/4Ueo//AB+iigA/4QPSP+fzxJ/4Ueo//H6P+ED0j/n88Sf+FHqP/wAfoooAP+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6KKAD/hA9I/5/PEn/hR6j/8fo/4QPSP+fzxJ/4Ueo//AB+iigA/4QPSP+fzxJ/4Ueo//H6P+ED0j/n88Sf+FHqP/wAfoooAP+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6KKAD/hA9I/5/PEn/hR6j/8fo/4QPSP+fzxJ/4Ueo//AB+iigA/4QPSP+fzxJ/4Ueo//H6P+ED0j/n88Sf+FHqP/wAfoooAP+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6KKAD/hA9I/5/PEn/hR6j/8fo/4QPSP+fzxJ/4Ueo//AB+iigA/4QPSP+fzxJ/4Ueo//H6P+ED0j/n88Sf+FHqP/wAfoooAlsfBOj2ep2eoK+r3FzZu0kBvNYvLlI3ZGjLBJZWXO13GcfxGpdY8I6Vq+qtqVydShvWhS3aSy1S6tN8aM7KGEMihsGR8EjPzGiigCr/wgekf8/niT/wo9R/+P0f8IHpH/P54k/8ACj1H/wCP0UUAH/CB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wAKPUf/AI/RRQAf8IHpH/P54k/8KPUf/j9H/CB6R/z+eJP/AAo9R/8Aj9FFAB/wgekf8/niT/wo9R/+P0f8IHpH/P54k/8ACj1H/wCP0UUAH/CB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wAKPUf/AI/RRQAf8IHpH/P54k/8KPUf/j9H/CB6R/z+eJP/AAo9R/8Aj9FFAB/wgekf8/niT/wo9R/+P0f8IHpH/P54k/8ACj1H/wCP0UUAH/CB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wAKPUf/AI/RRQAf8IHpH/P54k/8KPUf/j9H/CB6R/z+eJP/AAo9R/8Aj9FFAB/wgekf8/niT/wo9R/+P0f8IHpH/P54k/8ACj1H/wCP0UUAH/CB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wAKPUf/AI/RRQAf8IHpH/P54k/8KPUf/j9H/CB6R/z+eJP/AAo9R/8Aj9FFAB/wgekf8/niT/wo9R/+P0f8IHpH/P54k/8ACj1H/wCP0UUAH/CB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wAKPUf/AI/RRQAf8IHpH/P54k/8KPUf/j9H/CB6R/z+eJP/AAo9R/8Aj9FFAB/wgekf8/niT/wo9R/+P0f8IHpH/P54k/8ACj1H/wCP0UUAH/CB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wAKPUf/AI/RRQBa0fwjpWkaqupWx1Ka9WF7dZL3VLq72RuyMwUTSMFyY0yQM/KK6CiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Watchman left atrial appendage (LAA) closure technology.",
"    <br/>",
"    (B) Watchman LAA closure technology in anatomical position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Jain AK, Gallagher S. Technology and guidelines Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism: NICE guidance. Heart 2011; 97:762, with permission from BMJ Publishing Group Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22950=[""].join("\n");
var outline_f22_26_22950=null;
var title_f22_26_22951="Hysteroscopy: Managing fluid and gas distending media";
var content_f22_26_22951=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hysteroscopy: Managing fluid and gas distending media",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/26/22951/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/26/22951/contributors\">",
"     Linda D Bradley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/26/22951/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/26/22951/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/26/22951/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/26/22951/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/26/22951/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysteroscopy is a procedure in which a telescope is used to inspect the cervical canal and uterine cavity. This technology has provided a minimally invasive option for diagnosis or treatment of women with common gynecologic issues, such as abnormal uterine bleeding or uterine fibroids.",
"   </p>",
"   <p>",
"    Panoramic hysteroscopy is the most common method. A uterine distending medium is used to allow a global view of the endometrial cavity. Carbon dioxide and low viscosity fluids are the most frequently used distending media. Each medium has advantages and disadvantages, including specific safety concerns.",
"   </p>",
"   <p>",
"    Contact hysteroscopy is another method, but it is rarely performed. Since no distending medium is used, only tissue in direct contact with the scope can be viewed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of and prevention and management of complications from hysteroscopic distending media will be reviewed here. Other hysteroscopic topics are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link\">",
"     \"Overview of hysteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS OF DISTENDING MEDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Types of media, biochemical properties, adverse effects, and safety measures are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef71692 \" href=\"UTD.htm?21/17/21789\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ideal characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideal characteristics of a distending medium are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Allows clear visualization",
"     </li>",
"     <li>",
"      Nonconductive (to avoid electrocautery-related injury)",
"     </li>",
"     <li>",
"      Inexpensive",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since distending media are absorbed, a medium should also be:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nontoxic",
"     </li>",
"     <li>",
"      Hypoallergenic",
"     </li>",
"     <li>",
"      Non-hemolytic",
"     </li>",
"     <li>",
"      Isoosmolar",
"     </li>",
"     <li>",
"      Rapidly cleared from the body",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fluid media",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-viscosity fluids are used for uterine distension during hysteroscopy. High-viscosity fluids (ie, 32 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    70 [Hyskon&reg;]) have little role in modern hysteroscopy because they are associated with increased risk of complications (eg, electrolyte imbalance, anaphylaxis, and disseminated intravascular coagulation) and can ruin expensive hysteroscopic equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluid distending media may be either electrolyte (eg, normal saline, lactated Ringer's) or electrolyte-poor (eg, glycine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    ). The choice of fluid type depends upon whether a diagnostic or operative procedure is planned and on the surgeon's choice of equipment (ie, monopolar or bipolar energy source). Each type of fluid can result in complications if not used properly (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Complications and adverse effects'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Electrolyte",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of low-viscosity distending media: those that contain electrolytes and those that do not. The electrolyte-containing media include normal saline and lactated Ringer's solution and cannot be used with monopolar electrocautery because they conduct electric current (but can be used with mechanical, laser, or bipolar energy). The electrolyte-poor solutions are 5 percent dextrose, 1.5 percent glycine, 3 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    and 5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , and are used with monopolar energy systems.",
"   </p>",
"   <p>",
"    The electrolyte fluids used for hysteroscopy are isoosmolar (isotonic), and thus do not disturb the osmolar balance between intracellular and extracellular fluid. While the risks of fluid absorption are associated mainly with electrolyte-poor fluids, intravasation of large volumes of electrolyte fluid can also lead to fluid overload (eg, pulmonary edema) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Electrolyte-poor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrolyte-poor fluids that are used most commonly for hysteroscopy are: 1.5 percent glycine, 3 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , 5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    . Each has different properties and is metabolized by a different mechanism (",
"    <a class=\"graphic graphic_table graphicRef71692 \" href=\"UTD.htm?21/17/21789\">",
"     table 1",
"    </a>",
"    ). The physiology of these fluids is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8858?source=see_link\">",
"     \"Hyponatremia following transurethral resection or hysteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All the electrolyte-poor fluids used in hysteroscopy can lead to hyponatremia if a large volume is absorbed.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     Mannitol",
"    </a>",
"    differs from the others because it is isoosmolar, but is not commonly used because it is not available in the 3 L bags typically used for hysteroscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Inflow and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflow and monitoring are controlled by the hysteroscope and the fluid inflow system. The surgeon should be frequently updated regarding the fluid deficit, particularly when the deficit approaches 500 mL. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnosis and management of fluid overload'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We prefer a hysteroscope that has a dual outer sheath or dual port system with an outflow port that can be directly connected to a vacuum collecting system. This gives an accurate assessment of the fluid deficit, as less media is lost in the drapes, towels, or on the operating room floor.",
"   </p>",
"   <p>",
"    Use of an automated fluid pump and monitoring system is advocated by both the American College of Obstetricians and Gynecologists and the American Association of Gynecologic Laparoscopists [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Automated systems have the following advantages over manual set-ups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Continually measure fluid deficit and provide automated alerts",
"     </li>",
"     <li>",
"      Measure and titrate intrauterine fluid pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most automated hysteroscopic pump systems allow you to set the desired intrauterine pressure manually, and the system will then adjust the flow of fluid to maintain this pressure. In addition, automated pump systems should be set to give audible alerts at each 250 mL of additional fluid deficit.",
"   </p>",
"   <p>",
"    Titrating intrauterine pressure is important to manage bleeding, facilitate full resection of endometrial lesions, and decrease \"false-negative\" views of the endometrial cavity that may occur with higher or constant endometrial pressure. The surgeon should use the lowest pressure that allows optimal visualization. Typically, intrauterine pressure ranges from 70 to 80 mmHg. Higher pressures (up to 100 mmHg) may be required for patients with intrauterine bleeding, blood clots, or other debris; a uterine wall that is less compliant than average; or a uterus that is large",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    has intramural fibroids. A higher intrauterine pressure may result in increased absorption or extravasation of the distending medium. Thus, if a higher pressure is used, the fluid deficit should be monitored closely, the procedure should be performed as quickly as possible, and the pressure should be lowered if the higher pressure is no longer needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8858?source=see_link&amp;anchor=H13#H13\">",
"     \"Hyponatremia following transurethral resection or hysteroscopy\", section on 'Minimize fluid pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Where automated systems are not available, a manual technique is used. Fluid is infused using the force of gravity (ie, elevating the fluid bag) or by placing the fluid bag in a large blood pressure cuff and inflating the cuff. Fluid input and output are recorded manually.",
"   </p>",
"   <p>",
"    A surgical staff member should be designated to frequently measure the input and output and report the deficit to the surgeon. To record fluid input manually, the volume of fluid in each bag must be known. Some surgeons make calculations based on the common assertion that fluid bags are generally overfilled by 10 percent or more (eg, a 1000 mL bag of normal saline is considered to have 1100 mL or more); this leads to an overestimate of the fluid deficit. However, a study of bags of normal saline, glycine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    found that the average overfill was only 3 to 6 percent of the bag volume [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/7\">",
"     7",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H11\">",
"     'Fluid overload'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    To avoid hypothermia during longer procedures (ie, operative versus diagnostic hysteroscopy), fluid distending media should be warmed to room temperature at a minimum; hypothermia may potentiate the risk of acidemia and cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gaseous media",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon dioxide is the only gaseous medium used in hysteroscopy; it is used solely for diagnostic hysteroscopy. It provides a clear field of view, is rapidly absorbed, and has a long history of safety in tubal patency testing [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/9\">",
"     9",
"    </a>",
"    ]; it is also widely available and makes cleaning of instruments easy. However, it is best suited for diagnostic rather than operative hysteroscopy, since gas bubbles form in association with intrauterine bleeding and impair visualization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carbon dioxide must be insufflated with a special instrument known as a hysteroinsufflator (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Prevention of gas embolism'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effects on operative visualization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The angle of view and magnification vary with the refractory index of the distending medium. Gaseous media (eg, carbon dioxide) allow perception of the maximal angle of view, while liquid media reduce the angle of view [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/11\">",
"     11",
"    </a>",
"    ]. Use of gaseous media is usually limited to diagnostic procedures, since gas bubble may interfere with visualization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AND ADVERSE EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fluid overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid overload is rare, occurring in 0.06 to 0.2 percent of operative hysteroscopy procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Complications related to distending media vary according to the patient population and the medium used.",
"   </p>",
"   <p>",
"    A patient's ability to adapt to fluid overload varies with age and comorbid conditions. Absorption of large volumes of electrolyte-poor fluid may result in the following complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Volume overload &ndash; acute decompensated heart failure, pulmonary edema, dilutional anemia",
"     </li>",
"     <li>",
"      Electrolyte or other plasma imbalance &ndash; hyponatremia, hypoosmolality, hyperammonemia, hyperglycemia, acidosis",
"     </li>",
"     <li>",
"      Neurologic sequelae &ndash; slurred speech, visual disturbances, hypersomnia, confusion, seizures, coma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During hysteroscopy, absorption is increased when venous sinuses are exposed (eg, during myomectomy). In addition, minimal fluid extravasates through the Fallopian tubes; history of prior sterilization does not alter total absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyponatremia is a particular risk with electrolyte-poor fluids. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8858?source=see_link\">",
"     \"Hyponatremia following transurethral resection or hysteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prevention of fluid overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid overload and electrolyte imbalance can be prevented by following several operative principles (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Fluid media'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use isoosmolar, electrolyte fluids whenever possible",
"     </li>",
"     <li>",
"      Monitor fluid deficit closely and halt the procedure and evaluate for fluid-related complications at absorption thresholds",
"     </li>",
"     <li>",
"      Maintain intrauterine fluid pressure at or 70 to 80 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Limit surgical time to &lt;1 hour [",
"      <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These measures are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8858?source=see_link&amp;anchor=H9#H9\">",
"     \"Hyponatremia following transurethral resection or hysteroscopy\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measures specific to hysteroscopy for prevention of excessive fluid absorption include use of a vasoconstrictor. This was illustrated in randomized trials in women undergoing operative hysteroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Intracervical injections of a dilute vasopressin solution (eg, 1 unit per 20 mL normal saline) at two sites around the cervix, 10 mL each, before the procedure compared with placebo resulted in a three-fold decrease in fluid absorption. Blood loss was also decreased.",
"   </p>",
"   <p>",
"    Other methods of limiting fluid absorption during hysteroscopy have not been widely adopted. Treatment with a gonadotropin-releasing hormone analog reduced deficits in one small randomized trial (n = 17), however, these results have not been further evaluated and the side effects (eg, hot flashes) induced by these drugs may outweigh possible benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, to improve detection of fluid absorption, it has been proposed to add an easily measurable tracer to distending media (eg, ethanol) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, this has not proven to improve monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Diagnosis and management of fluid overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious complications of electrolyte-poor fluid overload have been reported at a fluid deficit of 500 to 1000 mL and are more likely to occur in patients with comorbidities (eg, heart disease). Thus, depending upon the type of fluid used and the health status of the patient, when the fluid deficit reaches 500 mL, the surgical team should pause and assess patient status. After estimating the amount of time necessary to complete the procedure, the team should either expedite the completion of the procedure or terminate the procedure.",
"   </p>",
"   <p>",
"    For nonconductive, electrolyte-poor fluids, the procedure should be terminated when 1000 mL has been absorbed and the patient evaluated for hyponatremia. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8858?source=see_link&amp;anchor=H9#H9\">",
"     \"Hyponatremia following transurethral resection or hysteroscopy\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For electrolyte-containing media, the criteria for terminating a procedure are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      2500 mL for younger patients with no comorbidities; some data suggest that fluid intravasation of &gt;1000 mL is associated with an increased risk of gas embolism [",
"      <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Gas embolism'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For other patients, the threshold must be individualized according to cardiovascular status or other comorbidities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Terminating the infusion at lower thresholds is reasonable in outpatient settings with limited acute care and laboratory services. In addition, all procedures should be terminated if uterine perforation occurs, since large volumes of fluid may rapidly enter the circulation via the peritoneal cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4408?source=see_link\">",
"     \"Uterine perforation during gynecologic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a criterion for stopping a procedure is met, the following steps should be taken to evaluate the patient:",
"   </p>",
"   <p>",
"    &nbsp;(1) &nbsp;Halt procedure &mdash; discontinue fluid inflow, remove all instruments; if there is active bleeding, a 30 to 50 mL Foley catheter can be inserted in the uterine cavity, inflated, and removed after six to eight hours",
"   </p>",
"   <p>",
"    &nbsp;(2) &nbsp;Ask about symptoms of volume overload, hyponatremia, or glycine toxicity (in patients who are not under sedation or general anesthesia) &mdash; nausea, headache, visual disturbance, prickling or burning sensation in the face and neck, chest pain, shortness of breath [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/15\">",
"     15",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    &nbsp;(3) &nbsp;Evaluate hemodynamic status &mdash; vital signs, central venous pressure, oxygen saturation",
"   </p>",
"   <p>",
"    &nbsp;(4) &nbsp;Evaluate mental status",
"   </p>",
"   <p>",
"    &nbsp;(5) &nbsp;Perform laboratory evaluation &mdash; hematocrit, platelets, blood urea nitrogen, creatinine, sodium, potassium, bicarbonate, chloride, glucose, ammonia (glycine is metabolized to ammonia), and plasma osmolality",
"   </p>",
"   <p>",
"    Evaluation of the patient should be individualized according to a patient's comorbidities. For example, there is a higher risk of sequelae from metabolism of glycine to ammonia in a patient with liver disease. The metabolites of each distending medium are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef71692 \" href=\"UTD.htm?21/17/21789\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients who have an excessive fluid deficit but show no signs or symptoms of fluid overload can be observed, but this observation must be continued postoperatively. Plasma dilution peaks at approximately 15 to 20 minutes after fluid infusion, but fluid and electrolyte shifts continue for several hours afterward [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a fluid-related complication is suspected, a management plan must be initiated by the surgeon and anesthesiologist. Depending on the degree of fluid overload or electrolyte imbalance, management may include observation, diuresis, intravenous administration of corrective fluids (eg, hypertonic saline), or hemodialysis. Consultation with a nephrologist or cardiologist, or transfer of the patient to a critical care setting, may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gas embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gas embolism appears to occur frequently in patients undergoing operative hysteroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Gas embolism may result in cardiovascular collapse or pulmonary edema, but few hysteroscopy patients experience clinically significant cardiac or pulmonary complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gas embolism may result from use of carbon dioxide for distension. It may also occur with either gas or fluid media with introduction of air through the open cervix or with removal and reinsertion of instruments or tissue or, alternatively, through creation of gas bubbles with electrosurgical vaporization of tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/4,25\">",
"     4,25",
"    </a>",
"    ]. Gas embolism can cause cardiovascular collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Prevention of gas embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive steps for gas embolism during hysteroscopy include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Keep the patient in flat or reverse Trendelenburg position",
"     </li>",
"     <li>",
"      Avoid use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"       nitrous oxide",
"      </a>",
"      for anesthesia (this may enlarge air bubbles)",
"     </li>",
"     <li>",
"      Purge air from all tubing prior to insertion into the uterus",
"     </li>",
"     <li>",
"      Maintain intrauterine pressure at &lt;100 mmHg",
"     </li>",
"     <li>",
"      Limit removal and re-introduction of the hysteroscope (this may force air or gas into the uterus)",
"     </li>",
"     <li>",
"      Remove intrauterine gas bubbles (ideally with a continuous outflow system)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limiting the distension fluid deficit may also be associated with a decrease in the risk of gas embolism, regardless of the type of fluid or type of electrosurgical instrument. This was illustrated in a randomized trial (n = 50) that found that use of either monopolar and bipolar electrosurgery for operative hysteroscopy resulted in evidence of intracardiac gas bubbles in nearly all patients, although no patients required treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/25\">",
"     25",
"    </a>",
"    ]. A subset analysis found that the likelihood of gas embolism was significantly higher with a fluid deficit of &gt;1000 mL compared with &lt;1000 mL.",
"   </p>",
"   <p>",
"    Carbon dioxide must be insufflated with a special instrument known as a hysteroinsufflator. The laparoscopic insufflator delivers 1",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    or more of flow and should",
"    <strong>",
"     NEVER",
"    </strong>",
"    be used for hysteroscopy, as a gas embolism may occur.",
"   </p>",
"   <p>",
"    Hysteroinsufflators can be set to reach a target intrauterine pressure of less than 100 mmHg or to deliver a constant rate of flow of less than 100",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/5,6,28,29\">",
"     5,6,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Diagnosis and management of gas embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspnea is the most common symptom; other signs and symptoms are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef76772 \" href=\"UTD.htm?20/14/20716\">",
"     table 2",
"    </a>",
"    ). A fall in a patient's end-tidal carbon dioxide pressure may raise intraoperative suspicion of gas embolism, but may also be present in other conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If gas embolism is suspected, the procedure should be terminated immediately, the uterus deflated, and sources of fluid or gas removed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supportive care (eg, the use of mechanical ventilation, vasopressors, volume resuscitation as indicated) is the cornerstone of management, but active measures may also be helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Shoulder pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrequently, patients will complain of shoulder pain, likely due to diaphragmatic irritation from carbon dioxide. Symptoms usually subside in less than 15 minutes, without treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/30\">",
"     30",
"    </a>",
"    ]. The type of distension medium may affect the likelihood of shoulder pain. A systematic review of randomized trials found that shoulder pain was significantly reduced when normal saline was used compared with carbon dioxide (OR 0.2; 95% CI 0.1-0.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8775396\">",
"    <span class=\"h1\">",
"     CHOOSING A DISTENDING MEDIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;While diagnostic procedures can be performed using either carbon dioxide or normal saline, randomized trials have found that saline is associated with decreased pain, increased satisfaction, better visualization, and decreased operative time [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22951/abstract/9,12,29,31-33\">",
"     9,12,29,31-33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Shoulder pain'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For operative procedures that use monopolar electrosurgical instruments, a nonconductive fluid (eg, glycine) is required to avoid thermal injury. Bipolar electrosurgical procedures may be performed using an isotonic fluid (eg, normal saline or lactated Ringer's), which avoids the risks of electrolyte and osmolar imbalances associated with nonconductive solutions.",
"   </p>",
"   <p>",
"    Types of media, biochemical properties, adverse effects, and safety measures are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef71692 \" href=\"UTD.htm?21/17/21789\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most hysteroscopic procedures use a fluid or gaseous uterine distending medium to allow a global view. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Operative hysteroscopy can be performed with either monopolar or bipolar electrical energy. Electrolyte-poor fluids are used with monopolar systems. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Fluid media'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Excessive absorption of any fluid medium can lead to complications of fluid overload. The most serious complication is intravasation of large volumes of electrolyte-poor media resulting in hyponatremia. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Fluid overload'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women undergoing hysteroscopy using a fluid distending medium, we suggest using an automated rather than a manual fluid monitoring system (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Inflow and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women undergoing hysteroscopy using an electrolyte-poor fluid distending medium:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For procedures that involve myometrial resection, we recommend an intracervical injection of dilute vasopressin immediately prior to the procedure (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prevention of fluid overload'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest halting the procedure at a fluid deficit of 1000 mL (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis and management of fluid overload'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women undergoing hysteroscopy using an electrolyte fluid, we suggest halting the procedure at a fluid deficit of 2500 mL in women who are less than 50 years old and have no comorbid conditions (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For other patients, the threshold must be individualized according to cardiovascular status. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis and management of fluid overload'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of carbon dioxide for uterine distension requires insufflation with a hysteroscopic insufflator. A laparoscopic insufflator should never be used because it can result in gas embolism. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Gaseous media'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carbon dioxide or air embolism are rare complications of hysteroscopy. These may occur when carbon dioxide is used for distension, or also, if air bubbles are introduced while using fluid media. Dyspnea is the most common symptom. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Gas embolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If gas embolism is suspected, the procedure should be terminated immediately, the uterus deflated, sources of fluid or gas removed, and supportive care provided.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/1\">",
"      Barbot J, Parent B, Dubuisson JB. Contact hysteroscopy: another method of endoscopic examination of the uterine cavity. Am J Obstet Gynecol 1980; 136:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/2\">",
"      Siegler AM. A comparison of gas and liquid for hysteroscopy. J Reprod Med 1975; 15:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/3\">",
"      McLucas B. Hyskon complications in hysteroscopic surgery. Obstet Gynecol Surv 1991; 46:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/4\">",
"      Grove JJ, Shinaman RC, Drover DR. Noncardiogenic pulmonary edema and venous air embolus as complications of operative hysteroscopy. J Clin Anesth 2004; 16:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/5\">",
"      American College of Obstetricians and Gynecologists. ACOG technology assessment in obstetrics and gynecology, number 4, August 2005: hysteroscopy. Obstet Gynecol 2005; 106:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/6\">",
"      Loffer FD, Bradley LD, Brill AI, et al. Hysteroscopic fluid monitoring guidelines. The ad hoc committee on hysteroscopic training guidelines of the American Association of Gynecologic Laparoscopists. J Am Assoc Gynecol Laparosc 2000; 7:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/7\">",
"      Nezhat CH, Fisher DT, Datta S. Investigation of often-reported ten percent hysteroscopy fluid overfill: is this accurate? J Minim Invasive Gynecol 2007; 14:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/8\">",
"      Ananthanarayan C, Paek W, Rolbin SH, Dhanidina K. Hysteroscopy and anaesthesia. Can J Anaesth 1996; 43:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/9\">",
"      Pellicano M, Guida M, Zullo F, et al. Carbon dioxide versus normal saline as a uterine distension medium for diagnostic vaginoscopic hysteroscopy in infertile patients: a prospective, randomized, multicenter study. Fertil Steril 2003; 79:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/10\">",
"      Raimondo G, Raimondo D, D'Aniello G, et al. A randomized controlled study comparing carbon dioxide versus normal saline as distension media in diagnostic office hysteroscopy: is the distension with carbon dioxide a problem? Fertil Steril 2010; 94:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/11\">",
"      Gardner FM. Optical physics with emphasis on endoscopes. Clin Obstet Gynecol 1983; 26:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/12\">",
"      Cooper NA, Smith P, Khan KS, Clark TJ. A systematic review of the effect of the distension medium on pain during outpatient hysteroscopy. Fertil Steril 2011; 95:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/13\">",
"      Aydeniz B, Gruber IV, Schauf B, et al. A multicenter survey of complications associated with 21,676 operative hysteroscopies. Eur J Obstet Gynecol Reprod Biol 2002; 104:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/14\">",
"      Jansen FW, Vredevoogd CB, van Ulzen K, et al. Complications of hysteroscopy: a prospective, multicenter study. Obstet Gynecol 2000; 96:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/15\">",
"      Hahn RG. Fluid absorption in endoscopic surgery. Br J Anaesth 2006; 96:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/16\">",
"      Olsson J, Berglund L, Hahn RG. Irrigating fluid absorption from the intact uterus. Br J Obstet Gynaecol 1996; 103:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/17\">",
"      Paschopoulos M, Polyzos NP, Lavasidis LG, et al. Safety issues of hysteroscopic surgery. Ann N Y Acad Sci 2006; 1092:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/18\">",
"      Corson SL, Brooks PG, Serden SP, et al. Effects of vasopressin administration during hysteroscopic surgery. J Reprod Med 1994; 39:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/19\">",
"      Goldenberg M, Zolti M, Bider D, et al. The effect of intracervical vasopressin on the systemic absorption of glycine during hysteroscopic endometrial ablation. Obstet Gynecol 1996; 87:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/20\">",
"      Phillips DR, Nathanson HG, Milim SJ, et al. The effect of dilute vasopressin solution on blood loss during operative hysteroscopy: a randomized controlled trial. Obstet Gynecol 1996; 88:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/21\">",
"      Taskin O, Buhur A, Birincioglu M, et al. Endometrial Na+, K+-ATPase pump function and vasopressin levels during hysteroscopic surgery in patients pretreated with GnRH agonist. J Am Assoc Gynecol Laparosc 1998; 5:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/22\">",
"      Aydeniz B, Wallwiener D, Rimbach S, et al. [Is co-administration of ethanol to the distension medium in surgical hysteroscopy a screening method to prevent fluid overload? A prospective randomized comparative study of ablative versus non-ablative hysteroscopy and various ethanol concentrations]. Gynakol Geburtshilfliche Rundsch 1995; 35 Suppl 1:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/23\">",
"      Wallwiener D, Aydeniz B, Rimbach S, et al. [Addition of ethanol to the distension medium in surgical hysteroscopy as screening to prevent \"fluid overload\". A prospective randomized comparative study of ablative versus non-ablative surgical hysteroscopy and different ethanol concentration]. Geburtshilfe Frauenheilkd 1996; 56:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/24\">",
"      Molnar BG, Magos AL, Kay J. Monitoring fluid absorption using 1% ethanol-tagged glycine during operative hysteroscopy. J Am Assoc Gynecol Laparosc 1997; 4:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/25\">",
"      Dyrbye BA, Overdijk LE, van Kesteren PJ, et al. Gas embolism during hysteroscopic surgery using bipolar or monopolar diathermia: a randomized controlled trial. Am J Obstet Gynecol 2012; 207:271.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/26\">",
"      Imasogie N, Crago R, Leyland NA, Chung F. Probable gas embolism during operative hysteroscopy caused by products of combustion. Can J Anaesth 2002; 49:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/27\">",
"      Leibowitz D, Benshalom N, Kaganov Y, et al. The incidence and haemodynamic significance of gas emboli during operative hysteroscopy: a prospective echocardiographic study. Eur J Echocardiogr 2010; 11:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/28\">",
"      Groenman FA, Peters LW, Rademaker BM, Bakkum EA. Embolism of air and gas in hysteroscopic procedures: pathophysiology and implication for daily practice. J Minim Invasive Gynecol 2008; 15:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/29\">",
"      Litta P, Bonora M, Pozzan C, et al. Carbon dioxide versus normal saline in outpatient hysteroscopy. Hum Reprod 2003; 18:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/30\">",
"      Nagele F, Bournas N, O'Connor H, et al. Comparison of carbon dioxide and normal saline for uterine distension in outpatient hysteroscopy. Fertil Steril 1996; 65:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/31\">",
"      Brusco GF, Arena S, Angelini A. Use of carbon dioxide versus normal saline for diagnostic hysteroscopy. Fertil Steril 2003; 79:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/32\">",
"      Shankar M, Davidson A, Taub N, Habiba M. Randomised comparison of distension media for outpatient hysteroscopy. BJOG 2004; 111:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22951/abstract/33\">",
"      Paschopoulos M, Kaponis A, Makrydimas G, et al. Selecting distending medium for out-patient hysteroscopy. Does it really matter? Hum Reprod 2004; 19:2619.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3300 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22951=[""].join("\n");
var outline_f22_26_22951=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHARACTERISTICS OF DISTENDING MEDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ideal characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fluid media",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Electrolyte",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Electrolyte-poor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Inflow and monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gaseous media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effects on operative visualization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COMPLICATIONS AND ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fluid overload",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prevention of fluid overload",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Diagnosis and management of fluid overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gas embolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Prevention of gas embolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Diagnosis and management of gas embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Shoulder pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8775396\">",
"      CHOOSING A DISTENDING MEDIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3300\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3300|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/17/21789\" title=\"table 1\">",
"      Hysteroscopy distend media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/14/20716\" title=\"table 2\">",
"      Air embolism clinical findings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8858?source=related_link\">",
"      Hyponatremia following transurethral resection or hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=related_link\">",
"      Overview of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4408?source=related_link\">",
"      Uterine perforation during gynecologic procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_26_22952="Management of nonsustained ventricular tachycardia";
var content_f22_26_22952=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of nonsustained ventricular tachycardia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/26/22952/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/26/22952/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/26/22952/contributors\">",
"     Mark E Josephson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/26/22952/contributors\">",
"     John V Wylie, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/26/22952/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/26/22952/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/26/22952/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/26/22952/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/26/22952/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsustained ventricular tachycardia (NSVT) is a common but poorly understood arrhythmia. It is usually asymptomatic and most often diagnosed on a routine electrocardiogram or on an exercise test performed for other reasons.",
"   </p>",
"   <p>",
"    The presence of NSVT has long been recognized as a potential marker for the development of sustained ventricular arrhythmias and sudden death. Unfortunately, our understanding of which patients with NSVT are at greatest risk for lethal arrhythmias or how the NSVT relates to the lethal arrhythmias is still quite rudimentary. One clearly established premise is that NSVT in the presence of structural heart disease carries a more serious prognosis than NSVT in the absence of a cardiac abnormality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13974?source=see_link\">",
"     \"Nonsustained VT in the absence of apparent structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two general goals in the treatment of NSVT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of malignant, sustained arrhythmias and sudden cardiac death (SCD).",
"     </li>",
"     <li>",
"      Elimination of symptoms caused by NSVT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It remains controversial which patients with NSVT should be treated and what agents should be used. Moreover, it is unclear whether suppression of NSVT is causally related to outcome. Therapeutic trials have been limited to patients with NSVT and coronary heart disease (CHD), a group at higher risk of lethal arrhythmias. Patients with hypertrophic cardiomyopathy are also at increased risk but there is little data concerning the efficacy of antiarrhythmic therapy in this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39702?source=see_link\">",
"     \"Prognosis of nonsustained VT in the presence of structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the data available pertaining to the major therapeutic options, including empiric and electrophysiology (EP)-guided drug therapy and implantable cardioverter-defibrillators (ICDs). The significance and prognosis of NSVT in patients with and without structural heart disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39702?source=see_link\">",
"     \"Prognosis of nonsustained VT in the presence of structural heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13974?source=see_link\">",
"     \"Nonsustained VT in the absence of apparent structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Detailed discussions of risk stratification for arrhythmic death after a myocardial infarction (MI), and the roles of ICDs and antiarrhythmic drugs are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=see_link\">",
"     \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9005219\">",
"    <span class=\"h1\">",
"     DEFINITION OF NSVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of definitions of NSVT have been published, but the most commonly used definition is as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Three or more consecutive ventricular beats",
"     </li>",
"     <li>",
"      A rate of &gt;120",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"     </li>",
"     <li>",
"      A duration of less than 30 seconds",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some definitions allow a rate as low as 100",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    or require a rate as high as 140",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    Others require five complexes, limit NSVT to fewer than 15 beats or to as many as 99 beats, and vary the duration from as short as 15 seconds to as high as one minute.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIARRHYTHMIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies conducted in the 1970s and early 1980s assessed the efficacy of class I antiarrhythmic drugs in suppressing ventricular ectopy after myocardial infarction (MI). The purpose of such therapy was to reduce the incidence of malignant arrhythmias and SCD in post-MI patients with NSVT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39702?source=see_link\">",
"     \"Prognosis of nonsustained VT in the presence of structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These trials showed no substantial benefit but were all too small to draw meaningful conclusions. More recent studies have shown that some antiarrhythmic drugs are associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], while beta blockers and perhaps low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    are beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Class I agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cardiac Arrhythmia Suppression Trial (CAST) evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    , encainide, and moricizine in suppressing ventricular ectopy in almost 1500 post-MI patients, many of whom had depressed left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The average ejection fraction was 39 percent and in 52 percent it was &ge;40 percent. Additionally, only 20 percent of patients had NSVT and only 10 percent had more than one run in 24 hours. The findings were dramatic, showing an increase in sudden death and total cardiovascular mortality in the treated patients even though the original ventricular ectopy was suppressed (",
"    <a class=\"graphic graphic_figure graphicRef59975 \" href=\"UTD.htm?19/4/19534\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The administration of encainide and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      was associated with a significantly increased rate of arrhythmic death or nonfatal cardiac arrest when compared to placebo (4.5 versus 1.5 percent, relative risk of 3.6).",
"     </li>",
"     <li>",
"      Treatment with encainide and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      increased overall mortality (7.7 versus 3.0 percent, relative risk of 2.5).",
"     </li>",
"     <li>",
"      There was an increase in nonarrhythmic death due to myocardial infarction with shock (11 versus 3).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, these class IC agents are not used in the treatment of NSVT in coronary disease. These agents are, in fact, not used for any indication in patients with CHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Beta blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protective value of beta blocker therapy after MI has been well established in many studies, the most notable of which was the Beta Blocker Heart Attack Trial (BHAT) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/3\">",
"     3",
"    </a>",
"    ]. This study randomized 3,837 post-MI patients to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    or placebo. The propranolol group had a 26 percent reduction in total mortality. Subgroup analysis of patients with NSVT revealed a benefit similar to that in patients without NSVT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The agent of greatest interest for treating NSVT in high risk patients is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . In the BASIS trial, for example, 212 post-MI patients with NSVT were treated with low-dose amiodarone (200",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    Holter guided drug therapy, or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with intact left ventricular function, but not those with a left ventricular ejection fraction below 40 percent, had a significant reduction in mortality (1.5 versus 8.9 percent) and arrhythmic events at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/5\">",
"     5",
"    </a>",
"    ]. Although encouraging, the results of a subgroup analysis from a small randomized trial should be interpreted with caution.",
"   </p>",
"   <p>",
"    The efficacy of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    in post-MI patients with NSVT was addressed more completely in the Canadian Myocardial Infarction Amiodarone Trial (CAMIAT) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/6\">",
"     6",
"    </a>",
"    ]. This trial evaluated 1202 survivors of myocardial infarction who had frequent (&ge;10 per hour) ventricular premature depolarizations (present in 60 percent of patients) or nonsustained ventricular tachycardia, documented in 40 percent of patients (although 82 percent had only one run in 24 hours); the patients were randomly assigned to amiodarone or placebo, and approximately 60 percent were also treated with a beta blocker. The following were the major findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arrhythmia suppression was more common with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      (84 versus 35 percent with placebo).",
"     </li>",
"     <li>",
"      The yearly rate of arrhythmic death or resuscitated ventricular fibrillation was significantly lower in the patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , whether intention-to-treat (2.3 versus 3.7 percent) or efficacy analysis (1.8 versus 3.4 percent) was performed.",
"     </li>",
"     <li>",
"      The antiarrhythmic benefit was greatest in patients with heart failure, and was additive to the benefit of a beta blocker.",
"     </li>",
"     <li>",
"      There was no significant difference in yearly all-cause or cardiac mortality between groups (4.0 versus 5.2 percent, p = 0.11).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The factors responsible for the lack of cardiac mortality benefit are not well understood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=see_link\">",
"     \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     EP-guided antiarrhythmic drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that the efficacy of antiarrhythmic drug therapy may be enhanced by the use of EP study to guide selection of a drug for chronic use. The hypothesis is that the ability of a drug to prevent the induction of a sustained ventricular arrhythmia during EP study may predict the efficacy of that drug in that patient.",
"   </p>",
"   <p>",
"    The results of four studies using EP-guided antiarrhythmic drug therapy in post-MI patients with NSVT have been reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/7\">",
"     7",
"    </a>",
"    ]. Over the four studies, approximately 50 percent of patients had inducible ventricular arrhythmias at baseline, and 40 to 75 percent of these patients were no longer inducible after antiarrhythmic drug therapy. Among those patients who were not inducible at baseline, the arrhythmia-free survival over 14 to 28 months was 91 percent. All patients who were inducible were treated with appropriate drugs, and among those who became noninducible on drug therapy there was a 7 percent incidence of a significant ventricular arrhythmia during follow-up. In comparison, subjects who remained inducible despite drug therapy were discharged on an empirically chosen agent and had a 45 percent chance of a ventricular arrhythmia during follow up [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data suggest that the inability to induce sustained monomorphic VT in post-MI patients with NSVT is associated with a good prognosis. It is not clear, however, if EP-guided antiarrhythmic therapy is superior to empiric therapy, or if chronic antiarrhythmic therapy caused the mortality reduction. It is possible that the ability to suppress inducibility simply identifies patients with a better prognosis.",
"   </p>",
"   <p>",
"    As discussed below, however, post-MI patients with inducible VT are usually treated with an implantable cardioverter-defibrillator (ICD), especially those with left ventricular systolic dysfunction. Although the ability to suppress inducibility with antiarrhythmic medications appears to have prognostic implications in such patients, these results do not alter the indications for ICD placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATIENTS WITH CORONARY HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICD has emerged as an effective therapy for the primary prevention of sudden cardiac death in selected high-risk populations, particularly those with coronary heart disease (CHD). High-risk populations are defined by the presence of one or more risk factors, including NSVT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two trials, MADIT I and MUSTT, assessed the mortality benefit of ICDs in patients with coronary disease, depressed left ventricular (LV) function, and NSVT. The MADIT I and MUSTT trials demonstrate that ICD implantation reduces the risk of SCD in post-MI patients with LV dysfunction (LVEF &le;40 percent), NSVT, and inducible VT at EP study. However, the later MADIT II and SCD-HeFT trials showed a reduction in mortality with ICD therapy in patients with moderate-to-severe LV dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    moderate-to-severe heart failure, regardless of the presence of NSVT or the results of EP study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these later trials, evolving guidelines for ICD implantation have reduced the significance of NSVT in determining which patients should be treated with an ICD. However, these later trials have not contradicted the results of MADIT I and MUSTT. Rather, they have broadened ICD indications by evaluating different patient populations. For post-MI patients with moderate LV dysfunction (ie, LVEF 30 to 40 percent), who do not otherwise meet current criteria for ICD implantation, NSVT remains an indication for EP study and possible ICD implantation.",
"   </p>",
"   <p>",
"    SAECG, T-wave alternans, and other noninvasive risk stratification modalities also show promise for identifying patients at risk for SCD, but the data available do not support their use in determining an indication for ICD implantation in patients with NSVT and depressed LV function who have had a negative EP study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     MADIT I trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Multicenter Automatic Defibrillator Implantation Trial (MADIT, now called MADIT I) randomly assigned 196 subjects, inducible at EP study, to an ICD or to \"conventional\" therapy consisting of EP-guided drug therapy, empiric",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , or no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/8\">",
"     8",
"    </a>",
"    ]. Study subjects had the following clinical characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of a myocardial infarction more than three weeks prior to study entry",
"     </li>",
"     <li>",
"      Left ventricular ejection fraction &le;35 percent",
"     </li>",
"     <li>",
"      A documented episode of asymptomatic NSVT on monitoring",
"     </li>",
"     <li>",
"      Inducible at EP study despite the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MADIT I randomly assigned 95 patients to an ICD and 101 to conventional antiarrhythmic therapy (primarily with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    but also including a class I antiarrhythmic drug,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , or a beta blocker) or even no therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/8\">",
"     8",
"    </a>",
"    ]. The major findings at 27 month follow-up were significant reductions in the incidence of overall mortality (15 versus 39 deaths); (",
"    <a class=\"graphic graphic_figure graphicRef76854 \" href=\"UTD.htm?38/48/39693\">",
"     figure 2",
"    </a>",
"    ), cardiac mortality (11 versus 27 deaths), and arrhythmic deaths (3 versus 13 deaths) in the patients treated with an ICD. There was no evidence that any of the antiarrhythmic drugs had a significant effect on mortality.",
"   </p>",
"   <p>",
"    Subset analysis found a survival benefit from the ICD only in high-risk patients with more severe heart disease, ie, ejection fraction &lt;26 percent, heart failure requiring therapy, or a QRS duration &ge;12 sec [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/9\">",
"     9",
"    </a>",
"    ]. Benefit increased progressively as a function of the number of risk factors; the greatest reduction in mortality with the ICD was seen in those with two (hazard ratio 0.30) or three risk factors (hazard ratio 0.20).",
"   </p>",
"   <p>",
"    There are a number of important limitations to this study, in addition to its small size, that limit its applicability.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The number of patients with reproducible NSVT identified on sequential Holter monitoring is low, reported by one study to be 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/10\">",
"       10",
"      </a>",
"      ]. Reproducibility is especially low in those with infrequent NSVT episodes per 24 hours. Reproducibility was not associated with the induction of VT on electrophysiologic testing, suggesting that NSVT is of limited clinical value as a selection criterion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"       \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      By enrolling only patients in whom inducible sustained VT was not suppressed or slowed by the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      , the study selected patients who were less likely to respond to antiarrhythmic drugs.",
"     </li>",
"     <li>",
"      Two factors other than true benefit may have contributed to the better outcome in the ICD group. First, 23 percent of patients receiving conventional therapy were not taking any antiarrhythmic drugs at the last follow-up. Second, more patients given the ICD were taking a beta blocker at one month (26 versus 8 percent) and at the last follow-up visit (27 versus 5 percent). It is possible that beta blockade itself confers a survival benefit.",
"     </li>",
"     <li>",
"      By comparing the ICD to antiarrhythmic drugs that may increase mortality via their proarrhythmic effect, it was not demonstrated that the ICD was better than no therapy. However, the mortality rate in the \"conventional therapy\" group was 32 percent at two years, a figure that is in accord with previously reported results in high risk patients. Thus,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      did not appear to confer an increased mortality in this trial, and the results probably reflected a survival benefit of the ICD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It remains unclear how many patients with a recent myocardial infarction would be candidates for a prophylactic ICD based upon MADIT I criteria. Using data collected from the Cardiac Arrhythmia Suppression Trial (CAST) registry, it was estimated that between 0.3 and 1.1 percent of patients were at high enough risk to benefit from a prophylactic ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     MUSTT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MUSTT trial involved 704 patients with a prior MI (less than one month to more than three years previously), asymptomatic NSVT, a left ventricular ejection fraction (LVEF) &le;40 percent, and inducible sustained ventricular tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Patients were randomly assigned to no therapy or EP-guided antiarrhythmic therapy which included either an antiarrhythmic agent (class IA with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ) or an ICD if at least one antiarrhythmic agent was ineffective; the primary end point was arrhythmic death or resuscitated cardiac arrest.",
"   </p>",
"   <p>",
"    There were 353 patients discharged with no therapy and 351 who received electrophysiologically guided therapy, including an antiarrhythmic drug in 154 and an ICD in 161. The median follow-up was 39 months and the following results were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The two year (12 versus 18 percent) and five year (25 versus 32 percent) rates for the primary end point were significantly lower for electrophysiologically guided therapy compared to no therapy",
"     </li>",
"     <li>",
"      The secondary end point of total mortality was also lower at five years in the group receiving electrophysiologic guided therapy (42 versus 48 percent).",
"     </li>",
"     <li>",
"      The reduction in the primary and secondary end points in the electrophysiologically guided group was largely attributable to ICD therapy; at five years the primary end point occurred in 9 percent of those receiving an ICD, compared with 37 percent of those receiving an antiarrhythmic drug, and the secondary end point occurred in 24 and 55 percent, respectively. There was no difference in outcome between patients receiving no therapy and those treated with an antiarrhythmic drug (",
"      <a class=\"graphic graphic_figure graphicRef68247 \" href=\"UTD.htm?1/34/1582\">",
"       figure 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     MUSTT registry",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the MUSTT registry, patients with NSVT, depressed LV function, and prolonged filtered QRS duration (&gt;114 msec) on a signal averaged ECG (SAECG) or left bundle branch block had a high risk of SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/15\">",
"     15",
"    </a>",
"    ]. In the presence of a negative EP study, however, we do not feel that an abnormal SAECG is an indication for ICD implantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39702?source=see_link&amp;anchor=H10#H10\">",
"     \"Prognosis of nonsustained VT in the presence of structural heart disease\", section on 'Signal-averaged ECG'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OTHER FORMS OF STRUCTURAL HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSVT is common in other forms of structural heart disease. However, the prognostic significance of NSVT varies among these disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies using ambulatory electrocardiographic monitoring have shown that approximately 15 to 30 percent of patients with HCM have runs of NSVT, which are often asymptomatic. Furthermore, NSVT confers an increased risk for SCD in patients with HCM, although the increase in risk may be primarily limited to patients with episodes of NSVT that are prolonged, repetitive, or associated with symptoms of impaired consciousness. NSVT is more common and may have less significant prognostic value in patients over age 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2003 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/ESC)",
"    </span>",
"    consensus statement on the management of HCM identified seven major risk factors for SCD in HCM patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of cardiac arrest",
"     </li>",
"     <li>",
"      Spontaneous sustained VT",
"     </li>",
"     <li>",
"      Family history of premature SCD",
"     </li>",
"     <li>",
"      Unexplained syncope",
"     </li>",
"     <li>",
"      LV thickness &ge;30 mm",
"     </li>",
"     <li>",
"      Abnormal blood pressure response to exercise",
"     </li>",
"     <li>",
"      NSVT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether NSVT alone warrants ICD therapy is uncertain. The 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    guidelines for device-based therapy of cardiac rhythm abnormalities suggested that the weight of evidence and opinion is in favor of ICD implantation in patients with one or more major risk factor, including NSVT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Disorders in which NSVT does not predict SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several other forms of structural heart disease, NSVT is common, but does not appear to be useful for risk stratification. These disorders include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonischemic cardiomyopathy",
"     </li>",
"     <li>",
"      Mitral valve prolapse",
"     </li>",
"     <li>",
"      Mitral regurgitation",
"     </li>",
"     <li>",
"      Aortic stenosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of these patients will be treated with beta blockers and other medications as part of their overall management strategy. In addition, some will meet criteria for ICD implantation. However, the presence of NSVT does not impact decisions regarding these therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SYMPTOM CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to treatments directed at reducing the risk of SCD, some patients may be treated for the purpose of suppressing symptoms due to NSVT.",
"   </p>",
"   <p>",
"    NSVT is often asymptomatic, but some patients experience palpitations, lightheadedness, presyncope or dyspnea. Because many of the symptoms that may be attributed to NSVT are vague and nonspecific, it is important to try to correlate symptoms to episodes of NSVT before initiating therapy.",
"   </p>",
"   <p>",
"    Options for the treatment of symptomatic NSVT include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers &mdash; Beta blockers are favored for the initial treatment of symptomatic NSVT. These medications are safe and generally well tolerated.",
"     </li>",
"     <li>",
"      Nondihydropyridine calcium channel blockers &mdash; Calcium channel blockers can be useful, particularly in patients who do not have structural heart disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link\">",
"       \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antiarrhythmic medications &mdash; For some patients who have frequent, highly symptomatic NSVT not adequately suppressed by beta blockers or calcium channel blockers, the addition of antiarrhythmic medications may be helpful.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      are the agents most commonly used for suppression of symptomatic NSVT. In selected cases, Class IA agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      can be used for suppression of NSVT, but these medications must be used with caution. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=see_link\">",
"       \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Catheter ablation &mdash; In patients who have very frequent, monomorphic NSVT not controlled by medications or unable or unwilling to take medications, catheter ablation can be effective for reducing or eliminating NSVT and associated symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?22/26/22952/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who have indications for further risk stratification",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ICD implantation, these treatments should be considered adjunctive therapies. They are not adequate alternatives for the purpose of preventing malignant sustained arrhythmias and SCD in high-risk patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/51/27442?source=see_link\">",
"       \"Patient information: Ventricular tachycardia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summary and recommendations apply to the management of nonsustained ventricular tachycardia (NSVT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Prevention of SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with NSVT and certain forms of structural heart disease are at an increased risk of sudden cardiac death (SCD). This risk can be reduced in selected patients with an implantable cardioverter-defibrillator (ICD)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is our current practice to consider some form of treatment of NSVT in all patients with documented coronary heart disease (CHD), especially if there is left ventricular dysfunction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with NSVT who have had a prior myocardial infarction (MI) and a left ventricular ejection fraction (LVEF) &le;40 percent, who do not otherwise meet criteria for ICD implantation, should have an electrophysiology study (EPS), as in MUSTT and MADIT I. If the EPS is positive (ie, inducible VT), we recommend ICD implantation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Patients with coronary heart disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with NSVT who have CHD and an LVEF &gt;40 percent, we do not routinely perform additional risk stratification. Similarly, we do not give additional therapies (eg, ICD or antiarrhythmic drugs) for the purpose of primary prevention of SCD. Such patients, however, should be treated with a beta blocker as part of the standard management of patients with CHD, which may also reduce the risk of SCD. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Beta blockade'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSVT is one of several major risk factors that predict an increased risk of SCD in patients with hypertrophic cardiomyopathy (HCM). Whether NSVT alone warrants ICD therapy in patients with HCM is uncertain. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Hypertrophic cardiomyopathy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Detailed recommendations for the management of ventricular arrhythmias in patients with HCM are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link&amp;anchor=H26#H26\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Dilated cardiomyopathy and valve disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with idiopathic dilated cardiomyopathy or isolated valve disease, the presence of NSVT does not alter management. Such patients are treated with standard medical therapy for cardiomyopathy, including beta blockers and ACE inhibitors. Such therapy, particularly beta blockers, may reduce the risk of SCD regardless of the presence of NSVT. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Disorders in which NSVT does not predict SCD'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Management of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with NSVT may complain of symptoms such as palpitations, lightheadedness, presyncope, or dyspnea. Because such symptoms are often vague and nonspecific, it is important to try to document a direct correlation between the symptoms and the arrhythmia before initiating treatment.",
"   </p>",
"   <p>",
"    If the symptoms are benign, such as palpitations, we institute long-term monitoring (up to four weeks) or patient-triggered event recorders in an attempt to document the cause. Not infrequently, no arrhythmia is identified.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the patient with symptomatic NSVT, we suggest a beta blocker as initial therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Symptom control'",
"      </a>",
"      above.) Alternatives include a nondihydropyridine calcium channel blocker, particularly in patients with normal left ventricular function, or catheter ablation in patients with frequent symptoms that are refractory to medical therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"       \"Catheter ablation for ventricular arrhythmias\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who have indications for further risk stratification",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ICD implantation, treatments that control symptoms should be considered adjunctive therapies. They are not adequate alternatives for the purpose of preventing malignant sustained arrhythmias and SCD in high-risk patients.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/1\">",
"      Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/2\">",
"      Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992; 327:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/3\">",
"      Friedman LM, Byington RP, Capone RJ, et al. Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. J Am Coll Cardiol 1986; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/4\">",
"      Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990; 16:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/5\">",
"      Pfisterer M, Kiowski W, Burckhardt D, et al. Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol 1992; 69:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/6\">",
"      Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349:675.",
"     </a>",
"    </li>",
"    <li>",
"     Buxton AE. Patients with nonsustained ventricular tachycardia. In: Sudden Cardiac Death: Prevalence, Mechanisms, and Approach to Diagnosis and Management, Akhtar M, Myerburg R, Ruskin J (Eds), Williams &amp; Wilkins, Baltimore 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/8\">",
"      Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/9\">",
"      Moss AJ, Fadl Y, Zareba W, et al. Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease. Am J Cardiol 2001; 88:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/10\">",
"      Senges JC, Becker R, Schreiner KD, et al. Variability of Holter electrocardiographic findings in patients fulfilling the noninvasive MADIT criteria. Multicenter Automatic Defibrillator Implantation Trial. Pacing Clin Electrophysiol 2002; 25:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/11\">",
"      Every NR, Hlatky MA, McDonald KM, et al. Estimating the proportion of post-myocardial infarction patients who may benefit from prophylactic implantable defibrillator placement from analysis of the CAST registry. Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1998; 82:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/12\">",
"      Buxton AE, Fisher JD, Josephson ME, et al. Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis 1993; 36:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/13\">",
"      Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/14\">",
"      Wyse DG, Talajic M, Hafley GE, et al. Antiarrhythmic drug therapy in the Multicenter UnSustained Tachycardia Trial (MUSTT): drug testing and as-treated analysis. J Am Coll Cardiol 2001; 38:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/15\">",
"      Gomes JA, Cain ME, Buxton AE, et al. Prediction of long-term outcomes by signal-averaged electrocardiography in patients with unsustained ventricular tachycardia, coronary artery disease, and left ventricular dysfunction. Circulation 2001; 104:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/16\">",
"      Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/17\">",
"      Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003; 42:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/18\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/19\">",
"      Singh SN, Fisher SG, Carson PE, Fletcher RD. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. Department of Veterans Affairs CHF STAT Investigators. J Am Coll Cardiol 1998; 32:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/20\">",
"      Larsen L, Markham J, Haffajee CI. Sudden death in idiopathic dilated cardiomyopathy: role of ventricular arrhythmias. Pacing Clin Electrophysiol 1993; 16:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/21\">",
"      Kligfield P, Levy D, Devereux RB, Savage DD. Arrhythmias and sudden death in mitral valve prolapse. Am Heart J 1987; 113:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/22\">",
"      Kligfield P, Hochreiter C, Niles N, et al. Relation of sudden death in pure mitral regurgitation, with and without mitral valve prolapse, to repetitive ventricular arrhythmias and right and left ventricular ejection fractions. Am J Cardiol 1987; 60:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/23\">",
"      Wolfe RR, Driscoll DJ, Gersony WM, et al. Arrhythmias in patients with valvar aortic stenosis, valvar pulmonary stenosis, and ventricular septal defect. Results of 24-hour ECG monitoring. Circulation 1993; 87:I89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22952/abstract/24\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 917 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-9F549ED38C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22952=[""].join("\n");
var outline_f22_26_22952=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9005219\">",
"      DEFINITION OF NSVT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIARRHYTHMIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Class I agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Beta blockade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EP-guided antiarrhythmic drug therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATIENTS WITH CORONARY HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MADIT I trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MUSTT trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - MUSTT registry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OTHER FORMS OF STRUCTURAL HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Disorders in which NSVT does not predict SCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SYMPTOM CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Prevention of SCD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Dilated cardiomyopathy and valve disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Management of symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/917\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/917|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/4/19534\" title=\"figure 1\">",
"      Proarrhythmia with class Ic antiarrhythmic drugs in CAST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/48/39693\" title=\"figure 2\">",
"      ICD in NSVT in MADIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/34/1582\" title=\"figure 3\">",
"      ICD vs no ICD MUSTT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13974?source=related_link\">",
"      Nonsustained VT in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/51/27442?source=related_link\">",
"      Patient information: Ventricular tachycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39702?source=related_link\">",
"      Prognosis of nonsustained VT in the presence of structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=related_link\">",
"      Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_26_22953="Leukocyte adhesion deficiency";
var content_f22_26_22953=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Leukocyte adhesion deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/26/22953/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/26/22953/contributors\">",
"     Amos Etzioni, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/26/22953/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/26/22953/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/26/22953/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/26/22953/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/26/22953/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocyte trafficking from the bloodstream to tissue is important for the continuous surveillance of foreign antigens, as well as for rapid leukocyte accumulation at sites of inflammatory response or tissue injury. Leukocyte emigration to sites of inflammation is a dynamic process, involving multiple steps in an adhesion cascade. Various adhesion molecules are expressed on both resting and stimulated endothelial cells and leukocytes.",
"   </p>",
"   <p>",
"    Defects in a number of these adhesion molecules result in recognized clinical syndromes. Three Leukocyte Adhesion Deficiency (LAD) syndromes have been delineated and a fourth category of newly-described defects will be reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LAD I, in which the beta 2-integrin family is deficient or defective",
"     </li>",
"     <li>",
"      LAD II, in which the fucosylated carbohydrate ligands for selectins are absent",
"     </li>",
"     <li>",
"      LAD III, in which activation of all beta&ndash;integrins (1, 2, and 3) is defective",
"     </li>",
"     <li>",
"      Other defects of neutrophil adhesion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues related to the LAD syndromes will be reviewed here. Other neutrophil disorders, and the process of leukocyte-endothelial adhesion during inflammation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF LEUKOCYTE MIGRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation is characterized histologically by the accumulation of leukocytes at the involved site due to the directional migration of circulating leukocytes. Migration out of the vasculature is first initiated by contact between the leukocyte and the inflamed vascular endothelium. Both the vascular endothelium and leukocytes actively mediate this adhesive interaction, which will be reviewed briefly here. A detailed review of the adhesion cascade is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adhesion molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both leukocytes and vascular endothelial cells express a variety of surface adhesion molecules that help mediate leukocyte trafficking. Three families of adhesive molecules are responsible for the majority of leukocyte-endothelial interactions (",
"    <a class=\"graphic graphic_table graphicRef71824 \" href=\"UTD.htm?13/15/13564\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Selectins",
"      </strong>",
"      &mdash; Selectins are found on both leukocytes and endothelial cells and primarily mediate cellular margination and rolling.",
"     </li>",
"     <li>",
"      <strong>",
"       Integrins",
"      </strong>",
"      &mdash; Integrins are largely responsible for adhesion of leukocytes to endothelial cells and are composed of heterodimers of covalently-associated alpha and beta protein chains. Certain members of the beta 1 and beta 2 subclasses of integrins are primarily responsible for the migration of leukocytes into areas of inflammation. Integrins are named and categorized based upon their particular alpha and beta chain.",
"      <br/>",
"      <br/>",
"      CD18 is the beta chain common to all members of the beta 2 subclass of integrins, and CD11a, CD11b, and CD11c are the alpha chains associated with LFA-1, Mac-1, and p150,95 respectively (",
"      <a class=\"graphic graphic_figure graphicRef54103 \" href=\"UTD.htm?6/25/6557\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Members of the immunoglobulin superfamily of proteins",
"      </strong>",
"      &mdash; Immunoglobulin (Ig) superfamily molecules expressed on endothelial cells interact with integrins on leukocytes and are involved in firm adhesion and transmigration. The molecules of this family that play a role in leukocyte-endothelial adhesion are intercellular adhesion molecule-1 (ICAM-1) and ICAM-2.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Steps of leukocyte migration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The movement of leukocytes from the bloodstream to the tissue occurs in several distinct steps (",
"    <a class=\"graphic graphic_figure graphicRef73528 \" href=\"UTD.htm?16/63/17392\">",
"     figure 2",
"    </a>",
"    ). First, under conditions of flow, loose adhesion to the vessel wall causes leukocyte rolling on the endothelium, which primarily occurs in postcapillary venules. This transient and reversible step is a prerequisite for the next stage, the activation of leukocytes. This is followed by firm adhesion, (ie, sticking), after which transmigration occurs. Each of these steps involves different adhesion molecules and can be differentially regulated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link&amp;anchor=H10#H10\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\", section on 'The adhesion cascade'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LEUKOCYTE ADHESION DEFICIENCY SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In each of the LAD syndromes, leukocytes (particularly neutrophils) cannot leave the vasculature to migrate normally into tissues under conditions of inflammation or infection.",
"   </p>",
"   <p>",
"    Three LAD syndromes have been defined:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LAD I, in which the beta 2-integrin family is deficient or defective",
"     </li>",
"     <li>",
"      LAD II, in which the fucosylated carbohydrate ligands for selectins are absent",
"     </li>",
"     <li>",
"      LAD III, in which activation of all beta&ndash;integrins (1, 2, and 3) is defective",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is an additional and growing group of LAD syndromes that results from various defects in the regulation of adhesion proteins. These include abnormal E-selectin expression and Rac-2 deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LAD I",
"    </span>",
"    &nbsp;&mdash;&nbsp;LAD I is an autosomal recessive syndrome resulting from deficiency of",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    defects in CD18, the common beta chain of the beta 2-integrin family. Hundreds of cases have now been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies found that leukocytes from patients with LAD I were deficient in the expression of the three integrins containing CD18 (",
"    <a class=\"graphic graphic_figure graphicRef54103 \" href=\"UTD.htm?6/25/6557\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lymphocyte function associated antigen-1 (LFA-1,",
"      <span class=\"nowrap\">",
"       CD11a/CD18)",
"      </span>",
"     </li>",
"     <li>",
"      Mac-1",
"      <span class=\"nowrap\">",
"       (CD11b/CD18)",
"      </span>",
"      and",
"     </li>",
"     <li>",
"      gp",
"      <span class=\"nowrap\">",
"       150/95",
"      </span>",
"      <span class=\"nowrap\">",
"       (CD11c/CD18)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In vitro studies demonstrated a marked defect in random migration and chemotaxis. Leukocyte adhesion and transmigration through endothelial cells were also severely impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/3\">",
"     3",
"    </a>",
"    ]. LAD I is an autosomal recessive genetic disease with mutation in the integrin beta 2 gene (ITGB2) encoding the CD18 subunit [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/2\">",
"     2",
"    </a>",
"    ]. Deficient expression of CD18 leads to impaired T cell function as well, which probably contributes to the severity of the immunodeficiency. In contrast to neutrophil and lymphocyte functions, NK activity is not affected [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, the syndrome proved more heterogeneous, with the discovery of mutations leading to quantitatively normal, but functionally defective, CD18. The molecular basis for CD18 deficiency varies, with mutations resulting in aberrant beta mRNA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    protein [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are a number of reported point mutations, some of which lead to the biosynthesis of defective proteins with single amino acid substitutions.",
"     </li>",
"     <li>",
"      Other mutations lead to splicing defects, resulting in the production of truncated and unstable proteins. Many of these mutations occur in a highly conserved 240 residue domain, which constitutes the binding site of the beta 2-integrins to their ligands, ICAM-1 and -2.",
"     </li>",
"     <li>",
"      Some genetic defects result in the lack of diminished expression of CD18 mRNA. In other cases, there is expression of mRNA or protein precursors of aberrant size giving rise to both larger and smaller CD18 subunits.",
"     </li>",
"     <li>",
"      A few mutations lead to a defect in beta 2-integrin adhesive functions despite normal surface expressions of CD18 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variant form of the disease was described in three young adults who had somatic reversion mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/10\">",
"     10",
"    </a>",
"    ]. In all three, a T cell subset of predominantly cytotoxic T lymphocytes (CTLs) expressed CD18. Normal CD18 expression was due to a further mutation in one CD18 allele in these T cell subsets. This somatic mosaicism was associated with a milder clinical phenotype. However, all three patients had inflammatory bowel disease, which suggests that altered regulation of this T cell subset is important to the pathogenesis of this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=see_link&amp;anchor=H3#H3\">",
"     \"Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease\", section on 'Cellular immunity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;LAD I is characterized clinically by the following (",
"    <a class=\"graphic graphic_table graphicRef66375 \" href=\"UTD.htm?38/8/39052\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Delayed separation of the umbilical cord",
"     </li>",
"     <li>",
"      Recurrent bacterial infections, primarily localized to skin and mucosal surfaces",
"     </li>",
"     <li>",
"      Leukocytosis",
"     </li>",
"     <li>",
"      Periodontitis (later in life)",
"     </li>",
"     <li>",
"      Absent pus formation",
"     </li>",
"     <li>",
"      Impaired wound healing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The severity of infectious complications among patients with LAD I appears to be directly related to the degree of CD18 deficiency. Two phenotypes, designated severe deficiency and moderate deficiency, have been defined [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Severe deficiency",
"      </strong>",
"      &mdash; Patients with less than 2 percent of the normal surface expression exhibit a severe form of the disease characterized by earlier, more frequent, and more serious episodes of infection, often leading to death in infancy if appropriate treatment is not given.",
"     </li>",
"     <li>",
"      <strong>",
"       Mild to moderate deficiency",
"      </strong>",
"      &mdash; Patients with some surface expression of CD18 (variably characterized as 2 to 30 percent of normal) manifest a mild to moderate phenotype with fewer serious infectious episodes and survival into adulthood.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Infections and periodontitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections affecting the skin, respiratory tract, bowel, and perirectal areas are usually apparent from birth onward [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/12\">",
"     12",
"    </a>",
"    ]. A classic presenting infection is omphalitis with delayed separation of the umbilical cord stump (ie, later than 30 days) (",
"    <a class=\"graphic graphic_picture graphicRef63960 graphicRef71634 \" href=\"UTD.htm?26/17/26898\">",
"     picture 1A-B",
"    </a>",
"    ). Otitis media, perirectal abscess, and bacterial sepsis are noted in many patients. Severe gingivitis and periodontitis are major features among all patients who survive infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Infections can become necrotizing and lead to ulceration (eg, pyoderma gangrenosum) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infections are frequently caused by Staphylococcus aureus and gram negative bacilli. In contrast to their difficulties in defense against bacterial pathogens, patients do not exhibit a marked increase in susceptibility to viral infections. However, there have been reports of deaths due to viral infections in young adults, possibly reflecting poor cell-cell interaction and impaired specific antibody production [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/17\">",
"     17",
"    </a>",
"    ]. More frequent fungal infections are also observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Absence of pus formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absence of pus formation at the sites of infection is a hallmark of LAD I (",
"    <a class=\"graphic graphic_picture graphicRef81988 \" href=\"UTD.htm?36/15/37119\">",
"     picture 2",
"    </a>",
"    ). There is a profound impairment of leukocyte mobilization into extravascular sites of inflammation, and biopsies of infected tissues demonstrate inflammation completely devoid of neutrophils.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Impaired wound healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously noted, delayed separation of the umbilical cord is one manifestation of impaired wound healing. In addition, scars can acquire a \"cigarette paper\" appearance (",
"    <a class=\"graphic graphic_picture graphicRef81988 \" href=\"UTD.htm?36/15/37119\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A moderate neutrophilia is usually seen in the absence of infection. During infection, a marked peripheral blood leukocytosis (5 to 20 times normal values or up to",
"    <span class=\"nowrap\">",
"     100,000/mL)",
"    </span>",
"    can be observed because of impaired mobilization to extravascular sites of inflammation. Typically, the neutrophilia is accompanied by a mild lymphocytosis, although band forms are uncommon. Biopsies of infected tissues demonstrate inflammatory infiltrates completely devoid of neutrophils.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis should be considered in any infant, male, or female with recurrent soft tissue infection and a very high leukocyte count. Criteria for diagnosis were published in 1999. These include clinical features for definitive, possible, and probable diagnosis (",
"    <a class=\"graphic graphic_table graphicRef53344 \" href=\"UTD.htm?39/55/40827\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To confirm the diagnosis, the absence of CD18 and the associated alpha subunit molecules CD11a, CD11b, and CD11c on the surface of leukocytes must be demonstrated by flow cytometry using CD11 and CD18 monoclonal antibodies. These tests are commercially available and are highly accurate.",
"     </li>",
"     <li>",
"      Sequence analysis to define the exact molecular defect in the beta 2-subunit is recommended, especially for prenatal diagnosis in subsequent pregnancies and genetic counseling [",
"      <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/18\">",
"       18",
"      </a>",
"      ]. Sequence analysis is available in many laboratories working in genetic molecular testing. Preimplantation genetic diagnosis of LAD I was reported [",
"      <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, the clinical and laboratory findings are very suggestive of LAD I and the diagnosis is clear. The elevated leukocyte count is a constant feature in LAD I. A variety of other non-malignant conditions are also associated with more modest increases in neutrophil count. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=see_link\">",
"     \"Causes of neutrophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31303?source=see_link\">",
"     \"Definition and mechanisms of leukocytosis and neutrophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extremely high leukocyte counts can be observed in the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infections can occasionally cause leukocyte counts in excess of 50,000",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"     </li>",
"     <li>",
"      A leukemoid reaction in infants (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31303?source=see_link&amp;anchor=H5#H5\">",
"       \"Definition and mechanisms of leukocytosis and neutrophilia\", section on 'Leukemoid reaction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rarely, leukemia and other lymphoproliferative disorders may also present with leukocytosis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Management and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of LAD I depends on the clinical severity. Mild to moderate disease usually responds to antibiotic therapy, while severe disease requires bone marrow or hematopoietic cell transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Mild to moderate phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections in patients with the mild to moderate LAD I phenotype usually respond to conservative therapy and the prompt use of appropriate antibiotics during acute episodes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Careful oral hygiene is important to control periodontitis and prevent oral infections. Care should be coordinated between medical and dental providers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/53/20313?source=see_link\">",
"       \"Complications, diagnosis, and treatment of odontogenic infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacterial infections should be aggressively managed with systemic antibiotics, guided by culture and sensitivity data whenever possible.",
"     </li>",
"     <li>",
"      Patients with LAD can receive routine vaccinations, including live virus vaccines.",
"     </li>",
"     <li>",
"      In the past, transfusion of granulocytes (freshly harvested by leukapheresis) was anecdotally reported to be of benefit in a small number of patients with infections that could not be otherwise controlled, although it was associated with pulmonary complications. This intervention is unlikely to be used in the future, as improved antibiotics and supportive care are sufficient for management of most infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4393?source=see_link\">",
"       \"Granulocyte transfusions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Granulocyte macrophage colony-stimulating factor (GM-CSF) is not helpful to patients with LAD (I, II, or III), as this agent would increase the neutrophil number, but the cells still cannot emigrate properly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26454810\">",
"    <span class=\"h4\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the mild to moderate phenotype may survive into adulthood. Lifespan has been lengthened by improvements in supportive care and antibiotics. In the early 1990s, approximately one-half of patients lived into their mid-thirties, and this figure may have improved further since then.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Severe phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, hematopoietic cell transplantation is the only corrective treatment for the severe phenotype, and patients respond well to this intervention. The largest available series describes 36 children at 14 centers treated with hematopoietic cell transplantation between 1993 and 2007 and followed for a median duration of five years post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/20\">",
"     20",
"    </a>",
"    ]. Overall survival was 75 percent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Success of transplantation appeared related to the degree of matching with the donor [",
"      <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/20\">",
"       20",
"      </a>",
"      ]. Survival was 50 percent among eight haploidentical transplant recipients versus 82 percent for those patients with matched (family or unrelated) transplants (n = 28). Reduced intensity conditioning regimens were successful in patients receiving matched unrelated transplants.",
"     </li>",
"     <li>",
"      Gene therapy has been studied in preclinical trials, as well as in vivo studies in animals, and has shown promise [",
"      <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. However, clinical trials have thus far been unsuccessful [",
"      <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/23\">",
"       23",
"      </a>",
"      ]. A dog model of gene therapy, using foamy virus vectors, may prove useful in humans [",
"      <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=see_link\">",
"       \"Gene therapy for primary immunodeficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A general discussion concerning the management of infants with severe immunodeficiency is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29726921\">",
"    <span class=\"h4\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the severe form of the disease often die in infancy unless hematopoietic cell transplantation is performed. If transplant is accomplished before severe infections have occurred, the prognosis is very good [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/20,24,25\">",
"     20,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     LAD II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocyte adhesion deficiency II (LAD II) is a rare, autosomal recessive syndrome that is due to the absence of fucosylated carbohydrate ligands, resulting in defective rolling of hematopoietic cells (",
"    <a class=\"graphic graphic_figure graphicRef73528 \" href=\"UTD.htm?16/63/17392\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef60382 \" href=\"UTD.htm?8/1/8223\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef72229 \" href=\"UTD.htm?3/28/3535\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef59192 \" href=\"UTD.htm?31/44/32462\">",
"     movie 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biochemical abnormality in LAD II is a general defect in fucosylation of macromolecules [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/27\">",
"     27",
"    </a>",
"    ], at the stage of specific transport of fucose to the Golgi apparatus (",
"    <a class=\"graphic graphic_figure graphicRef59631 \" href=\"UTD.htm?25/63/26614\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/28\">",
"     28",
"    </a>",
"    ]. Glycans that incorporate fucose, such as SLex (CD15a) and the H antigen (Bombay) are not expressed on myeloid cells.",
"   </p>",
"   <p>",
"    Genetic defects in patients with LAD II have been identified in the GDP-fucose transporter gene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Mutations in highly conserved transmembrane domains appear to be causative. The patients can be divided genetically into those with normal subcellular expression of the transporter but defective function, and those with no expression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/30\">",
"     30",
"    </a>",
"    ]. LAD II was also designated congenital disorder of glycosylation (CDG)-IIc, since it is a general defect in fucose metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/28\">",
"     28",
"    </a>",
"    ]. This dual identity has been maintained because patients who live into adulthood mainly demonstrate the metabolic manifestations.",
"   </p>",
"   <p>",
"    This abnormality in fucosylation in LAD II results in defective rolling of hematopoietic cells, as fucosylated glycoproteins serve as ligands for selectins on endothelial cells. Neutrophils of affected patients fail to bind to purified platelet-derived P-selectin and recombinant E-selectin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/31\">",
"     31",
"    </a>",
"    ]. Defective rolling and tethering have been observed using intravital microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Overview of leukocyte migration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Despite these abnormalities, LAD II neutrophils are able to adhere and transmigrate via beta 2-integrins under conditions of reduced shear forces [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/32\">",
"     32",
"    </a>",
"    ]. This allows some level of neutrophil defense against bacterial infections.",
"   </p>",
"   <p>",
"    There is evidence for lymphocyte dysfunction in LAD II. Patients can have reduced delayed-type hypersensitivity reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/33\">",
"     33",
"    </a>",
"    ]. This may be due in part to abnormal cytokine release from TH1 lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;LAD II has been reported in fewer than 10 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. They were born after uneventful pregnancies and were of normal height and weight at birth. Unlike those with the severe form of LAD I, there was no delay in the separation of the umbilical cord (",
"    <a class=\"graphic graphic_table graphicRef66375 \" href=\"UTD.htm?38/8/39052\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with LAD II have less severe and fewer infections than those with LAD I. Pus formation is impaired, and skin, lung, and periodontal infections are reported, but are generally not life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/39\">",
"     39",
"    </a>",
"    ]. The severity of infections may decrease with time, with adults suffering primarily from periodontitis.",
"   </p>",
"   <p>",
"    Non-immune clinical characteristics are an important feature of LAD II. Affected patients are severely mentally retarded, short in stature, and have a distinctive facial appearance (depressed nasal bridge). Microcephaly and cortical atrophy have been described. Children have delays in motor development, including sitting and walking, and in speech. Muscular hypotonia and skeletal abnormalities are also seen. Based upon the few patients who have survived to adulthood, it seems that the immune problems dominate clinically in infancy, while later on in life, the metabolic consequences (CDG-IIc) become more prominent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in LAD I, neutrophilia (ranging from 10,000 to",
"    <span class=\"nowrap\">",
"     40,000/mm3)",
"    </span>",
"    is a constant finding, and counts rise further during infection. LAD II is also associated with the rare Bombay (hh) blood phenotype, with red cells lacking A, B, and H antigens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link\">",
"     \"A primer of red blood cell antigens and antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of LAD II should be suspected in the patient with the physical features previously described, mental and growth retardation, recurrent but usually mild infections, marked leukocytosis, and the Bombay blood group. The combination of neutrophilia, Bombay blood group, and severe psychomotor retardation is unique to LAD II.",
"   </p>",
"   <p>",
"    The absence of SLeX expression (CD15a) is shown by an analysis of peripheral blood leukocytes by flow cytometry using a monoclonal antibody directed against SLeX, which is available commercially. To confirm the diagnosis, sequence analysis of the gene encoding the GDP-fucose transporter is required. Many commercial laboratories can perform this testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the LAD II patients described so far, infections were common but responded well to antibiotics, although periodontitis is difficult to treat, especially in children with severe mental retardation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/53/20313?source=see_link\">",
"     \"Complications, diagnosis, and treatment of odontogenic infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotic prophylaxis may be necessary in some children with very frequent infections. We typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      at dose of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily). After approximately five years of age, as the adaptive immune response matures, the frequency of infection declines dramatically in many patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Fucose supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the proposed defect in fucose metabolism, a trial of fucose supplementation is recommended in all patients diagnosed with LAD II [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/40\">",
"     40",
"    </a>",
"    ]. This would be particularly important in a very young child in whom developmental retardation was not yet apparent, as psychomotor function improved in the one successful case [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Very few centers have experience with this therapy, as it has only been administered to a handful of patients. In the one successful case, the initial dose of fucose was 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight per single dose, which was administered five times per day [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/40\">",
"     40",
"    </a>",
"    ]. This was titrated upwards over nine months to a single dose of 492",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight, given five times per day.",
"   </p>",
"   <p>",
"    In this child, fucose supplementation caused a dramatic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/36,40\">",
"     36,40",
"    </a>",
"    ]. However, this was not observed in two other patients. This variability is probably explained by the existence of different mutations in the GDP-fucose transporter gene. A mutation that altered substrate affinity could be overcome with excess fucose; by comparison, exogenous fucose administration had no effect on a second mutation associated with normal affinity but slower sugar transport.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to generalize about the prognosis of LAD II, as so few patients have been reported. Still, most children survive infancy but suffer from chronic periodontitis and severe mental and growth retardation. The oldest reported child is now in his early twenties and is also afflicted with epilepsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     LAD III",
"    </span>",
"    &nbsp;&mdash;&nbsp;LAD III (previously referred to as LAD I variant) is a rare, autosomal recessive syndrome characterized by severe infections with marked leukocytosis, and accompanied by a life-threatening bleeding disorder. Fewer than 20 patients with LAD III have been reported, many of whom are of Turkish origin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/41-46\">",
"     41-46",
"    </a>",
"    ]. The beta 1, beta 2, and beta 3 integrin families are affected, so both leukocytes (which express beta 1 and 2) and platelets (which express beta 3) are defective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with LAD III, integrin expression and structure is intact, but there is a defect in integrin activation by physiological stimuli. Earlier studies identified defects in the \"inside-out\" intracellular integrin activation processes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/44,47\">",
"     44,47",
"    </a>",
"    ]. Subsequently, a mutation in diacylglycerol guanine nucleotide exchange factor (CAL DAG GEF1) was found (",
"    <a class=\"graphic graphic_figure graphicRef63985 \" href=\"UTD.htm?13/53/14164\">",
"     figure 4",
"    </a>",
"    ). Although defects in CAL DAG GEF1 cause a syndrome resembling LAD III in a mouse model [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/48\">",
"     48",
"    </a>",
"    ], their importance in humans is not yet clear [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following this earlier work, mutations both in Cal DAG GEF 1 and the gene for Kindlin-3 were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/45\">",
"     45",
"    </a>",
"    ]. Kindlin-3 is an adaptor protein that binds to the intracellular portions of beta 1, 2, and 3 integrins, and is believed to enhance their binding to the protein talin at the cell membrane, leading to increased integrin activation and stronger binding of ligands (ie, immunoglobulin superfamily molecules). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link&amp;anchor=H3#H3\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\", section on 'Adhesion molecules'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional patients have been reported with mutations in both Cal DAG GEF 1 and Kindlin-3, or with mutations only in the Kindlin-3 gene (FERM3) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/41,46,50\">",
"     41,46,50",
"    </a>",
"    ]. Complementation studies showed that the functional defect can be restored with transfection of normal Kindlin-3, while normal CAL DAG GEF1 did not correct the defect [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/41,46\">",
"     41,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LAD III is characteristic of a newly-described group of genetic deficiencies of important adaptor molecules involved in activation of integrins on hematopoietic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/41,47,51\">",
"     41,47,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In LAD III, leukocyte dysfunction leads to severe, recurrent bacterial infections, delayed separation of the umbilical cord, and leukocytosis, similar to the clinical presentation of LAD I.",
"   </p>",
"   <p>",
"    Dysfunctional platelet aggregation causes bleeding complications such as cerebral hemorrhage at birth, hematuria, melana, and petechial lesions of the skin and mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/41\">",
"     41",
"    </a>",
"    ]. The bleeding disorder is similar to that of patients with Glanzmann thrombasthenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H30#H30\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Glanzmann thrombasthenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for LAD III should be performed in infants with bleeding complications from birth, severe infections with delayed separation of the umbilical cord, and marked leukocytosis. Diagnosis requires the demonstration of impaired integrin activation, with intact integrin expression. Genetic analysis for mutations in KINDLIN3 should be performed in all suspected cases. These studies are available in a few select laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow or hematopoietic cell transplantation is the only corrective treatment for LAD III. The prognosis is poor unless transplantation is performed early in infancy. Only a handful of patients with LAD III have been transplanted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of the associated bleeding disorder is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H35#H35\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A general discussion concerning the management of infants with severe immunodeficiency is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     OTHER SYNDROMES OF POOR NEUTROPHIL ADHESION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are other syndromes of defective leukocyte adhesion that have not been as well characterized or have only been described in one or two patients. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal E-selectin expression",
"     </li>",
"     <li>",
"      Rac2 deficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Abnormal E-selectin expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A defect in the selectin system was described in a child with severe recurrent infections and impaired pus formation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/52\">",
"     52",
"    </a>",
"    ]. In contrast to the other LAD syndromes, only moderate neutropenia was observed. Neutrophil number increased normally during infection. Reported infections included Pseudomonas omphalitis, recurrent ear and urinary tract infections, severe soft tissue infections, and sepsis.",
"   </p>",
"   <p>",
"    There was markedly reduced expression of E-selectin on blood vessels of inflamed tissue with increased levels of circulating soluble E-selectin. This suggests increased cleavage of surface E-selectin. The underlying defect is unclear, as the E-selectin gene sequence was normal in this child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Rac2 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rac2 (Ras-related C3 botulinum toxin substrate 2) is a Rho-GTPase that is essential for several important neutrophil functions. These include rolling via L-selectin, F-actin assembly, chemotaxis, and superoxide generation in response to some agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Neutrophils from mice deficient in Rac2 have defects in rolling on endothelium, chemotaxis, and phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rac2 deficiency (also called neutrophil immunodeficiency syndrome, MIM #608203) is a syndrome of global neutrophil dysfunction that has been described in a male infant with delayed separation of the umbilical cord, poor pus formation, leukocytosis, neutrophilia, and non-healing perirectal and periumbilical abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. In contrast to LAD I, wound biopsies showed appropriate numbers of neutrophils. Defects in rolling on endothelium, chemotaxis, and phagocytosis were observed with the child's neutrophils, as well as in a murine model.",
"   </p>",
"   <p>",
"    Infections in this patient healed with granulocyte transfusions. He subsequently underwent successful bone marrow transplantation.",
"   </p>",
"   <p>",
"    An unrelated female child with similar neutrophil defects had been previously identified [",
"    <a class=\"abstract\" href=\"UTD.htm?22/26/22953/abstract/59\">",
"     59",
"    </a>",
"    ]; however, she died of sepsis prior to the exact characterization of the underlying defect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a Leukocyte Adhesion Deficiency (LAD) syndrome, leukocytes (particularly neutrophils) cannot leave the vasculature to migrate normally into tissues under conditions of inflammation or infection.",
"   </p>",
"   <p>",
"    Three LAD syndromes have been delineated (",
"    <a class=\"graphic graphic_figure graphicRef73528 \" href=\"UTD.htm?16/63/17392\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66375 \" href=\"UTD.htm?38/8/39052\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LAD I, in which the beta 2-integrin family is deficient or defective",
"     </li>",
"     <li>",
"      LAD II, in which the fucosylated carbohydrate ligands for selectins are absent",
"     </li>",
"     <li>",
"      LAD III, in which beta-integrin activation is defective",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An additional group of LAD syndromes is emerging that is composed of various defects in adhesion proteins or their regulation. These include abnormal E-selectin expression and Rac-2 deficiency. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Other syndromes of poor neutrophil adhesion'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Leukocyte adhesion deficiency I",
"    </span>",
"    &nbsp;&mdash;&nbsp;LAD I is characterized clinically by recurrent bacterial infections, a persistent neutrophilia that increases markedly during infection, absent pus formation (a hallmark finding), and impaired wound healing (",
"    <a class=\"graphic graphic_picture graphicRef81988 \" href=\"UTD.htm?36/15/37119\">",
"     picture 2",
"    </a>",
"    ). A classic presenting infection is omphalitis, with delayed separation of the umbilical cord (",
"    <a class=\"graphic graphic_picture graphicRef63960 graphicRef71634 \" href=\"UTD.htm?26/17/26898\">",
"     picture 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'LAD I'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LAD I should be considered in any infant with recurrent soft tissue infection and a very high leukocyte count. The diagnosis is made by demonstrating the absence of both CD18 and the associated alpha subunit molecules (CD11a, CD11b, and CD11c) by flow cytometry using CD11 and CD18 monoclonal antibodies. Severe and moderate phenotypes are delineated based upon the degree of leukocyte CD18 expression. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with moderate LAD I require meticulous oral and dental care to control periodontitis and oral infections, and prompt and complete treatment of other bacterial infections as they arise. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe LAD I and acceptably matched donors are candidates for hematopoietic cell transplantation. Gene therapy may be available in the future. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Severe phenotype'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Leukocyte adhesion deficiency II",
"    </span>",
"    &nbsp;&mdash;&nbsp;LAD II results from the absence of fucosylated carbohydrate ligands on hematopoietic cells. Because these glycoproteins serve as ligands for selectins, this abnormality results in defective rolling of leukocytes. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'LAD II'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with LAD II have less severe and fewer infections than those with LAD I. Skin, lung, and periodontal infections are common, although generally not life-threatening. However, non-immunologic sequelae are prominent, as affected patients have severe mental retardation, short stature, and a distinctive facial appearance (depressed nasal bridge). Children have delays in motor development and speech (",
"      <a class=\"graphic graphic_table graphicRef66375 \" href=\"UTD.htm?38/8/39052\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'LAD II'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis should be suspected in children with neutrophilia and psychomotor retardation. The presence of Bombay blood group in such a child strongly suggests the diagnosis. Flow cytometry demonstrates the absence of SLeX expression (CD15a), and the diagnosis is confirmed with sequence analysis of the gene encoding the GDP-fucose transporter. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with LAD II require careful oral and dental care to control periodontitis and oral infections, and prompt and complete treatment of other bacterial infections as they arise. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For young children with frequent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe infections despite the above measures, we suggest prophylactic administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We administer a dose of 5 mg per kg once daily. Antibiotic prophylaxis is not usually needed once the child exceeds about five years of age. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a trial of fucose supplementation in all patients with LAD II (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This is most likely to be successful in patients diagnosed early in life. The initial dose of fucose is 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      body weight (per dose), administered five times daily. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Fucose supplementation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Leukocyte adhesion deficiency III",
"    </span>",
"    &nbsp;&mdash;&nbsp;LAD III is a rare, autosomal recessive syndrome that results from defective integrin activation by physiological stimuli. Both leukocytes and platelets are affected, resulting in severe bacterial infections, similar to those seen in LAD I, as well as bleeding complications due to defective platelet function (",
"    <a class=\"graphic graphic_table graphicRef66375 \" href=\"UTD.htm?38/8/39052\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H26\">",
"     'LAD III'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis requires a demonstration of impaired integrin activation with intact integrin expression, and mutations in the KINDLIN3 gene. These studies are performed in a few select laboratories. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe LAD III and acceptably matched donors, hematopoietic cell transplantation may correct the presumed hematopoietic defect. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Treatment and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Stiehm ER, Ochs HD, Winkelstein JA. Immunodeficiency disorders: General considerations. In: Immunologic disorders in infants and children, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier Saunders, Philadelphia 2004. p.423.",
"    </li>",
"    <li>",
"     Etzioni A, Harlan JM. Cell adhesion and leukocyte adhesion defects. In: Primary immunodeficiency diseases, 2nd ed, Ochs HD, Smith CIE, Puck JM (Eds), Oxford, 2007. p.550.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/3\">",
"      Harlan JM, Killen PD, Senecal FM, et al. The role of neutrophil membrane glycoprotein GP-150 in neutrophil adherence to endothelium in vitro. Blood 1985; 66:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/4\">",
"      Castriconi R, Dondero A, Cantoni C, et al. Functional characterization of natural killer cells in type I leukocyte adhesion deficiency. Blood 2007; 109:4873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/5\">",
"      Roos D, Law SK. Hematologically important mutations: leukocyte adhesion deficiency. Blood Cells Mol Dis 2001; 27:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/6\">",
"      Mathew EC, Shaw JM, Bonilla FA, et al. A novel point mutation in CD18 causing the expression of dysfunctional CD11/CD18 leucocyte integrins in a patient with leucocyte adhesion deficiency (LAD). Clin Exp Immunol 2000; 121:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/7\">",
"      Solomon E, Palmer RW, Hing S, Law SK. Regional localization of CD18, the beta-subunit of the cell surface adhesion molecule LFA-1, on human chromosome 21 by in situ hybridization. Ann Hum Genet 1988; 52:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/8\">",
"      Vihinen M, Arredondo-Vega FX, Casanova JL, et al. Primary immunodeficiency mutation databases. Adv Genet 2001; 43:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/9\">",
"      Hogg N, Stewart MP, Scarth SL, et al. A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins Mac-1 and LFA-1. J Clin Invest 1999; 103:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/10\">",
"      Uzel G, Tng E, Rosenzweig SD, et al. Reversion mutations in patients with leukocyte adhesion deficiency type-1 (LAD-1). Blood 2008; 111:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/11\">",
"      Fischer A, Lisowska-Grospierre B, Anderson DC, Springer TA. Leukocyte adhesion deficiency: molecular basis and functional consequences. Immunodefic Rev 1988; 1:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/12\">",
"      Movahedi M, Entezari N, Pourpak Z, et al. Clinical and laboratory findings in Iranian patients with leukocyte adhesion deficiency (study of 15 cases). J Clin Immunol 2007; 27:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/13\">",
"      Dababneh R, Al-Wahadneh AM, Hamadneh S, et al. Periodontal manifestation of leukocyte adhesion deficiency type I. J Periodontol 2008; 79:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/14\">",
"      Cox DP, Weathers DR. Leukocyte adhesion deficiency type 1: an important consideration in the clinical differential diagnosis of prepubertal periodontitis. A case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105:86.",
"     </a>",
"    </li>",
"    <li>",
"     Rosenzweig SD, Uzel G, Holland SM. Phagocyte disorders. In: Immunologic disorders in infants and children, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier Saunders, Philadelphia 2004. p.632.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/16\">",
"      Ganesh A, Al-Zuhaibi SS, Bialasiewicz AA, et al. Necrotizing Pseudomonas infection of the ocular adnexa in an infant with leukocyte adhesion defect. J Pediatr Ophthalmol Strabismus 2007; 44:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/17\">",
"      Anderson DC, Mace ML, Brinkley BR, et al. Recurrent infection in glycogenosis type Ib: abnormal neutrophil motility related to impaired redistribution of adhesion sites. J Infect Dis 1981; 143:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/18\">",
"      Weening RS, Bredius RG, Wolf H, van der Schoot CE. Prenatal diagnostic procedure for leukocyte adhesion deficiency. Prenat Diagn 1991; 11:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/19\">",
"      Lorusso F, Kong D, Jalil AK, et al. Preimplantation genetic diagnosis of leukocyte adhesion deficiency type I. Fertil Steril 2006; 85:494.e15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/20\">",
"      Qasim W, Cavazzana-Calvo M, Davies EG, et al. Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. Pediatrics 2009; 123:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/21\">",
"      Bauer TR Jr, Hai M, Tuschong LM, et al. Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy. Blood 2006; 108:3313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/22\">",
"      Bauer TR Jr, Allen JM, Hai M, et al. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med 2008; 14:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/23\">",
"      Bauer TR Jr, Hickstein DD. Gene therapy for leukocyte adhesion deficiency. Curr Opin Mol Ther 2000; 2:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/24\">",
"      Al-Ghonaium A. Stem cell transplantation for primary immunodeficiencies: King Faisal Specialist Hospital experience from 1993 to 2006. Bone Marrow Transplant 2008; 42 Suppl 1:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/25\">",
"      Gennery AR, Cant AJ. Advances in hematopoietic stem cell transplantation for primary immunodeficiency. Immunol Allergy Clin North Am 2008; 28:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/26\">",
"      Etzioni A, Frydman M, Pollack S, et al. Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency. N Engl J Med 1992; 327:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/27\">",
"      Becker DJ, Lowe JB. Fucose: biosynthesis and biological function in mammals. Glycobiology 2003; 13:41R.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/28\">",
"      L&uuml;bke T, Marquardt T, Etzioni A, et al. Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency. Nat Genet 2001; 28:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/29\">",
"      Gazit Y, Mory A, Etzioni A, et al. Leukocyte adhesion deficiency type II: long-term follow-up and review of the literature. J Clin Immunol 2010; 30:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/30\">",
"      Helmus Y, Denecke J, Yakubenia S, et al. Leukocyte adhesion deficiency II patients with a dual defect of the GDP-fucose transporter. Blood 2006; 107:3959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/31\">",
"      Phillips ML, Schwartz BR, Etzioni A, et al. Neutrophil adhesion in leukocyte adhesion deficiency syndrome type 2. J Clin Invest 1995; 96:2898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/32\">",
"      von Andrian UH, Berger EM, Ramezani L, et al. In vivo behavior of neutrophils from two patients with distinct inherited leukocyte adhesion deficiency syndromes. J Clin Invest 1993; 91:2893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/33\">",
"      Kuijpers TW, Etzioni A, Pollack S, Pals ST. Antigen-specific immune responsiveness and lymphocyte recruitment in leukocyte adhesion deficiency type II. Int Immunol 1997; 9:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/34\">",
"      Austrup F, Vestweber D, Borges E, et al. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. Nature 1997; 385:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/35\">",
"      Borges E, Tietz W, Steegmaier M, et al. P-selectin glycoprotein ligand-1 (PSGL-1) on T helper 1 but not on T helper 2 cells binds to P-selectin and supports migration into inflamed skin. J Exp Med 1997; 185:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/36\">",
"      Wild MK, L&uuml;hn K, Marquardt T, Vestweber D. Leukocyte adhesion deficiency II: therapy and genetic defect. Cells Tissues Organs 2002; 172:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/37\">",
"      Hidalgo A, Ma S, Peired AJ, et al. Insights into leukocyte adhesion deficiency type 2 from a novel mutation in the GDP-fucose transporter gene. Blood 2003; 101:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/38\">",
"      Yakubenia S, Wild MK. Leukocyte adhesion deficiency II. Advances and open questions. FEBS J 2006; 273:4390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/39\">",
"      Etzioni A, Gershoni-Baruch R, Pollack S, Shehadeh N. Leukocyte adhesion deficiency type II: long-term follow-up. J Allergy Clin Immunol 1998; 102:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/40\">",
"      Marquardt T, L&uuml;hn K, Srikrishna G, et al. Correction of leukocyte adhesion deficiency type II with oral fucose. Blood 1999; 94:3976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/41\">",
"      Svensson L, Howarth K, McDowall A, et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med 2009; 15:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/42\">",
"      McDowall A, Inwald D, Leitinger B, et al. A novel form of integrin dysfunction involving beta1, beta2, and beta3 integrins. J Clin Invest 2003; 111:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/43\">",
"      Kuijpers TW, van Bruggen R, Kamerbeek N, et al. Natural history and early diagnosis of LAD-1/variant syndrome. Blood 2007; 109:3529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/44\">",
"      Kinashi T, Aker M, Sokolovsky-Eisenberg M, et al. LAD-III, a leukocyte adhesion deficiency syndrome associated with defective Rap1 activation and impaired stabilization of integrin bonds. Blood 2004; 103:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/45\">",
"      Mory A, Feigelson SW, Yarali N, et al. Kindlin-3: a new gene involved in the pathogenesis of LAD-III. Blood 2008; 112:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/46\">",
"      Malinin NL, Zhang L, Choi J, et al. A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans. Nat Med 2009; 15:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/47\">",
"      Alon R, Aker M, Feigelson S, et al. A novel genetic leukocyte adhesion deficiency in subsecond triggering of integrin avidity by endothelial chemokines results in impaired leukocyte arrest on vascular endothelium under shear flow. Blood 2003; 101:4437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/48\">",
"      Bergmeier W, Goerge T, Wang HW, et al. Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III. J Clin Invest 2007; 117:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/49\">",
"      Hidalgo A, Frenette PS. When integrins fail to integrate. Nat Med 2009; 15:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/50\">",
"      Kuijpers TW, van de Vijver E, Weterman MA, et al. LAD-1/variant syndrome is caused by mutations in FERMT3. Blood 2009; 113:4740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/51\">",
"      Alon R, Etzioni A. LAD-III, a novel group of leukocyte integrin activation deficiencies. Trends Immunol 2003; 24:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/52\">",
"      DeLisser HM, Christofidou-Solomidou M, Sun J, et al. Loss of endothelial surface expression of E-selectin in a patient with recurrent infections. Blood 1999; 94:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/53\">",
"      Dharmawardhane S, Bokoch GM. Rho GTPases and leukocyte cytoskeletal regulation. Curr Opin Hematol 1997; 4:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/54\">",
"      Knaus UG, Heyworth PG, Evans T, et al. Regulation of phagocyte oxygen radical production by the GTP-binding protein Rac 2. Science 1991; 254:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/55\">",
"      Roberts AW, Kim C, Zhen L, et al. Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense. Immunity 1999; 10:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/56\">",
"      Ambruso DR, Knall C, Abell AN, et al. Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proc Natl Acad Sci U S A 2000; 97:4654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/57\">",
"      Williams DA, Tao W, Yang F, et al. Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. Blood 2000; 96:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/58\">",
"      Kurkchubasche AG, Panepinto JA, Tracy TF Jr, et al. Clinical features of a human Rac2 mutation: a complex neutrophil dysfunction disease. J Pediatr 2001; 139:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/26/22953/abstract/59\">",
"      Roos D, Kuijpers TW, Mascart-Lemone F, et al. A novel syndrome of severe neutrophil dysfunction: unresponsiveness confined to chemotaxin-induced functions. Blood 1993; 81:2735.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3918 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22953=[""].join("\n");
var outline_f22_26_22953=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF LEUKOCYTE MIGRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adhesion molecules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Steps of leukocyte migration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LEUKOCYTE ADHESION DEFICIENCY SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LAD I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Infections and periodontitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Absence of pus formation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Impaired wound healing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Mild to moderate phenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26454810\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Severe phenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29726921\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      LAD II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Fucose supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      LAD III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      OTHER SYNDROMES OF POOR NEUTROPHIL ADHESION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Abnormal E-selectin expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Rac2 deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Leukocyte adhesion deficiency I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Leukocyte adhesion deficiency II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Leukocyte adhesion deficiency III",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3918\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3918|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/25/6557\" title=\"figure 1\">",
"      Structure of beta 2 integrins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/63/17392\" title=\"figure 2\">",
"      Defects in leukocyte adhesion deficiency disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/63/26614\" title=\"figure 3\">",
"      Fucosylation macromolecules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/53/14164\" title=\"figure 4\">",
"      Inside out signl integr",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3918|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/60/33742\" title=\"picture 1A\">",
"      Omphalitis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/1/40991\" title=\"picture 1B\">",
"      Omphalitis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/15/37119\" title=\"picture 2\">",
"      Absence of pus in LAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3918|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?8/1/8223\" title=\"movie 1\">",
"      Normal leukocyte movement - no inflammatory stimulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?3/28/3535\" title=\"movie 2\">",
"      Normal leukocyte movement in presence of inflammatory tissue signals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?31/44/32462\" title=\"movie 3\">",
"      Abnormal leukocyte movement in LAD II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3918|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/15/13564\" title=\"table 1\">",
"      Expression adhesion molecules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/8/39052\" title=\"table 2\">",
"      Leukocyte adhesion deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/55/40827\" title=\"table 3\">",
"      Leukocyte adhesion defects I",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=related_link\">",
"      Causes of neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/53/20313?source=related_link\">",
"      Complications, diagnosis, and treatment of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31303?source=related_link\">",
"      Definition and mechanisms of leukocytosis and neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=related_link\">",
"      Gene therapy for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4393?source=related_link\">",
"      Granulocyte transfusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=related_link\">",
"      Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_26_22954="Oblit bronchiolitis BMT I";
var content_f22_26_22954=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53459%7EPULM%2F65164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53459%7EPULM%2F65164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchiolitis obliterans following allogeneic bone marrow transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrographs of a partially obliterated bronchiole in a patient who has received an allogeneic bone marrow transplant. Left: Hematoxylin and eosin stained section shows a largely obliterated bronchiole with peribronchiolar fibrosis and an associated infiltrate of mononuclear inflammatory cells. Right: An elastic tissue stain outlines the elastic layer of the same bronchiole pictured on the left and shows a compressed but patent lumen (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchiolitis obliterans following bone marrow transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrographs of a completely obliterated bronchiole in a patient who has received an allogeneic bone marrow transplant. Left: Hematoxylin and eosin stained section shows complete replacement of a bronchiole by a collagenous scar associated with a scant inflammatory infiltrate and so-called cholesterol clefts, a nonspecific finding. Right: An elastic tissue stain is helpful in outlining the elastic layer of the same bronchiole pictured on the left and shows complete replacement of the bronchiole lumen by scar tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22954=[""].join("\n");
var outline_f22_26_22954=null;
var title_f22_26_22955="Hepatocyte transplantation";
var content_f22_26_22955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential indications for hepatocyte transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inherited metabolic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allogeneic (with immunosuppression or tolerization)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autologous with ex-vivo gene transfer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acute liver failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        As a \"bridge\" while awaiting liver transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        As definitive therapy in selected cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Chronic liver failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For improving metabolic function and encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To \"buy time\" while awaiting liver transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rescuing patients who require curative doses of hepatic irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        As a part of treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Generating animal models",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For human hepatocyte-specific infections by transplanting human hepatocytes into immunodeficient animals",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22955=[""].join("\n");
var outline_f22_26_22955=null;
var title_f22_26_22956="Prelim class criteria JSS";
var content_f22_26_22956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Provisional classification criteria for juvenile systemic sclerosis by the Pediatric Rheumatology European Society, the American College of Rheumatology, and the European League against Rheumatism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       Major criterion",
"      </td>",
"      <td colspan=\"2\">",
"       Proximal sclerosis/induration of the skin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\" rowspan=\"20\">",
"       Minor criteria",
"      </td>",
"      <td>",
"       Skin",
"      </td>",
"      <td>",
"       Sclerodactyly",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Vascular",
"      </td>",
"      <td>",
"       Raynaud's phenomenon",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nailfold capillariy abnormalities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Digital tip ulcers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Gastrointestinal",
"      </td>",
"      <td>",
"       Dysphagia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastro-esophageal reflux",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Renal",
"      </td>",
"      <td>",
"       Renal crisis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       New onset arterial hypertension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Cardiac",
"      </td>",
"      <td>",
"       Arrhythmias",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Heart failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Respiratory",
"      </td>",
"      <td>",
"       Pulmon fibrosis (HRCT/Xray)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       DLCO",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pulmonary hypertension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Muskulo Skeletal",
"      </td>",
"      <td>",
"       Tendon friction rubs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arthritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myositis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Neurological",
"      </td>",
"      <td>",
"       Neuropathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Carpal tunnel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Serology",
"      </td>",
"      <td>",
"       Antinuclear antibodies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       SSc selective autoantibodies (anticentromere, antitopoisomerase I, antifibrillarin, anti-PM-Scl, anti-fibrillin or anti-RNA polymerase  I or III)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    In a patient less than 16 years of age, juvenile systemic sclerosis is diagnosed if the major criterion and at least 2 of 20 minor criteria are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zulian, F, Woo, P, Athreya, BH, et al. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum 2007; 57:203. Copyright &copy;2007 Wiley-Liss, Inc. a subsidiary of John Wiley &amp; Sons Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22956=[""].join("\n");
var outline_f22_26_22956=null;
var title_f22_26_22957="TW alternans and arrhythmic events post-MI";
var content_f22_26_22957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Repolarization alternans (RPA) predicts arrhythmic events following myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 356px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 102 patients with a prior myocardial infarction (MI) followed for 13 months, the event-free survival was significantly higher in those without repolarization alternans (RPA negative) compared to those with repolarization alternans (RPA positive). The sensitivity and negative predictive value of RPA for predicting an arrhythmic event were 93 and 98 percent, respectively, but the positive predictive value was only 28 percent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ikeda T, Sakata T, Takami M, et al, J Am Coll Cardiol 2000; 35:722.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22957=[""].join("\n");
var outline_f22_26_22957=null;
var title_f22_26_22958="Epiglottitis x-ray";
var content_f22_26_22958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epiglottitis: Lateral radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral neck radiograph demonstrating swollen epiglottis (arrow) and aryepiglottic folds in a child with epiglottitis due to",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    type b. The swollen epiglottis is often called a \"thumb sign.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Evelyn Y Anthony, MD, Wake Forest University School of Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22958=[""].join("\n");
var outline_f22_26_22958=null;
var title_f22_26_22959="GRAALL 2003 regimen";
var content_f22_26_22959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    GRAALL-2003 chemotherapy regimen for acute lymphoblastic leukemia (ALL) in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"3\">",
"        Remission induction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Remission induction begins with a seven-day corticosteroid prephase followed by induction chemotherapy. The intensity of induction is modified based upon response. \"Poor early responders\" include those with a peripheral-blood blast cell count &ge;1 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L after the corticosteroid prephase (corticoid-resistant) and/or bone marrow blast cells &ge;5 percent after the first week of chemotherapy (chemotherapy-resistant). Patients who fail to obtain a complete remission (CR) with induction proceed to salvage therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"3\">",
"        Corticosteroid prephase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        The \"corticosteroid prephase\" consists of daily prednisone and a single administration of intrathecal methotrexate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Prednisone",
"       </td>",
"       <td>",
"        oral",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day on days minus 7 to minus 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Methotrexate",
"       </td>",
"       <td>",
"        IT",
"       </td>",
"       <td>",
"        15 mg administered once between days minus 7 and minus 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"3\">",
"        Induction course",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        Induction therapy is administered over 28 days. The intensity of cyclophosphamide is increased for \"poor early responders.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Prednisone",
"       </td>",
"       <td>",
"        oral",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day on days 1 to 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Daunorubicin",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        <p>",
"         50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         per day on days 1, 2, and 3",
"        </p>",
"        <p>",
"         30 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         per day on days 15 and 16",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Vincristine",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        2 mg on days 1, 8, 15, and 22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Asparaginase*",
"       </td>",
"       <td>",
"        IM",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        6000 units/m",
"        <sup>",
"         2",
"        </sup>",
"        per day on days 8, 10, 12, 20, 22, 24, 26, and 28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        <p>",
"         750 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         per day on day 1",
"        </p>",
"        <p>",
"         <strong>",
"          then",
"         </strong>",
"        </p>",
"        <p>",
"         Good early responders: 750 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         on day 15",
"        </p>",
"        <p>",
"         Poor early responders: 500 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         every 12 hours on days 15 and 16",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lenograstim",
"       </td>",
"       <td>",
"        SC",
"       </td>",
"       <td>",
"        150 mcg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day from day 17 to myeloid recovery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"3\">",
"        Salvage course",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        For patients who fail to obtain a complete remission with induction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Idarubicin",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        12 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day on days 1 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cytarabine",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        2 grams/m",
"        <sup>",
"         2",
"        </sup>",
"        every 12 hours on days 1 to 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lenograstim",
"       </td>",
"       <td>",
"        SC",
"       </td>",
"       <td>",
"        150 mcg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day from day 9 until myeloid recovery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"3\">",
"        Consolidation blocks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Consolidation consists of nine \"blocks\" of therapy scheduled to be administered every two weeks, with some modifications of schedule based upon hematologic recovery. Late intensification is administered between consolidation blocks 6 and 7. Allogeneic HCT is offered to patients with high risk disease after consolidation blocks 3 or 6, depending upon donor availability.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"3\">",
"        Blocks 1, 4, and 7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cytarabine",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        2 grams/m",
"        <sup>",
"         2",
"        </sup>",
"        every 12 hours on days 1 and 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Dexamethasone",
"       </td>",
"       <td>",
"        oral",
"       </td>",
"       <td>",
"        10 mg every 12 hours on days 1 and 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Asparaginase*",
"       </td>",
"       <td>",
"        IM",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        10,000 units/m",
"        <sup>",
"         2",
"        </sup>",
"        on day 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lenograstim",
"       </td>",
"       <td>",
"        SC",
"       </td>",
"       <td>",
"        150 mcg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day on days 7 to 13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"3\">",
"        Blocks 2, 5, and 8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Methotrexate",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        3 grams/m",
"        <sup>",
"         2",
"        </sup>",
"        continuous infusion over 24 hours on day 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Leucovorin",
"       </td>",
"       <td>",
"        IV/oral",
"       </td>",
"       <td>",
"        15 mg every 6 hours for 8 doses starting 12 hours after the completion of methotrexate infusion; dose modifications made based upon methotrexate levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Vincristine",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        2 mg on day 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Asparaginase*",
"       </td>",
"       <td>",
"        IM",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        10,000 units/m",
"        <sup>",
"         2",
"        </sup>",
"        on day 16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Mercaptopurine",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day on days 15 to 21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lenograstim",
"       </td>",
"       <td>",
"        SC",
"       </td>",
"       <td>",
"        150 mcg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day on days 22 to 27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"3\">",
"        Blocks 3, 6, and 9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day on days 29 and 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Etoposide",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day on days 29 and 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Methotrexate",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        25 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        on day 29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lenograstim",
"       </td>",
"       <td>",
"        SC",
"       </td>",
"       <td>",
"        150 mcg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day from day 31 until myeloid recovery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"3\">",
"        Late intensification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Administered between consolidation blocks 6 and 7.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"3\">",
"        For patients in CR after the first induction course",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Prednisone",
"       </td>",
"       <td>",
"        oral",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day on days 1 to 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Vincristine",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        2 mg on days 1, 8, and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Daunorubicin",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        30 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day on days 1 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Asparaginase*",
"       </td>",
"       <td>",
"        IM",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        6000 units/m",
"        <sup>",
"         2",
"        </sup>",
"        per day on days 8, 10, 12, 18, 20, and 22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        every 12 hours on day 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lenograstim",
"       </td>",
"       <td>",
"        SC",
"       </td>",
"       <td>",
"        150 mcg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day if neutrophil count &lt;500/microL, continued until myeloid recovery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"3\">",
"        For patients in CR after the salvage course",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Idarubicin",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        9 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day on days 1 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cytarabine",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        2 grams/m",
"        <sup>",
"         2",
"        </sup>",
"        every 12 hours on days 1 to 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lenograstim",
"       </td>",
"       <td>",
"        SC",
"       </td>",
"       <td>",
"        150 mcg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day from day 9 until myeloid recovery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"3\">",
"        Maintenance therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Maintenance therapy is administered for two years after the completion of consolidation therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Prednisone",
"       </td>",
"       <td>",
"        oral",
"       </td>",
"       <td>",
"        40 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day on days 1 to 7 of a 28 day cycle, for 12 cycles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Vincristine",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        2 mg on day 1 of a 28 day cycle, for 12 cycles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Methotrexate",
"       </td>",
"       <td>",
"        oral",
"       </td>",
"       <td>",
"        25 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        weekly for 24 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Mercaptopurine",
"       </td>",
"       <td>",
"        oral",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        daily for 24 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"3\">",
"        CNS-directed therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"3\">",
"        Prophylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Triple intrathecal injections",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td colspan=\"2\">",
"        Days 1 and 8 of induction; day 29 of each series of consolidation blocks; day 1 of late intensification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cranial irradiation",
"       </td>",
"       <td colspan=\"2\">",
"        18 Gy administered before start of maintenance therapy. Oral daily mercaptopurine 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day is administered concurrent with radiation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"3\">",
"        Treatment of patients with initial CNS involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Triple intrathecal injections",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         Induction: Eight IT injections administered between days minus 7 and 21.",
"        </p>",
"        <p>",
"         Consolidation: Four IT injections administered during the first two blocks",
"         <strong>",
"          AND",
"         </strong>",
"         an IT injection administered on day 29 each of blocks 3 and 6.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cranial irradiation",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         15 Gy administered before HCT. Oral daily mercaptopurine 60 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         per day is administered concurrent with radiation.",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         24 Gy administered before start of maintenance therapy. Oral daily mercaptopurine 60 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         per day is administered concurrent with radiation.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GRAALL: Group for Research on Adult Acute Lymphoblastic Leukemia; CR: complete remission; HCT: hematopoietic cell transplantation; IT: intrathecal; IM: intramuscular; IV: intravenous; SC: subcutaneous; CNS: central nervous system.",
"     <br>",
"      * Escherichia coli L-asparaginase.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       A preferred route of administration was not included in the original publication. Intravenous (IV) and, in some cases subcutaneous, administration of asparaginase are alternates. Intramuscular administration is not recommended in patients with severe thrombocytopenia. IV administration is associated with more frequent and severe immediate hypersensitivity reactions. For additional information see \"Infusion reactions to systemic chemotherapy\", section \"L-asparaginase.\"",
"       <br>",
"        &Delta; In the original publication, triple IT injections consisted of methotrexate 15 mg, cytarabine 40 mg, and methylprednisolone 40 mg. Some clinicians prefer to use a combination of methotrexate, cytarabine, and hydrocortisone due to concerns regarding neurotoxicity with the intrathecal administration of methylprednisolone.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Huguet F, Leguqy T, Raffoux E, et al. Pediatric-inspiried therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009; 27:911.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_26_22959=[""].join("\n");
var outline_f22_26_22959=null;
